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Pancreatic ductal adenocarcinoma (PDAC) remains a cancer with few effective 
therapeutic options, and patient prognosis is poor. Immunotherapy has yet to yield 
significant benefit in treatment of PDAC. Understanding the key molecular pathways 
that drive resistance to immunotherapy may enable development of new therapeutic 
strategies for this cancer of unmet clinical need. The non-receptor protein tyrosine 
kinase, Focal Adhesion Kinase (FAK), is up-regulated in PDAC, and recent studies have 
identified an important role for FAK in regulating the fibrotic and immunosuppressive 
pancreatic tumour microenvironment (TME). However, the mechanisms underpinning 
FAK-dependent regulation of the immunosuppressive TME remain poorly understood. 
Using CRISPR, I have depleted FAK expression in pancreatic cancer cells isolated from 
PDAC arising on LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice (KPC mice), and 
show that FAK-depletion results in a tumour growth delay that is associated with 
reprogramming of the tumour associated macrophage (TAM) phenotype. 
Mechanistically I identify FAK-dependent regulation of interleukin-6 secretion from 
pancreatic cancer cells as an important regulator of the TAM phenotype, and further 
show that this axis requires CD4+ T-cells. These results provide new insights into the 
complexity of FAK-dependent immune regulation in cancer, and support continued 
evaluation of FAK kinase inhibitors in combination with immunotherapy for the 











Pancreatic cancer patients currently face a very poor prognosis. More than 95% of 
patients die within 5 years of diagnosis. There are currently no effective long-term 
treatments for patients who have been diagnosed with advanced disease and are 
ineligible for surgery, a situation representing the majority of pancreatic cancer 
patients.  
Many tumour types including pancreatic cancer are made of up lots of different types 
of cells. Cancer cells talk to the other surrounding cells and manipulate them to aid 
cancer cell multiplication. Tumour associated macrophages are an example of one of 
these cell types. These can be manipulated by signals derived from cancer cells to 
become one of two types: M1 or M2, and by using markers on the surface of these 
macrophages, we can identify them within pancreatic tumours. The two types of 
macrophages have very different functions within tumours. M2 macrophages 
promote tumour progression whereas M1 macrophages help attack tumour cells. By 
manipulating macrophages within the tumour to the M2 type, this is one way in 
which pancreatic tumour cells hide from the immune system. This is termed 
‘immune evasion’.  
Immunotherapy works by stimulating the body’s immune system to recognise and 
attack the cancer cells. By inhibiting a protein called Focal Adhesion Kinase (FAK) 
within the pancreatic tumour cells, I have discovered a way of inhibiting the ability 
of cancer cells to talk to the macrophages within the tumour and cause them to take 
on the M2 type. I show that this allows other cells that make up the immune system 
better able to destroy pancreatic tumours. The results of this study suggest that by 
using drugs that inhibit the FAK protein in pancreatic cancer, this potentially leads to 
a more effective treatment response and could be useful as part of the treatment 
regime in this disease. 
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1 Introduction 
1.1 Pancreatic cancer 
1.1.1 Defining the problem 
Despite our increased understanding of the biology of pancreatic cancer, major 
clinical advances have not been forthcoming. Pancreatic cancer is currently the 
fourth leading cause of cancer death in both the US1 and Europe2, and is expected to 
become the second most common in the developed world within the next decade3, 
making this an increasingly lethal cancer type. Hence there is a real and urgent need 
to identify new strategies for the treatment of pancreatic cancer.  
1.1.1.1 Epidemiology 
Approximately 9,800 pancreatic cancer diagnoses are made in the UK every year, 
making pancreatic cancer the 11th most common cancer, accounting for 3% of all 
newly diagnosed cancer cases  (http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer). Over the 
last decade the incidence has increased by 11% and this trend is expected to continue 
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/pancreatic-cancer). There are several factors contributing to this rising 
trend. Pancreatic cancer has a strong association with increasing age4 and therefore 
the global burden of this disease will likely increase due to rising population 
longevity. Additionally, the incidence of pancreatic cancer varies greatly between 
different countries with reported incidence higher in developed countries5. Although 
the number of cases reported in some countries could be attributed to better access to 
advanced diagnostics, generally this geographical distribution of cases reflects 
recognised socioeconomic risk factors such as obesity, diabetes, dietary factors, 
alcohol consumption, cigarette smoking, and pancreatitis4, all playing a role in the 
aetiology of this disease. The relationship between chronic pancreatitis and 
pancreatic cancer is well established6. Although this relationship is difficult to 
quantify, as individuals with pancreatic cancer also suffer episodes of pancreatitis as 
a consequence of their tumour, it is reported that patients with chronic pancreatitis 
have a 13.3 fold increased relative risk of developing pancreatic cancer7. The 
relationship between chronic inflammatory insult with neoplastic development and 
progression is well recognised, and is thought to be influenced by inflammatory 
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cytokines6, however the higher incidence of chronic pancreatitis compared to 
pancreatic cancer and the lack of pancreatitis in the clinical history of some cancer 
patients would suggest that inflammation is only part of the disease process.  
The genetic alterations underpinning pancreatic tumourogenesis and progression are 
now well defined, and will be described in more detail in later sections of this 
chapter, however the genetic basis underlying familial pancreatic cancer remains 
controversial8. A family history of pancreatic cancer considerably increases an 
individual's risk of developing the disease, with 10% of cases reported to have a 
familial basis8. In a study of 102 familial pancreatic cancer patients, three mutations 
in the BRACA2 gene and one mutation in BRACA1 and p16 were identified9.  
1.1.1.2 Survival 
Pancreatic cancer has an extremely poor prognosis with a 5-year survival rate of less 
than 5%1,10 and a 10- year survival rate of less than 1% in the UK. There has been 
little improvement in the survival rate of pancreatic cancer patients over the last 40 
years (http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/pancreatic-cancer/survival), highlighting a clear 
and urgent unmet clinical need. This poor survival rate is thought to be due to a 
variety factors, mainly attributed to aspects of pancreatic tumour biology, resulting in 
late diagnosis, and a poor response to treatment. The majority of patients have 
aggressive and metastatic cancer at the time of diagnosis11,12 due to metastasis 
occurring early in the disease course and clinically silent disease until advanced 
stages13.  
1.1.1.3 Current treatment options 
Poor clinical response to current therapeutic regimes and the lack of substantive 
advancement in effective new treatments are major issues in treatment success of 
pancreatic cancer. Surgical resection is at present the only treatment modality to 
significantly prolong survival times. Unfortunately the clinically silent nature of this 
disease in the early stages, coupled with the lack of early detection methods, results 
in diagnosis often being made after the tumour has invaded surrounding tissues or 
spread to distant sites. For this reason only approximately 15% of patients are 
eligible for curative intent surgery14. Even in those patients who are suitable surgical 
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candidates, there still remains only a modest survival benefit of 14-20 months15 due 
to a high rate of recurrence. Neoadjuvant chemotherapy or adjuvant chemotherapy 
following surgery is often employed. Although a number of randomised controlled 
trials demonstrate a significant survival advantage in patients treated with adjuvant 
chemotherapy after resected pancreatic tumours and neoadjuvant gemcitabine-
radiotherapy regimes8,14, a significant overall survival benefit was not established in 
surgical patients receiving neoadjuvant or adjuvant therapy from recent meta-
analysis data15.   
 
Once the tumour has locally advanced into surrounding structures or spread to distant 
sites, palliative chemotherapy is often considered. Currently the standard of care for 
most patients with advanced pancreatic cancer is gemcitabine-based regimens either 
as a single agent or more recently in combination with nab-paclitaxel, a nanoparticle 
albumen-bound form of paclitaxel, giving mean survival benefit of 1.8 months 
compared to gemcitabine alone16, or aggressive multi-drug regimes such as 
FOLFIRINOX, a multi-drug combination of leucovorin, fluorouracil, irinotecan and 
oxaliplatin, giving a mean survival benefit of 4.3 months compared to gemcitabine 
alone17. These survival benefits can arguably be regarded as only incremental at best 
and therefore justify the importance of further research to identify new strategies 
with the potential for long-term clinical responses for this devastating cancer type.  
 
1.1.2 Pancreatic cancer biology and molecular pathology 
Pancreatic cancers are classified according to the cell type they arise from with the 
majority developing from the ductal lineage. Pancreatic ductal adenocarcinoma 
(PDAC) is the predominant histological type of pancreatic cancer, occurring in 90% 
of cases18. Less common non-ductal pancreatic cancers include: fibrous 
histiocytoma, juvenile haemangioendothelioma, schwannoma, leiomyosarcoma, 
malignant schwannoma, fibrosarcoma, malignant fibrous histiocytoma, liposarcoma, 
rhabdomyosarcoma, malignant haemangiopericytoma, extramedullary plasmacytoma 
and neuroendocrine tumours arising from the islets of Langerhan.  
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PDAC arises from various precursor lesions, in most cases from microscopic non-
invasive epithelial proliferations within the pancreatic ducts, referred to as pancreatic 
intraepithelial neoplasias (PanINs)19. Less commonly, PDAC can also arise from 
larger macroscopic cystic precursors namely mucinous cystic neoplasms (MCNs) 
and intraductal papillary mucinous neoplasms (IPMNs)20. 
The precursor lesions (PanIN-1, 2 and 3) have been traditionally categorised on the 
basis of increasing cytological and architectural disorganisation. PanINs have been 
described as ducts measuring less than 5mm in diameter and multiple stages can 
occur in the same pancreas, displaying increasing cytoarchitectural atypia as lesions 
progress from PanIN-1 to PainIN-321. PanIN-3 demonstrates severe nuclear and 
cellular atypia and can be considered ‘carcinoma in-situ’22. These eventually develop 
into invasive carcinoma with a marked stromal reaction and ultimately into 
disseminated metastatic disease (figure 1.1). More recently an international 
consensus meeting has recommended a two-tiered classification system to replace 
the original three-tiered classification. This low-grade verses high-grade 
classification system is based on histological appearance and is thought to better 
reflect the clinical significance of the lesions23. In addition to the ductal 
carcinogenesis sequence, two alternative precursors pathways of invasive carcinoma 
have also been proposed, namely acinar-ductal metaplasia (ADM)24 and atypical flat 
lesions (AFLs)25, however their clinical and biological significance requires further 
research23. 
The cytological changes described in the step-wise progression from PanIN-1, 
through PanIN-2 to PanIN-3 are accompanied by progressive accumulation of well 
described genetic alterations as shown in the adapted figure below (figure 1.1) from 
Bardeesy et al26. The process begins in early PanIN-1 with telomere shortening and 
activation of the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 
oncogene, most commonly an activating point mutation in codon 1227–29. KRAS is 
involved in the regulation of cell division as a result of its ability to relay external 
signals to the cell nucleus. Activating mutations in the KRAS gene result in a 
permanently active KRAS protein, and resultant downstream pathway activation 
leads to cell transformation30. KRAS is mutated in over 90% of all PDACs18,31,32 and 
the remainder of PDACs that do not harbour KRAS mutations tend to exhibit de-
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regulated KRAS signalling through mutations of other genes in the KRAS signalling 
pathway, suggesting that KRAS and /or pathway mutations are critical initiating 
genetic alterations in this disease31–33. Loss of function mutations in tumour 
suppressor gene CDKN2A, a gene encoding p16, a protein playing an important role 
in regulating the cell cycle, is also a frequent early event31. PanIN-2 and PanIN-3 
often acquire additional loss of function mutations in the tumour suppressor genes 
TP53 (tumour protein 53) and SMAD4 (Mothers against decapentaplegic homolog 4), 
that drive progression towards PDAC34. Mutations in TP53, a key protein involved in 
the cellular stress response, and SMAD4, a gene mediating signalling downstream of 
transforming growth factor β (TGFβ), occur in greater than 50% of cases35. In 
addition to these four driver gene mutations, recent data from whole exome and 
whole genome sequencing on expansive sets of patient derived tumour samples have 
revealed a large number of additional, less frequent gene mutations, exposing the 
complex mutational landscape underlying pancreatic tumourogenesis32,35,36. These 
studies have greatly increased our understanding of additional genetic alterations 
underlying tumourogenesis in pancreatic cancer and furthermore have identified 
subtypes of pancreatic cancer. These subtypes are categorised based on mutational 
signatures, accompanying histological changes and differences in patient survival, 
inferring distinctive mechanisms underpinning molecular evolution. The four 
proposed subtypes are: 1) squamous, with increased levels of TP53 and KDM6A 
(Lysine-specific demethylase 6A) mutations, up-regulation of the TP63∆N 
transcriptional network and down-regulation of pancreatic endodermal cell-fate 
determining genes resulting in loss of endodermal identity; 2) the pancreatic 
progenitor or classical PDAC subtype which expresses early pancreatic development 
genes (i.e., PDX1, FOXA2/3, MNX1); 3) aberrantly differentiated endocrine/exocrine 
(ADEX) tumours, which overexpresses genes involved in KRAS activation and those 
in later stages of pancreatic development such as exocrine (NR5A, RBPJL) and 
endocrine (NEUROD1, NKX2-2) markers; and 4) immunogenic PDAC. 
Immunogenic PDAC has molecular resemblances to the progenitor/ classical PDAC 
subtype but also contains over-expressed genes associated with infiltration of 
immune cells. For example increased expression of genes associated with CD4+ T-
cells, CD8+ T-cells and immune network pathways including those associated with 
acquired immune suppression and immune evasion such as up-regulation of the 
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immune checkpoint molecules CTLA4 and PD-136. Categorising patients into these 
subtypes may be of clinical relevance. For example, patients with the immunogenic 
PDAC subtype may represent suitable patients for immunotherapy and therefore 




Figure 1.1 Histological progression from normal epithelium through pancreatic intraepithelial 
neoplasia (PanIN 1, 2 and 3) and to pancreatic adenocarcinoma.  
Images of histological progression depict increasing cell dysplasia, nuclear abnormalities and local 
invasion. KRAS mutations increase in frequency as the disease progresses, as does frequency of other 
mutations such as, but not limited to, TP53 tumour-suppressor gene mutations. KRAS mutations are 
generally found in early stage disease whereas TP53 mutations arise in later stages. Cells derived in 
this study are derived from LSL-KrasG12D/+;LSL-Trp53R172H/+ pancreatic cancer cells at the 
adenocarcinoma stage.  
 
 
1.1.3 The pancreatic tumour microenvironment  
 
Components of the tumour microenvironment (TME) are now known to be key 
factors in tumour growth and development. Cancer cells themselves are instigators of 
the disease and the driving force behind tumourogenesis, but the cancer cell’s ability 
to manipulate the surrounding TME components is crucial to tumour survival37,38.  
A highly fibrotic and immunosuppressive TME is characteristic of PDAC and 
occupies the majority of the tumour mass39–41. This pronounced stromal compartment 
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EGFR alleles27,30,31. Many pathways are likely to con-
tribute to the pathogenic role of activated KRAS, and a
deeper understanding of this oncogenic programme will
be vital for the development of new treatment
approaches towards this disease.
CDKN2A. Germline mutations in the CDKN2A
tumour-suppressor gene are associated with the familial
atypical mole-malignant melanoma (FAMMM) syn-
drome. In addition to a very high incidence of
melanoma, the inheritance of mutant CDKN2A alleles
co fers a 13-fold increased risk of pancreatic cancer32,33.
Although pancreatic adenocarcinoma arises in some,but
not all, FAMMM kindreds with CDKN2A mutations,
there are no clear genotype–phenotype associations,
indicating a modulating role for environmental factors
in disease penetrance34,35. FAMMM kindreds that har-
bour mutant loci other than CDKN2A, such as cyclin-
dependent kinase 4 (CDK4) alleles that abrogate INK4A
binding or other uncharacterized loci, do not have
increased incidence of pancreatic adenocarcinoma33,36.
Loss of CDKN2A function — brought about by
mutation, deletion or promoter hypermethylation —
also occurs in 80–95% of sporadic pancreatic adenocar-
cinomas21. CDKN2A loss is generally seen in moderately
advanced lesions that show features of dysplasia (FIG. 2).
The dissection of the role of CDKN2A has been a fasci-
nating story as this tumour-suppressor locus, at 9q21,
encodes two tumour suppressors — INK4A and ARF
— via distinct first exons and alternative reading frames
found in nearly 100% of pancreatic adenocarcinomas;
they seem to be a virtual rite of passage for this malig-
nancy21.WAF1 (also known as p21 and CIP1) seems to
be coordinately induced with the onset of KRAS muta-
tions,perhaps due to activation of the mitogen-activated
protein kinase (MAPK) PATHWAY22.
Activating mutations of RAS-family oncogenes pro-
duce a remarkable array of cellular effects, including
induction of proliferation, survival and invasion through
the stimulation of several effector pathways (reviewed in
REF. 23). Although the roles of specific KRAS effector
pathways in pancreatic cancer patho enesis have not
been resolved, there is evidence for an important contri-
bution of AUTOCRINE epidermal growth-factor (EGF)-
family signalling24–27,31.This autocrine loop and resulting
stimulation of the phosphatidylinositol 3-kinase (PI3K)
PATHWAY is required for transformation of several cell lin-
eages by RAS-family oncogenes28. Consistent with the
existence of such an autocrine loop, pancreatic adeno-
carcinomas overexpress EGF-family ligands (such as
transforming growth factor-a (TGF-a) and EGF) and
receptors (EGFR, ERBB2 (also known as HER2/neu)
and ERBB3)24,26,28. EGFR and ERBB2 induction occurs
in low-grade PanINs, indicating that autocrine EGF-
family signalling might be operative at the earliest stages
of pancreatic neoplasia29. The functional importance of
this pathway is illustrated by the growth inhibition of
pancreatic adenocarcinoma cell lines in vitro and in
xenografts following attenuation of EGFR signalling by
blocking antibodies or expression of dominant-negative
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Fi ure 2 | Genetic progression model of pancreatic adenocarcinoma. Pancreatic intraepithelial neoplasias (P nINs) eem to
represent progressive s ges of neoplastic growth that ar  precur ors to pancreatic adenocarcinomas. The genetic alterations
documented in adenocarcinomas also occur in PanIN in what seems to be a temporal sequence, although these alterations have
not been correlated with the acquisition of specific histopathological features. The stage of onset of these lesions is depicted. The
thickness of the line corresponds to the frequency of a lesion. The temporal alterations in telomerase activity and telomere length are
by inference from REFS 62,139 and need further substantiation in PanIN. Normal duct, PanIN-1A/PanIN-1B and PanIN-3 images
reproduced with permission from REF. 14 (2001) Lippincott Williams & Wilkins; PanIN-2 and adenocarcinoma images kindly provided
by Dr Ralph Hruban, Johns Hopkins University (http://pathology.jhu.adu/pancreas/panin/).
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Figure 2 | Genetic progression model of pancreatic adenocarcinoma. Pancreatic intraepithelial neoplasias (PanINs) seem to
represent progressive stages of neoplastic growth that are precursors to pancreatic adenocarcinomas. The genetic alterations
documented in adenocarcinomas also occur in PanIN in what seems to be a temporal sequence, although these alterations have
not been correlated with the acquisition of specific histopathological features. The stage of onset of these lesions is depicted. The
thickness of the line corresponds to the frequency of a lesion. The temporal alterations in telomerase activity and telomere length are
by inference from REFS 62,139 and need further substantiation in PanIN. Normal duct, PanIN-1A/PanIN-1B and PanIN-3 images
reproduced with permission from REF. 14 (2001) Lippincott Williams & Wilkins; PanIN-2 and adenocarcinoma images kindly provided
by Dr R lph Hruban, Johns Hopkins University (http://pathology.jhu.adu/pancreas/panin/).
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Figure 2 | Genetic progression model of pancreatic adenocarcinoma. Pancreatic intraepithelial neoplasias (PanINs) seem to
represent progressive stages of neoplastic growth that are precursors to pancreatic adenocarcinomas. The genetic alterations
documented in adenocarcinomas also occur in PanIN in what seems to be a temporal sequence, although these alterations have
not been correlated with the acquisition of specific histopathological features. The stage of onset of these lesions is depicted. The
thickness of the line corresponds to the frequency of a lesion. The temporal alterations in telomerase activity and telomere length are
by inference from REFS 62,139 and need further substantiation in PanIN. Normal duct, PanIN-1A/PanIN-1B and PanIN-3 images
reproduced with permission from REF. 14 (2001) Lippincott Williams & Wilkins; PanIN-2 and adenocarcinoma images kindly provided
by Dr Ralph Hr ban, Johns Hopkins University (http://pathology.jh .adu/ ancreas/panin/).
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Figure 2 | Genetic progression model of pancreatic adenocarcinoma. Pancr atic intra pithelial ne plasias (PanINs) seem to
represent progressive stages of neoplastic growt  that are precursors to pancreatic adenocarcinom s. The genetic alterations
docum nted in adenocarcinomas also occur in PanIN in what seems to be a temporal equenc , although these alterations have
not been correlated with the acquisiti n of specific histopathological f atu es. The stage of onset of these lesions is depicted. The
thickness of the line corresponds to the frequency of a lesion. The temporal alterations in telomerase activity and telomere length are
by inference from REFS 62,139 and need further substantiation in PanIN. Normal duct, PanIN-1A/PanIN-1B and PanIN-3 images
reproduced with permission from REF. 14 (2001) Lippincott Williams & Wilkins; PanIN-2 and adenocarcinoma images kindly provided
by Dr Ralph Hruban, Johns H pkins University (http: /pathol gy.jhu.adu/pancreas/p nin/).
Adapted	from	Bardeesy,	N.,	&	DePinho,	R.	A.	(2002).	Pancrea c	cancer	biology	and	gene cs.	Nature	
Reviews.	Cancer,	2(12)	
NORMAL	DUCT	 PanIN	1	 PanIN	2	 PanIN	3	 ADENOCARCINOMA	
  INTRODUCTION 
 7 
(figure 1.2) is comprised of cellular and acellular elements: immune cells, 
fibroblasts, myofibroblasts, pancreatic stellate cells, endothelial cells, extracellular 
matrix (ECM) and soluble proteins such as cytokines and growth factors. The 
pancreatic tumour stroma is thought to play a major part in poor treatment response 
and resistance to therapy42 through supporting tumour growth and metastasis and 








1.1.3.1 Immune cells within the pancreatic TME 
It is becoming increasingly apparent that inflammatory cells within the TME are 
recruited to help rather than hinder tumour cell growth46,47. Cancer cell ability to 
hijack the TME immune cell compartment in order to escape the immune response is 
now recognised as one of the key hallmarks of cancer37. Immune cell types within 
the pancreatic TME are mainly of the immunosuppressive type and include: 
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and low numbers of CD8+ T-cells48,49. The presence of immunosuppressive cell types 
from the earliest of PanIN lesions which increase in frequency through progression 
to carcinoma is suggestive of the importance of such cell types in progression of this 
tumour from the earliest stages50.  
1.1.3.1.1 Tumour associated macrophages in PDAC 
Macrophages are mononuclear phagocytes playing a central role in tissue 
homeostasis and immunity. Under normal inflammatory conditions, monocytes 
localise to sites of inflammation in tissues, after which they are termed macrophages 
and act to fight infection or mediate wound healing through release of growth factors 
and cytokines51. The most abundant inflammatory cell type in the majority of solid 
tumours are macrophages and can contribute up to 50% of the total tumour mass47,52. 
PDAC is an example of one of these tumour types and is very heavily infiltrated by 
tumour associated macrophages (TAMs)53. TAMs are comprised of two major 
macrophage subtypes: resident and inflammatory macrophages54. In PDAC these are 
largely derived from embryonic and bone marrow derived (BMD) sources 
respectively55,56. Macrophages are highly plastic cells and can be polarised to 
opposing phenotypes: M1 (classical) and M2 (alternative). Classical activation 
occurs in response to T-helper 1 (TH1) cytokines, for example interferon γ (IFNγ) 
and Toll-like receptor (TLR)-ligands such as lipopolysacharide (LPS). In infectious 
disease, macrophages are activated to the M1 phenotype to fight intracellular 
pathogens, and in cancer drive an anti-tumour response57 by secreting tumouricidal 
factors such as tumour necrosis factor α (TNF-α), interleukin-12 (IL12) and reactive 
oxygen intermediates (ROI)42. M1 macrophages can be identified in various ways 
such as expression of ‘M1 genes’: IL12b, Ciita (Class II Major Histocompatibility 
Complex Transactivator) and Nos2 (nitric oxide synthase)54,58 and increased 
expression of CD86 and major histocompatibility complex class II  (MHC-II)59. In 
contrast, alternative macrophage activation to the M2 phenotype occurs in response 
to TH2 cytokines
60. TH2 derived IL4, in addition to Treg derived IL10 is linked to the 
induction of pro-tumour macrophage polarisation. It is also thought that TH2 derived 
IL13 may have an overlapping role with IL4 as both their resultant signalling 
cascades lead to signal transduction and transcription (STAT) 6 transcription61. TH2 
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cells then release immunosuppressive cytokines such as IL10, IL6 and TGF-β62 into 
the TME.  
M2 macrophages promote wound healing through activation of fibroblasts, 
angiogenesis, matrix remodelling and reducing inflammation60,63. These mechanisms 
support tumour growth in the context of cancer, hence M2 macrophages are regarded 
as having a pro-tumour phenotype. M2 macrophages can be identified by increased 
expression of ‘M2 genes’ such as MMR (macrophage mannose receptor, also known 
as CD206), Tie2 (Tyrosine-protein kinase receptor Tie-2), Arg1 (arginase 1) and 
Retnla (Resistin-like molecule alpha) and have increased surface expression of the 
mannose receptor (MMR/CD206), reduced CD86 expression, reduced MHC-II 
expression59 and are therefore poor antigen presenters. M2 macrophages also express 
immune checkpoint ligands such as programmed death ligand-1 and 2 (PD-L1 and 
PD-L2)60 which bind to the programmed cell death-1 (PD-1) receptor on the surface 
of CD8+ T-cells, inhibiting T-cell function through T-cell anergy or death. In 
pancreatic cancer, the majority of TAMs are of the M2 phenotype60,64 and a higher 
M2:M1 ratio is associated with poorer survival48. Additionally, peripheral 
accumulation of M2 macrophages in PDAC is associated with increased tumour size, 
earlier lymphatic metastasis, earlier post-surgical local recurrence and ultimately a 
poorer prognosis65,66. Partecke et al show that culture media from pancreatic cancer 
cells growing in-vitro can polarise macrophages to the M2 phenotype and that 
culture supernatants from M2 macrophages induce a significant increase in 
pancreatic cancer cell growth64. There is also evidence that other cells in the TME 
may be involved in macrophage polarisation. In cancer, T-cell derived IL4 in 
addition to tumour-cell derived colony-stimulating factor-1 (CSF-1) has been shown 
to elicit a switch from the M1 to the M2 phenotype as part of an immune evasion 
strategy67. It is therefore becoming increasingly evident that TAMs promote PDAC 
tumourogenesis and growth through a variety of mechanism and are thus a critical 
component of the PDAC TME.  
1.1.3.1.2 Myeloid derived suppressor cells  
Myeloid derived suppressor cells (MDSCs) are a commonly expanded cell 
population in a variety of tumour types, including PDAC47. They originate from bone 
marrow myeloid progenitor cells and are undifferentiated, immature cells of the 
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myeloid lineage that include immature stages of macrophages, granulocytes and 
dendritic cells (DCs)60,68,69. Like macrophages, they show phenotypic plasticity. This 
phenotypic regulation is dependent on signals received from cancer cells and the 
tumour stroma70. There are two main phenotypes: polymorphonuclear MDSCs, 
sometimes known as granulocytic MDSCs (G-MDSCs), and monocytic MDSCs (M-
MDSCs)70,71. In mice these can be identified as CD11b+Ly6G+Ly6Clo, and 
CD11b+Ly6G−Ly6Chi respectively71. Differentiating G-MDSCs from subpopulations 
of neutrophils is contentious and currently lacks clear definition. Therefore for 
simplicity, this group will be referred to as G-MDSCs hereafter72. 
In humans, MDSCs are not only increased in the pancreatic TME but also in the 
circulation, which correlates with clinical stage and circulating Treg levels73,74. In 
addition to circulating in the blood, MDSCs are also frequently detected in the bone 
marrow and spleen of pancreatic cancer patients, raising the possibility that they are 
expanded systemically before being recruited to the tumour47.  
There is growing evidence that after MDSCs are recruited and activated by tumour-
cell and stromal derived signals, they then in turn directly support tumour 
progression, neovascularization, metastasis, and are a major source of 
immunosuppression within the TME. Genetic deletion or inhibition of CXCR2, a 
receptor shown to be up-regulated on neutrophils/MDSCs in human pancreatic 
cancer have been shown to reduce metastasis in in-vivo models75. Studies utilising 
the KPC mouse model of pancreatic cancer have shown that cancer cell derived GM-
CSF is a key cytokine in the development and recruitment of MDSCs that promote 
pancreatic tumour growth by suppression of cytotoxic CD8+ T-cell activation50,76. 
Additionally, treatment of mice with GM-CSF depleting antibody to selectively 
inhibit GM-CSF, reduced pancreatic tumour development76.  
MDSCs inhibit cytotoxic T-cell activity to support tumour growth in a number of 
ways60: 1) they produce large quantities of arginase and sequester cysteine, thereby 
reducing availability of L-arginine and cysteine to T-cells within the TME, thus 
hampering T-cell protein synthesis and proliferation, 2) production of reactive 
oxygen species (ROS) leading to apoptosis of T-cells and NK cells, 3) production of 
immunosuppressive cytokines including IL10 and TGF-β which inhibits CD8+ T-cell 
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function, 4) down-regulation of L-selectin on CD4+ and CD8+ T-cells thus reducing 
T-cell homing and 5) up-regulation of immune checkpoint PD-L1 which binds to T-
cell PD-1 receptor to down regulate T-cell activity. Notably, MDSCs isolated from 
pancreatic cancer patients were found to express high levels of PD-L1 causing 
significant inhibition of T-cell proliferation in-vitro77. There is therefore a wealth of 
evidence confirming MDSCs as major contributors to the immunosuppressive 
pancreatic TME.  
1.1.3.1.3  Tumour infiltrating lymphocytes 
Tumour infiltrating lymphocytes (TILs) are critical components of the TME in 
cancer and have a variety of contrasting functions. TILs form part of the adaptive 
immune response, becoming activated after antigen exposure. There are two main 
TIL classes: cytotoxic CD8+ T-cells forming part of the tumour-specific cellular 
adaptive immunity and CD4+ T-helper (TH) cells.  
 
Activated CD8+ T-cells are the main cytotoxic effector cell type within the TME, 
attacking tumour cells that present tumour-associated peptides via MHC class I on 
their surface. CD8+ T-cells can directly eliminate tumour cells via secretion of 
effector cytokines IFN-γ and tumour necrosis factor (TNF)-α, localised release of 
cytotoxins such as perforin, and granzyme B, and indirectly by induction of 
macrophage tumouricidal activity78. However in PDAC, cancer cells frequently 
down-regulate or lose MHC class I expression thereby preventing attack from CD8+ 
T-cells79 and also express PD-L180 inducing T-cell anergy or death via PD-1. 
Additionally TGF-β derived from pancreatic cancer cells and other sources within 
the TME inhibits CD8+ T-cells from expressing effector cytotoxins60,79. CD8+ T-cells 
heavily infiltrate early PanINs but their numbers diminish through progression to 
carcinoma81. CD8+ T-cell infiltration is very poor in PDAC and correlates with 
prognosis48,82,83. Activated pancreatic stellate cells (PSCs) have been shown to 
produce the chemokine CXCL (C-X-C motif ligand) 2, mediating CD8+ T-cell 
sequestration, thus preventing CD8+ T-cell contact with malignant epithelial cells in 
the juxtatumoral compartment84. Other immunosuppressive cell types such as 
MDSCs, Tregs and certain CD4+ T-helper cell subsets also suppress cytotoxic CD8+ 
T-cells through various effector cytokine production47. 
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CD4+ T-helper cells can be subdivided based on the cytokine profile they secrete85,86: 
TH1 cells producing IFN-γ, TH2 cells producing IL4, IL5 and IL13, TH17 cells 
producing IL17, and immunosuppressive Tregs secreting TGF-β87. There are also 
more recently described subsets of CD4+ T helper cells such as TH9, TH22, and T-
follicular helper (TFH) cells
88
. CD4+ T-cell differentiation is determined by exposure 
to particular chemokines and cytokines they encounter in the TME.  IFN-γ, IL12 
mediate TH1 differentiation through activation of transcription factor T-Bet
89, STAT  
(signal transducer and activator of transcription)1 and STAT490. In most human 
cancer types including pancreatic cancer47, TH1 cells augment the anti-tumour 
immune response through enhancing M1 macrophage activity, CD8+ T-cell mediated 
killing and through recruitment of inflammatory cells to the tumour site91. IL4, IL2 
and IL33 induce TH2 differentiation through activation of GATA-3. IL6 is also 
thought to determine TH1/ TH2 fate through induction of Nuclear Factor of Activated 
T-cells (NFAT)c2 expression and STAT3 dependent up-regulation92,93 of the specific 
TH2 transcription factor c-maf (V-maf musculoaponeurotic fibrosarcoma oncogene 
homolog)92,94. A second mechanism of IL6 regulatory control of the TH1/ TH2 
balance towards TH2 is mediated through up-regulation of Silencer of Cytokine 
Signalling (SOCS)1 expression, leading to reduced IFNγ expression and loss of 
positive feedback through IFNγ signalling95. As a consequence, CD4+ T-cells 
become unresponsive to IFNγ signalling, and display reduced TH1 differentiation. 
More recent evidence has shown that IL6 inhibition in various murine cancer models 
increases TH1 differentiation
92,96–98. Specifically in a murine model of pancreatic 
cancer, IL6 inhibition by use of a neutralising antibody, in addition to PD-L1 
inhibition, led to an increase in TH1 differentiation, reduced tumour progression and 
increased infiltration of effector CD8+ T-cells into the tumour98. Thus a potential 
mechanism for impaired TH1 responses and an increased immunosuppressive TH2 
response in tumour bearing hosts may be linked to an increase in IL6. The pancreatic 
TME has been reported to have a higher frequency of TH2 cells when compared to 
TH1 and this infiltration correlates with reduced survival in pancreatic cancer 
patients99. Thus, the GATA3:Tbet ratio in post-surgical samples has been suggested 
as an independent predictive survival marker in PDAC patients47. TH2 cells facilitate 
pancreatic tumour growth through various mechanisms. For example, secretion of 
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IL13 and IL5 by TH2 cells is thought to drive collagen synthesis and deposition
100, 
contributing to the highly fibrotic stroma observed in PDAC. Importantly, cytokines 
released by TH2 cells induce M2 macrophage polarisation, further inducing an 
immunosuppressive, pro-tumour TME47. 
 
TH17 cells are another T-helper subset found in the pancreatic TME. IL6 and TGF-β 
are known as the critical cytokines in RORγt induction in naive CD4+ T-cells, in 
turn driving differentiation to the TH17 phenotype. Maintenance of this phenotype 
also requires IL21 and IL23101. The main effector cytokine that TH17 cells secrete 
is IL17, but they can also secrete IL21 IL22, and CCL20102. TH17 cells have been 
identified in a number of human cancers including pancreatic, ovarian103, 
gastric104, renal cell carcinoma105 and prostate cancers106. The role of these cells in 
cancer is controversial, having found to be both anti-107–110 or pro-tumourigenic111 
in different contexts102. Like many immune cell subsets, TH17 cells exhibit a 
certain degree of plasticity; exposure to IL12 induces differentiation into IFNγ 
producing TH1 cells, augmenting the action of CD8
+ T-cells102. In contrast, cancer 
cell derived TGF-β can induce TH17 cells to become regulatory and promote host 
tolerance112. In mouse models of pancreatic cancer, TH17 cells have been shown to 
both promote113 and inhibit114 pancreatic cancer progression. However in human 
pancreatic cancer, TH17 cells and IL17 secretion is associated with increased clinical 
stage and a poorer prognosis108,115,116. 
Regulatory T-cells (Tregs) are highly immunosuppressive cells characterised by the 
expression of the transcription factor forkhead box P3 (FoxP3+) and secretion of 
IL10 and TGF-β. Physiologically Tregs suppress unwanted autoimmune reactions, a 
function exploited by cancer cells. In addition to driving expression of 
immunosuppressive cytokines, FoxP3 also suppresses expression of the 
inflammatory cytokines TNF-α, IFNγ, IL17 and IL4, and promotes expression of 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), indoleamine 2,3-
dioxygenase (IDO), CD39 and CD73117,118. Expression of CTLA-4 by Tregs results 
in the down-regulation of CD80 and CD86 expression on DCs through trans-
endocytosis and subsequent degradation, thereby depleting the co-stimulatory signal 
required for T-cell activation119. IDO is a protein that functions as part of the 
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kynurenine pathway that catabolizes tryptophan to kynurenines, leading to a 
reduction in the availability of this essential amino acid for effector T-cells including 
cytotoxic T-cells, helper T-cells, and natural killer (NK) cells, resulting in arrest of 
their cell cycle and apoptosis118,120–122. Ectoenzymes CD39 and CD73 expressed on 
the cell surface hydrolyse extracellular ATP and ADP to adenosine. Reduced 
environmental availability results in local inhibition of effector T-cell proliferation 
and reduced DC function123,124. Mechanisms such as these result in repression of M2 
TAMs, NK cells, DCs and tumour-specific CD4+ and CD8+ T-cells to promote 
tumour progression60. Tregs numbers are increased in PDAC compared with normal 
pancreatic tissue and this increase is a negative prognostic factor48. They can be 
identified from early PanIN lesions and infiltration increases through carcinogenesis 
whilst inversely correlating with CD8+ T-cell infiltration81,125,126. 
1.1.3.1.4  Dendritic cells  
Dendritic cells (DCs) are ‘professional’ antigen presenting cells (APCs) that are 
essential for the adaptive immune response127. They prime an adaptive immune 
response by engulfing tumour material, proteolytically degrading proteins to generate 
peptide antigens, and presenting these peptide antigens to CD4+ and CD8+ T-cells 
using both MHC class I and II molecules respectively. DCs can also activate NK 
cells leading to potent cytotoxic responses in cancer128. DCs are derived from the 
bone marrow and can exist in mature and immature forms within the TME127,129. In 
PDAC, the presence of increased circulating DCs and DCs within the tumour 
microenvironment are associated with prolonged survival. However DCs infiltrate 
the PDAC TME in low numbers and often exhibit maturation defects or impaired 
function130–132. It is thought that cancer cell derived IL6, vascular endothelial growth 
factor (VEGF), macrophage colony stimulating factor (M-CSF) and also the hypoxic 
cancer TME leads to this impaired maturation and function47. More recently 
immunosuppressive DC subsets supporting Tregs and suppressing CD8+ T-cells have 
been identified in PDAC133.  
1.1.3.1.5  Natural killer cells  
Natural killer (NK) cells form part of the first line, innate immune response134, 
exerting their toxic effects through release of perforin and granzyme-mediated 
effects and through activation of the caspase pathway135. Increased circulating NK 
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cells are associated with a better prognosis in pancreatic cancer patients136. However 
typically low numbers of activated NK cells are found within the PDAC TME with 
reduced expression of activating receptors such as NKG2D (natural-killer group 2, 
member D) receptor79,137. 
1.1.3.2  The fibrotic TME in PDAC 
The desmoplastic reaction surrounding pancreatic cancer cells is extensive, 
accounting for a large proportion of the tumour mass. In addition to the infiltrating 
immune cells, this desmoplastic stroma is composed of blood vessels and large 
amounts of extra-cellular matrix (ECM), principally laid down by cancer-associated 
fibroblasts (CAFs)138. As with the immune cell compartment of the PDAC TME, 
there is a large amount of cross talk between cancer cells and the cellular and non-
cellular components of this desmoplastic stroma. Through this cross talk, cancer cells 
enable expansion of the desmoplastic reaction, which in turn supports and promotes 
cancer cell proliferation and tumour progression. 
 
1.1.3.2.1 Cancer associated fibroblasts 
Cancer-associated fibroblasts (CAFs) are the main effector cells establishing the 
desmoplastic reaction138. Pancreatic stellate cells (PaSCs) are the most important 
source of CAFs, the other being recruited from bone marrow stem cells139. Quiescent 
PaSCs are present in the normal pancreas in low numbers and contain large numbers 
of cytoplasmic lipid droplets that are high in vitamin A; these are lost once PaSCs 
become activated under inflammatory conditions. Other morphological changes 
occur upon activation such as taking on an α-smooth muscle actin (α-SMA) 
expressing myofibroblast phenotype, in addition to loss of fat droplets and increased 
proliferation39,140. CAFs derived from these PaSCs play a central role in orchestrating 
the fibrotic reaction in PDAC. They are responsible for laying down large amounts 
of ECM proteins including collagen I, III, XI, and fibronectin, and can remodel the 
ECM through expressing matrix metalloproteases (MMPs). Furthermore, they also 
produce multiple growth factors and cytokines such as platelet derived growth factor 
(PDGF), fibroblast growth factor: (FGF), TGFβ, IL-1β, IL8, VEGF and 
CXCL1243,141–143, all which have shown to promote cancer progression and/or 
promote the desmoplastic reaction. Therefore, CAFs play a central role in 
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orchestrating the characteristic desmoplastic reaction that is a feature of PDAC, and 
contributes to immune suppression within the TME. The relationship between CAFs 
and pancreatic cancer cells is further supported by in-vitro studies utilising co-culture 
methods demonstrating cross talk between CAFs and pancreatic tumour cells, both 
enhancing the proliferation of the other44,144,145. However, there is controversy in the 
literature regarding the role of this fibrotic reaction in-vivo. Several studies have 
shown that the stromal reaction creates a barrier to delivery of chemotherapeutics, 
thus provides protection from cancer treatment strategies such as chemotherapy, 
immunotherapy and also radiotherapy146. On the other hand, several mouse model 
studies have shown that depletion of this fibrous reaction alone leads to a more 
aggressive cancer phenotype147,148. Through production of VEGF in response to 
hypoxia and inflammation, CAFs are also intimately linked to the angiogenic 
response in PDAC, which will be discussed in more detail in the next section. 
1.1.3.2.2 Endothelial cells   
In many cancers, including PDAC, the supply of oxygen, nutrients and growth 
factors increases as the tumour progresses. Angiogenesis is the creation of new blood 
vessels and vascular networks from pre-existing vasculature, enabling increased 
supply of these resources to enable accelerated tumour growth149. This process 
requires molecular communication between the cancer cells and surrounding stroma 
via chemokines and cytokines to facilitate this process. The key mediator of this 
process is VEGF, a growth factor produced by pancreatic cancer cells, TAMs, CAFs 
and endothelial cells, levels of which are a negative prognostic marker in human 
PDAC147. Angiogenesis can be driven by hypoxia; direct intra-tumoral oxygenation 
measurements have revealed that the PDAC tumours are significantly hypoxic150. 
Under hypoxic conditions CAFs up-regulate hypoxia-inducible factors151,152, 
collagen I and VEGF153,154. However the resultant blood vessels are often 
morphologically abnormal and characterised by disordered branching and increased 
permeability, leading to poor perfusion and further contributing to the hypoxic 
environment155. This is evident in PDAC as there exists a poorly functional vascular 
supply within the tumour45 contributing to  therapy resistance by reducing delivery 
of cytotoxic agents and through selecting for slow-cycling, highly drug-resistant 
cancer cells39. 
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1.1.3.3     Cytokines in the PDAC TME 
Pancreatic cancer cells orchestrate the composition of their surrounding TME to 
promote tumour progression and to maintain an immunosuppressive environment in 
order to protect themselves from immune-mediated destruction. Communication 
between the neoplastic epithelial cells and the cells comprising the tumour stroma is 
mediated through autocrine and paracrine signalling pathways involving a wide 
variety of cytokines and chemokines to modulate the TME and promote pancreatic 
tumour progression156. In addition to cytokines, cancer cells communicate to the 
surrounding stroma via direct interactions between cancer cells and ECM 
components via cell surface receptors such as integrins signalling via focal adhesion 
complexes157. Multiple studies exist implicating cytokines and chemokines in cancer 
and a variety of other pathologies. In PDAC, increased circulating levels of several 
cytokines, including IL6, IL1-β, IL10 and TGF-β have been shown to promote 
tumour progression by modulating the TME, and higher circulating levels of these 
are generally associated with poorer clinical outcomes156,158. The primary tumour site 
is thought to be the source of elevated cytokine production; Bellone et al. observed 
m-RNA over-expression of several cytokines, such as IL6, IL8, IL-1β, IL10, and 
TGF-β from patient primary tumour site which correlated with higher circulating 
levels and reduced patient survival159. I will now discuss the role of some of these 
cytokines in PDAC in more detail. 
1.1.3.3.1 Interleukin-6 (IL6) 
Interleukin-6 (IL6) is an important pro-inflammatory cytokine, mediating 
inflammatory responses to infection and injury whilst also regulating cell 
proliferation and differentiation. Increased levels of IL6 are associated with several 
auto-immune diseases160 and various cancers161 via regulation of immune cell 
balance. High levels of IL6 together with TGF-β induces the development of Th17 
cells from naive CD4+ T-cells, and inhibits TGF-β induced differentiation162. 
Additionally it can regulate the TH1/TH2 balance in favour of TH2 polarisation
92–94,96–
98. 
Increased IL6 levels have been reported in a number of cancers, including breast163, 
prostate164, endometrial165, renal cell carcinoma166, oral squamous cell carcinoma 
(SCC)167, multiple myeloma168, colorectal cancer169 and pancreatic cancer170. Plasma 
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levels of IL6 have a highly inverse relationship with patient survival in patients with 
metastatic or untreatable PDAC171.  
IL6 engagement with the membrane bound IL6 receptor (IL6Rα) or the soluble form 
of the IL6R (sIL6R) leads to engagement of the common signal transducing receptor 
chain GP130 (glycoprotein 130)172, initiating downstream activation of JAK/STAT 
(Janus kinases/ Signal transducer and Activator of Transcription proteins), MAPK 
(mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase) 
pathways173,174. These pathways are involved in cell proliferation, survival and 
immune evasion in cancer. For example, IL6 induced STAT3 signalling directs 
myeloid cells to express immune-suppressive molecules such as arginase and 
VEGF175,176 whilst also being associated with increased differentiation of 
macrophages to the pro-tumour M2 macrophage phenotype176. Additionally IL6 can 
decrease DC MHC-II, CD80/86 and IL12 expression177 and can re-program DC 
differentiation to regulatory IL10 producing DCs178. This therefore reduces the DCs 
ability to activate TH1 cells and cytotoxic T-cells, thus further contributing to the 
immunosuppressive TME. IL6 induced STAT3 activation is relevant to clinical 
outcome in PDAC; activation of the IL6Rα-JAK-STAT3 pathway in surgically 
resected PDAC is associated with reduced survival179 and studies have shown 
STAT3 is critical in the early initiation180 and progression93,181 in KRAS driven 
murine models of PDAC. Additionally, when the aggressive KRAS driven PDAC 
murine model iKras*, created using three genetically modified mouse strains to 
generate triple transgenic p48-Cre;R26-rtTa-IRES-EGFP;TetO-KrasG12D mice, were 
crossed with IL6 -/- mice, PDAC progression is completely arrested182. 
There are a variety of cellular sources of IL6 in the PDAC TME including 
macrophages93, fibroblasts and epithelial cells182 and malignant epithelial cells such 
as PDAC cells, which are thought to be a major source of IL6 within the TME. IL6 is 
secreted by a number of PDAC cell lines170 and PDAC cancer cell derived IL6 has 
been shown to activate STAT3 in an autocrine fashion181. IL6 specifically secreted 
by cancer cells has also been shown to alter the TIL balance in-vivo with subsequent 
influence on tumour growth114,183. Additionally, Bellone el al demonstrated that 
pancreatic cancer cell derived IL6 acted together with IL10 and TGF-β to reduce 
activation and proliferation of dendritic cells (DCs), resulting in a reduced anti-
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tumour response184. Conversely however, Gnerlich et al. observed overexpression of 
IL6 in cancer cells derived from a TGF-β secreting murine model of pancreatic 
cancer skewed the balance from a Treg to a TH17 predominant environment, with a 
resultant delay in tumour growth and improved survival times. Therefore, though 
some controversy exists regarding the exact role of IL6 in PDAC, cancer cell derived 
IL6 is considered to play a crucial role. 
The growing body of evidence identifying IL6 as an important player in PDAC 
progression has ignited interest in the development of drugs targeting either IL6 itself 
or the IL6Rα-JAK-STAT3 pathway. It is thought that inhibiting IL6 will reprogram 
the TME to render it more responsive to immunotherapy regimens. In support of this 
hypothesis, a phase II clinical trial of the JAK 2 inhibitor ruxolitinib reported 
improved survival in pancreatic cancer patients with metastatic disease185. A phase II 
clinical trial is also underway in the USA aimed at evaluating the anti-tumour 
efficacy of the IL6 receptor antibody inhibitor tocilizumab in patients with 
unresectable pancreatic cancer (clinical trials.gov NCT02767557), however, the 
outcome has not been reported at this time. 
1.1.3.3.2 Interleukin-1-beta (IL1-β) 
Interleukin-1-beta (IL1-β) is another pro-inflammatory cytokine that like IL6, plays a 
role in both inflammatory disease186 and is implicated in the progression of 
pancreatic cancer. IL1-β has a reported role in regulating PDAC invasion and 
metastasis187,188. Inhibition of IL1-β results in a reduction in pancreatic tumour size 
and tumour related inflammation189. Acting primarily through nuclear factor κB (NF-
κB), IL1-β can also contribute to chemoresistance in pancreatic cancer190. Therefore, 
IL1-β can impact PDAC progression in multiple ways. 
1.1.3.3.3 Interleukin-10 (IL10) 
Interleukin-10 (IL10) is an anti-inflammatory cytokine. Acting through JAK-STAT 
signalling pathways, this cytokine prevents excessive tissue damage during 
infection191. Several studies have identified high levels of IL10 expression in PDAC, 
and levels correlate with worse overall survival and increasing tumour stage159,192. It 
is thought that IL10 can influence the inflammatory cell population within the TME. 
For example, IL10 has been found to reduce activation of natural killer (NK) cells 
and DCs184,193, and it can shift T-cell cytokine production from that of a TH1 
  INTRODUCTION 
 20 
phenotype to a more pro-tumour TH2 type phenotype
184.  
1.1.3.3.4 CC chemokines 
Both CCL5/ Regulated Upon Activation Normal T-Cell Expressed and Presumed 
Secreted (RANTES)194 and CCL2/MCP-1, (monocyte chemoattractant protein-1)195 
have been found to be important in PDAC. CCL5 is involved in PDAC immune 
evasion as it has been shown to recruit immunosuppressive CCR5 positive Tregs into 
the TME196. In a murine model of SCC FAK dependent regulation of CCL5 
expression in cancer cells led to elevated levels of Tregs in the TME and subsequent 
suppression of the anti-tumour CD8+ T-cell response197. 
1.1.3.3.5 CXC chemokines  
CXCR2/ interleukin-8 (IL8) is overexpressed in PDAC159 and negatively correlates 
with prognosis198. In PDAC, its main role is in angiogenesis through induction of 
VEGF199. However, it has also been shown that tumour cell derived CXCR2 can act 
in conjunction with fibroblast derived chemokine CXCL12 within the pancreatic 
TME to stimulate proliferation, migration and invasion of cancer cells200. Recently 
Jiang et al identified that levels of pancreatic cancer cell derived CXCL12 is 
modulated by FAK, and that this chemokine induced the proliferation of pancreatic 
fibroblasts cultured in-vitro, implying that CXCL12 may drive stromal fibroblast 
expansion in the pancreatic TME leading to excessive collagen deposition142. 
 
1.2 Immunotherapy  
The immune system is fundamental to the body’s defence against infectious disease 
and also elimination of cancerous cells. In recent decades, our understanding of the 
immune system and its intimate relationship with cancer has evolved; the interaction 
between immune cells and cancer cells results in either effective immunosurveillance 
or alternatively tumour growth and progression79. This knowledge has led to the 
development of cancer immunotherapy. The aim of cancer immunotherapy is to 
harness the power of the immune system, enabling recognition and eradication of 
tumour cells and generation of a long-lasting protective response201,202, whilst 
sparing normal healthy tissue.  
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Despite the remarkable success of cancer immunotherapy in the treatment of cancers 
including melanoma203 and non-small-cell-lung cancer204,205, no overall survival 
benefit has yet been demonstrated in clinical trials using single agent immunotherapy 
in PDAC patients206,207. However, immunotherapy is still regarded as an emerging 
therapeutic option in PDAC. As described in previous sections of this thesis, the 
PDAC TME is regarded as highly immunosuppressive. This represents both a 
significant obstacle to the success of immunotherapy, but also a potential therapeutic 
opportunity. An improved understanding of this uniquely fibrotic and 
immunosuppressive TME may have an important role to play in the future treatment 
of PDAC patients, by uncovering novel targets resulting in new approaches to cancer 
immunotherapy, or selection of more effective drug combinations targeting different 
aspects of the immunosuppressive TME208. A recent study by Jiang et al revealed 
encouraging evidence suggesting that immunotherapy could be effective in PDAC 
with optimal combinations of therapies. They demonstrate that FAK inhibition can 
result in broad regulation of the fibrotic and immuno-suppressive PDAC TME, 
rendering pancreatic tumours responsive to a combination of gemcitabine, one of the 
current chemotherapies used in the treatment of PDAC, and anti-PD-1 plus anti-
CTLA-4 immune checkpoint blockade142. These results have seen rapid clinical 
translation and a Phase I clinical trial testing FAK inhibition in combination with 
gemcitabine and anti-PD-1 in patients with pancreatic cancer is currently underway 
in the USA (clinicalTrials.gov NCT02546531). A further clinical trial testing the 
safety, tolerability, and anti-tumour efficacy of FAK inhibition in combination with 
anti-PD1 in patients with pancreatic cancer, mesothelioma, and non-small-cell lung 
cancer is also underway in the UK (ClinicalTrials.gov, NCT02758587). 
1.2.1 Mechanisms of escape 
Preclinical data suggests immune evasion is the basis of the underwhelming response 
to immunotherapies thus far in the treatment of pancreatic cancer40. Immunotherapy 
may only elicit an effective treatment response when multiple facets of the protective 
armoury shielding PDAC against immune destruction and promoting its development 
are targeted concurrently. There are several factors contributing to pancreatic 
cancer’s ability to escape immune recognition and circumvent the actions of single 
agent immunotherapies. First, as described earlier in this thesis, the PDAC TME is 
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highly infiltrated with immunosuppressive cell types secreting immunosuppressive 
cytokines blocking the function of CD8+ T-cell tumour recognition and clearance and 
creating a site of immune privilege. Second, the intense desmoplastic and fibrotic 
environment not only acts as a physical barrier to infiltration of immune cells and 
immunotherapeutic agents as well as other cytotoxic agents, but is also directly 
immunosuppressive39,44,144,145. Thirdly, analysis of mutational signatures have 
revealed that most pancreatic cancers are poorly immunogenic or display high 
tumour heterogeneity32,35,40 and therefore the less immunogenic clones could 
potentially be selected for in response to immunotherapy. Furthermore, neoantigen 
quality has been found to decline on cancer progression209 resulting in pancreatic 
cancer becoming less visible to the immune system as the tumour develops. This 
may in part be due to the genetic instability of pancreatic cancer, with consequential 
loss of tumour antigen expression and survival of cells expressing tumour antigen in 
a process known as ‘immunoediting’210. Finally, pancreatic cancer cells prevent 
immune recognition by altering expression of molecules on their cell surface; either 
by overexpressing inhibitory signals such as immune checkpoint ligands or down 
regulating antigen presenting pathways resulting in reduced expression of major 
histocompatibility complex (MHC) I proteins, TAP (transporter associated with 
antigen processing) proteins and LMPs (latent membrane proteins)211.  
1.2.2 Cancer vaccines 
A number of synthetic and cellular-based cancer vaccines have been trialled in the 
treatment of pancreatic cancer137. Cancer vaccines aim to break the acquired immune 
tolerance to cancer cells by expansion and activation of the DC population, resulting 
in generation of an anti-cancer humoral and/or cellular immune response67. Synthetic 
vaccines are generally comprised of proteins or peptides corresponding to a pre-
determined antigen that induces a T-cell response. Clinical trials have been 
conducted targeting VEGF212–214, MUC-1 (Mucin 1)215,216, survivin217, 
telomerase218,219, and KRAS peptides220–223. Some promising results were found at 
10-year follow up subsequent to anti-KRAS peptide vaccination220, but in general, 
use of synthetic vaccines have not translated into substantial improvement in patient 
survival. More favourable responses have been found using cellular based vaccines. 
The antigen source is generally whole cells and therefore cellular based vaccines 
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have multiple epitopes224. This potentially results in a more robust immune response. 
For example, GVAX (a GM-CSF vaccine) improved overall patient survival in phase 
II studies when used in combination with low dose cyclophosphamide to deplete 
Tregs225, 5-FU (fluorouracil) based chemo-radiation226, or with a live-attenuated 
strain of Listeria monocytogenes–encoded mesothelin (CRS-207)227. Additionally, 
phase II studies with Algenpantucel-L, a whole cell vaccine manufactured from 
irradiated allogeneic pancreatic cancer cells expressing the murine α-GT enzyme, 
demonstrated positive results in those patients showing an antibody response to the 
vaccine228,229. Another promising vaccine approach is dendritic cell vaccines. This 
involves isolating DCs from the patient’s peripheral blood mononuclear cells 
(PBMCs), stimulating them ex-vivo and re-injecting them back into the patient. This 
approach has shown significant increase in patient survival in prostate cancer and 
subsequently these has been approved for use in cancers such as prostatic cancer230. 
DC vaccines have also recently been shown to increase overall survival and disease 
free interval in pancreatic cancer patients231. Adoptive cell transfer (ACT) is another 
promising immunotherapy treatment in PDAC. This involves the infusion of 
allogenic tumour reactive T-cells or autologous T-cells derived from patient PBMCs, 
tumour draining lymph nodes or tumour tissue, which are isolated and expanded ex-
vivo232. The most widely used ACT approach is with T-cells genetically modified to 
express chimeric antigen receptors (CARs) specific to tumour-associated antigens. 
Despite showing great promise in pre-clinical studies233–236, CAR T-cell therapy has 
yet to demonstrate significant advantages in the clinical setting. It is thought that the 
immunosuppressive TME in PDAC is the source of failure in objective responses in 
the clinic237 and strategies are underway combining CAR T-cell therapy with 
methods to impede TME immunosuppression40.  
1.2.3 Macrophage targeted immunotherapy  
The pro-tumoural functions of TAMs have put the spotlight on macrophage-targeted 
therapies as a potential treatment in pancreatic cancer, either through ablation or re-
polarisation of macrophages within the tumour microenvironment. Gemcitabine in 
combination with an agonist of macrophage surface marker CD40, has been shown 
to elicit tumour regression through promotion of macrophages with an anti-tumour 
phenotype61,238. Another strategy for targeting TAMs is to block monocyte 
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recruitment into tumour tissues by blocking CCL2. Use of the CCL2 antagonist PF-
04136309 in a murine model of PDAC led to TAM depletion, subsequent reduction 
in tumour growth and inhibition of distant metastasis239. Additionally, objective 
tumour responses were seen in 49% of patients with inhibition of CCR2 in 
combination with FOLFIRINOX in a phase Ib clinical trial (NCT01413022)240. 
Colony-stimulating factor 1 receptor (CFS1R), expressed by macrophages and 
monocytes, has also shown potential in pre-clinical studies. Inhibition of this receptor 
has been shown to amplify antigen presentation and T-cell immune responses against 
murine pancreatic cancer241. Another promising immunotherapy targeting 
macrophages and enhancing their anti-tumour activity is Decoy receptor 3 (DcR3). 
DcR3 is a member of the TNF receptor superfamily and found to down regulate 
antigen presenting genes such as MHC-II and HLA-Dr (Human Leukocyte Antigen – 
antigen D Related)242. DcR3 is up-regulated in pancreatic cancer243 and correlates 
with reduced survival60.  
1.2.4 Immune checkpoint inhibition 
The immune system has a number of intrinsic mechanisms known as immune 
checkpoints that maintain self-tolerance to prevent autoimmunity and avert 
overwhelming immune reactions during infection244. Cancer cells have developed 
various strategies to commandeer some of these mechanisms to achieve cancer cell 
self-perseverance by inhibiting both the innate and adaptive immune system, leading 
to TME immunosuppression245. This has lead to treatment strategies targeting these 
co-stimulatory receptors and ligands that block the inhibitory receptor-ligand 
interaction on T-cells, cancer cells and other immune cells. Thus far the main focus 
has been on cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and 
programmed death protein-1 (PD-1)79, with other potential targets such as 
lymphocyte activation gene-3 (LAG-3)246 and T-cell immunoglobulin and mucin 
domain-3 (TIM-3)247 currently under investigation. 
CTLA-4 is an inhibitory receptor expressed on T-cells, regulating early stages of T-
cell activation. Upon CD80 or CD86 ligand binding, T-cell activation is prevented248. 
Anti CTLA-4 monoclonal antibodies (ipilimumab, tremelimumab) have been 
employed successfully in clinical trials against metastatic melanoma and are now 
approved for clinical use. Metastatic melanoma patients treated with ipilimumab, in 
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combination with the alkylating agent dacarbazine, have an improved overall 
survival of 3.7 months, compared to dacarbazine alone249. Clinical trials with CTLA-
4 inhibition are currently underway in pancreatic cancer (NCT00556023, 
NCT01473940) but despite the success in melanoma, no improvement in survival 
has yet been reported when used as a single agent in PDAC206, suggesting that 
combination therapy to target other areas of cancer immune evasion may be required.  
The PD-1 receptor is another immunotherapy target that has shown significant 
promise. Unlike CTLA-4, PD-1 expression is not limited to T-cells and can be 
expressed on a number of immune cell populations including B-cells and NK cells. 
Upon binding to either of it’s two ligands: PD-L1(also known as B7-H1/ CD274)  
and PD-L2 (also known as B7-DC/ CD273), PD-1 functions to inhibit cytotoxic T-
cell activation250 and enhance Treg activation and proliferation251 during an 
inflammatory response in order to prevent autoimmunity. Both PD-L1 and PD-L2 
are expressed on antigen presenting cells (APCs) such as macrophages and dendritic 
cells (DCs). Whilst PD-L2 expression is generally thought to be restricted to these 
cells, PD-L1 is also expressed on a variety of other cell types such haematopoietic 
cells and non-lymphoid cells including parenchymal cells and vascular endothelial 
cells in the peripheral tissues252. Ligation of PD-1 on T-cells leads to SHP-2 
recruitment and subsequent de-phosphorylation and inactivation of Zap 70, a major 
integrator of T-cell receptor (TCR)-mediated signalling, resulting in reduced effector 
function, proliferation and survival of CD8+ T-cells253. Additionally, PD-1 is 
expressed on Tregs and activation is thought to enhance Treg activation and 
proliferation254, again dampening the immune response. Physiologically the PD-1 
receptor plays an inhibitory role in regulating T-cell activation in peripheral tissues 
to restrain exaggerated T-cell responses to infection and to prevent autoimmune 
reactions against self antigens250. It is now known that cancer cells are able to hijack 
this mechanism through over-expression of PD-L1. Cancer cell PD-L1 binding of T-
cell PD-1 leads to evasion of the anti-tumour response via effector T-cell 
deactivation and Treg activation, thus PD-1 has recently become an attractive 
therapeutic target253. Considerable research has gone into PD-L1 expression in 
various cancer types but less emphasis has gone into PD-L2, the other PD-1 ligand. 
Response rates in clinical trials to PD-1 or PD-L1 inhibitors were 17–38% in 
advanced melanoma and 10–18% in advanced non-small-cell lung cancer255,256. PD-
L1 expression has been found to negatively correlate with pancreatic cancer patient 
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survival and a survival benefit has been demonstrated with use of PD-L1 blockade in 
PDAC murine models257. Both PD-L1 and PD-L2 have been found to be over 
expressed in post surgical PDAC specimens258. Despite this, no objective responses 
have yet been found in clinical trials in pancreatic caner when anti-PD-L1 antibodies 
were used alone80,259. Clinical trials with combination therapy are currently underway 
and one phase 1b trial with ipilimumab in combination with GVAX demonstrated 
increased survival in metastatic pancreatic cancer patients when compared to 
ipilimumab alone260. Combinational therapies targeting different arms of the 
immunosuppressive TME in order to overcome other components of the 
immunosuppressive TME that mediate immune evasion may therefore be more 
effective in PDAC treatment. Jiang et al reports a recent example of pre-clinical 
success using combinational therapy. In this study they utilised mouse models of 
pancreatic cancer, previously found to be unresponsive to inhibition of immune 
checkpoint blocker PD-1 alone, and found that the addition of a FAK inhibitor (VS-
4718) to a combination of anti-PD-1 and gemcitabine, resulted in increased overall 
mouse survival, when compared to the combination of anti-PD1 and gemcitabine142.  
 
1.3 Focal Adhesion Kinase (FAK) 
Focal adhesion kinase (FAK) is a ubiquitously expressed non-receptor tyrosine 
kinase261, originally identified in 1992 as a 125kDa protein that was tyrosine 
phosphorylated in Rous sarcoma virus-transformed chick embryos and localized to 
regions on the cell surface termed focal adhesions (FAs)262. Further characterisation 
has revealed FAK as a critical signal integrator, acting downstream of integrin and 
growth factor receptors, scaffolding macromolecular complexes to direct signals 
from the extracellular environment into the cytoplasmic space. This co-ordinates an 
array of cellular processes, many of which are important in cancer including: cell 
cycle progression, adhesion, polarisation, migration, apoptosis, proliferation and 
survival263. Multiple studies have revealed elevated FAK expression in a range of 
invasive cancers264 and this elevation generally correlates with poorer survival 
rates265, highlighting the potential  for FAK as a therapeutic target in cancer. 
1.3.1 Structure and function of FAK 
The FAK protein is highly conserved between species with approximately 90% 
amino acid sequence homology between human and mouse266. FAK consists of 3 
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functional domains: an N-terminal FERM (Four-point-one, Ezrin, Radixin and 
Moesin) domain, a central kinase domain, and a C-terminal FAT (Focal Adhesion 
Targeting) domain267 (figure 1.3). Studies have revealed that deletion of the FERM 
domain increases FAK activity268. This is as a result of FERM and kinase domain 
interactions, causing FAK to remain in an auto-inhibited conformation269, until 
clustering of integrin receptors at the cell membrane mediates binding of the 
cytoplasmic domains of integrins to the amino-terminal domain of FAK followed by 
FAK dimerization270. This leads to disassociation of the intra-molecular interactions 
mediating the auto-inhibitory configuration, and auto-phosphorylation of tyrosine 
residue 397 (Y397)268. Phosphorylated Y397 acts as a high affinity-binding site for 
Src, and on binding, results in a cascade of tyrosine residue phosphorylation (Y576, 
Y577, Y861 and Y925)271. Y397 and Y576/Y577 phosphorylation are essential for 
maximal catalytic activity, efficient disassembly of focal adhesions and therefore cell 
migration272, whilst phosphorylation of the remaining tyrosine residues create high 
affinity binding sites for other SH2 domain containing proteins273. This results in the 
open conformation and fully activated FAK-Src signalling complex, capable of 
functioning as both a scaffold and as a kinase. Subsequent protein binding partners to 
this FAK-Src scaffold include PI3K/AKT274, growth factor receptor bound protein 2 
(Grb2), phospholipase C gamma (PLCγ)275, the SH3 binding protein p130Cas276, 
nuclear p53277,278 and FAT binding proteins: talin279 and paxillin280 (figure 1.3) 
amongst others. FAK-FERM domain alterations can additionally be stimulated by 
changes in pH and increased cell–ECM tension, which can additionally increase the 
activity of FAK281–283. Force-mediated FAK activation promotes downstream 
signalling inducing mitotic spindle reorganisation284, triggering mechano-sensitive 
cell proliferation285, and can increase inflammatory cytokine production associated 
with fibrosis286, as has been demonstrated by Jiang and colleagues in a murine 
models of pancreatic cancer where FAK inhibition resulted in a reduction in 
fibrosis142. The amino terminal FERM domain also mediates protein-protein 
interactions with the cytoplasmic tails of β1 integrins and complexes containing key 
signalling molecules including growth factor receptors such as PDGFR (platelet 
derived growth factor receptor) and EGFR (epidermal growth factor receptor)287–289. 
These interactions also release the FAK-FERM conformation mediating the auto-
inhibitory conformation, resulting in activation of FAK.  
A nuclear export signal (NES) is located within the kinase domain and another in the 
FERM domain, which also contains nuclear localization sequences (NLS) (Figure 
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1.3). These allow events at the cell periphery to be transmitted co-ordinately to the 
nucleus267. Under normal conditions FAK resides in the cytoplasm of cells with only 
a very small quantity present within the nucleus. When cells are placed under stress, 
such as oxidative stress, FAK can shuttle from a cytoplasmic position associated with 
FAs, accumulate in the nucleus, and can cause changes in gene expression of various 
proteins290, as well as binding distinct nuclear protein complexes. This process is 
mediated by the NLS within the FERM domain291. Identification of FAK’s ability to 
translocate to the nucleus is a relatively new finding, and whilst a growing number of 
nuclear binding partners are being identified290,292,293, its full function within the 
nucleus or the method in which FAK translocates to the nucleus is not completely 
understood. TP53, a protein commonly deregulated in many cancer types including 
PDAC31 is one such protein that nuclear FAK associates with. Nuclear FAK allows 
cell proliferation by binding to TP53 in the nucleus, leading to TP53 degradation and 
therefore cell survival277. Other FAK dependent changes at the nuclear level have 
also been described. For example FAK alters cytokine gene expression, one of which 
is the IL6 gene in endothelial cells294. More recently transcriptional regulation of 



















Figure 1.3 Basic structure and binding partners of FAK 
A FAK is composed of a central kinase domain flanked by an N- terminal FERM domain and a C-
terminal region containing a FAT domain. Proline-rich motifs (PR1, PR2 and PR3) link the central 
kinase domain with the terminal domains. The NLS is located in the F2 domain of FERM domain. 
B FAK is a pivotal signal integrator that both controls and co-ordinates a number of cellular processes 
downstream of integrin and growth factor receptors. FAK interacts with and phosphorylates SRC. The 
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activated FAK/SRC complex directly or indirectly activates other kinases and shuttles to the nucleus 
where it interacts with nuclear binding partners to control cell proliferation, migration and survival.  
 
 
1.3.2 FAK in cancer 
FAK is central to multiple signalling pathways regulating various cellular processes 
and is over expressed in a number of cancer types including SCC of the skin, lung, 
head and neck, bladder carcinoma263,  breast295–297, oral298, prostate299 and 
pancreatic142,300 cancers amongst others. Therefore it is not surprising that FAK is 
implicated in cancer development and spread, and is considered a potential 
therapeutic target. FAK has been linked to the maintenance of cancer stem cells and 
has been implicated in promoting cancer cell survival, tumour growth, cell migration, 
invasion and angiogenesis263. Additionally, recent data has uncovered a novel role 
for nuclear FAK in controlling the composition of the immunosuppressive tumour 
microenvironment via FAK-dependent regulation of chemokines and cytokines. 
Using a syngeneic mouse model of SCC, FAK was found to translocate to the 
nucleus, where it interacts with a number of transcription factors and transcriptional 
regulators to enhance the expression of a variety of chemokines and cytokines301. 
CCL5 expression was up-regulated in FAK expressing SCC, resulting in elevated 
intra-tumoural Treg levels and suppression of the anti-tumour CD8+ T-cell response. 
This lead to unregulated tumour growth. Inhibition of FAK by genetic depletion or 
use of a FAK inhibitor drug was found to reverse this effect. FAK has also been 
implicated in the regulation of other cytokines and chemokines in the context of 
cancer. Through TNF-alpha induced FAK activation of MAPK, IL6 transcription and 
protein translation was induced in breast, neuroblastoma, lung and prostate 
carcinoma302. 
 
1.3.3 FAK in PDAC 
FAK is overexpressed in PDAC142,300. This increased expression positively correlates 
with increasing tumour size300. Two studies have indicated the potential for FAK 
inhibition in treatment of pancreatic cancer. Stokes et al demonstrated that the small 
molecule FAK/PYK2 inhibitor PF-562,271 inhibited in-vitro migration of human 
PDAC cells, murine CAFs and macrophages conditioned with tumour media. These 
findings were mirrored by their in-vivo findings whereby orthotopic implantation of 
PDAC cells into the murine pancreas resulted in reduced tumour proliferation, 
  INTRODUCTION 
 31 
invasion and metastasis when mice were treated with PF-562,271303. Jiang et al 
demonstrated administration of the small molecule FAK kinase inhibitor VS-4718 
increased survival time in the KPC murine model of PDAC and found that FAK 
modulated a variety of chemokines and cytokines in the pancreatic TME. They 
specifically focused on CXCL12 and found this chemokine drives fibroblast 
proliferation and stromal expansion. FAK inhibition reduced the desmoplastic 
reaction within these tumours and altered the immune populations; they 
demonstrated reduced MDSCs, MMR+ macrophages, and Tregs levels142. 
Additionally they found that FAK inhibition synergised with immune checkpoint 
blockade to improve anti-tumour response and survival time. Tumour regression 
however was not observed in these studies. These encouraging pre-clinical results 
identify a potentially important role for FAK in regulating the composition of the 
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1.4 Hypothesis and Objective 
 
Hypothesis 
FAK is a key modulator of immune signalling in pancreatic cancer  
 
Objective  
To identify novel mechanisms of FAK-dependent immune regulation in pancreatic 
cancer 
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2 Materials and Methods 
2.1 Material and methods (in-vitro) 
2.1.1 Cell lines and cell culture 
Panc47 cell lines were obtained from Jen Morton (The Beatson Institute for Cancer 
Research, Glasgow). This cell line was originally derived from the LSL-
KrasG12D/+;LSL-Trp53R172H/+; Pdx1 Cre (KPC) mouse. 
Panc47 and derivatives were cultured at 37oC / 5% CO2 in Dulbecco's Minimum 
Essential Medium - high glucose (DMEM - high glucose; Sigma Life Technologies) 
supplemented with 10% foetal bovine serum (FBS, Sigma Life Technologies). Cell 
lines were cultured in 25-, 75- and 150cm2 plastic tissue culture flasks (Cell Star, 
Greiner bio-one Falcon vented cell culture flasks). When cells were near to 80% 
confluent, they were washed with phosphate-buffered-saline (QMRI central services, 
Sterile PBS), and treated with 1x trypsin (Gibco™, Sigma Life Technologies) diluted 
in sterile PE (QMRI central services, Sterile PE). Once cells had detached from the 
surface of the flasks the trypsin was quenched by the addition of fresh culture media 
containing FBS. Cells were then diluted to an appropriate ratio depending on the 
intended use. Stocks of all cell lines were frozen in 10% dimethyl sulfoxide (DMSO, 
Sigma Life Technologies) in DMEM supplemented with 20% FBS and stored at -
196oC in liquid nitrogen.  
2.1.2 Generation of CRISPR model 
Type II CRISPR/Cas9 genome editing technology was used to deplete FAK from 
Panc47 as described in the protocol published by Ran et al304. 
2.1.2.1 Cloning of gRNA oligonucleotides into the Cas9 vector plasmid 
The online CRISPR design tool (http://crispr.mit.edu/) was used to generate two 
pairs of complementary 20bp length gRNAs: gFAK4 and gFAK6 (figure 3.3) with 
BbsI restriction enzyme overhangs to allow annealing into the expression plasmid. 
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Oligos were annealed by combining 1μl of forward and reverse sgRNA, 1μl T4 
ligation buffer (ThermoFisher Scientific), 1μl T4 PNK (New England Biolabs), 6ul 
ddH2O and incubated at 37
oC for 30 minutes; 95oC for 5 minutes; 25oC for 5 
minutes. The annealed oligos were diluted 1:100 by adding 1μl oligo to 100μl room 
temperature ddH2O. The guide expression plasmid pSPCas9(BB)-2A-GFP was 
chosen because it contains a GFP selection cassette to allow for easy identification of 
cell clones where retroviral transfection into target cells has been successful. The 
complementary guide oligonucleotides were annealed and cloned into a CRISPR 
guide expression plasmid pSPCas9(BB)-2A-GFP (PX458) by setting up ligation 
reactions combining 2μl diluted oligos, 100ng sPsCas9(BB)-2A-GFP, 2μl Tango 
buffer, 1μl 10mM DTT, 1μl 10mM ATP, 1μl FastDigest BbsI, 0.5μl T7 ligase (all 
ThermoFisher Scientific) and ddH2O up to 20μl. The ligation reaction was then 
incubated at 37oC for 5 minutes and 21oC for 5 minutes for 6 cycles. The expression 
plasmid was then transformed into chemically competent Top10 bacteria by adding 
2μl of the resulting ligation mix to transform the expression plasmid into one shot® 
TOP10 chemically competent E.coli (ThermoFisher Scientific) containing ampicillin 
resistance. Plates were incubated overnight at 37oC and 3 colonies from each plate 
were picked with a sterile pipette tip and incubated in 3ml LB (Lysogeny broth) with 
100μg ml-1 ampicillin overnight at 37oC in order to take advantage of selection using 
the ampicillin resistance gene within the plasmid. 1.5ml of culture medium was 
pelleted and DNA was extracted from bacterial colonies using QIAprep spin 
miniprep kit (Qiagen) as per manufacturer’s instructions. DNA was sent for 
sequencing at the IGMM sequencing facility using the U6 forward primer. 
Sequences were aligned to determine if they contained the inserted oligos. Clones 1 
of both gRNAs were positive (figure 3.3).  
2.1.2.2 Transfection into Panc47 cell lines  
To generate FAK-depleted Panc47 cell clones, cells were transfected with the 
expression plasmids containing either the gFAK4 or gFAK6 guide sequences. First 
plasmid DNA was amplified and isolated using QIAGEN Plasmid Maxi Kit 
(Qiagen), as per manufacturer’s instructions. In sterile, dark conditions, 2ml Opti-
MEM (ThermoFisher Scientific) was combined with 20μl lipofectamine® 2000 
(ThermoFisher Scientific). 2ml Opti-MEM was combined with 5μg gFAK DNA in a 
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separate sterile container. After 20 minutes of room temperature incubation, these 
were combined and left to incubate for a further 10 minutes. Cell culture media was 
removed from pancreatic cell lines to be transfected and replaced with transfection 
media for 5 hours. After 5 hours, this was then replaced with normal pancreatic 
culture media. After 24 hours, these cell lines were visually checked for GFP 
expression using fluorescent microscopy and split as normal (1 in 10). 7 days later, 
isolation of positively transfected cells via GFP expression was performed with 
FACS (Fluorescence-activated cell sorting) sorter FACSAria II (BD Biosciences). 
Cells were dissociated with 1ml 2.5% trypsin solution (Sigma Life Technologies), 
passed through a 70μm cell strainer (Becton Dickinson) to create a single cell 
suspension, pelleted at 1000rpm for 5 minutes and re-suspended in 500μl FACS 
buffer. Cells were sorted into a 96-well plate containing normal pancreatic culture 
media supplemented with Penicillin-Streptomycin (Gibco Life Technologies 
10,000U/mL, diluted 1:100).  
Once confluent, GFP positive cell lines were transferred into flasks. Resulting cell 
colonies were tested for successful depletion of FAK expression using anti-FAK 
western blotting. From a total of 16 colonies tested, 12 were identified to be FAK 
deficient (figure 3.4). 
2.1.2.3 Identification of the genetic mutation arising from CRISPR 
genome editing 
One FAK depleted clone (47-g4-clone2 hereafter referred to as FAK-/-) was 
selected, genomic cDNA was extracted and PCR amplified using FAK specific 
primers. Genomic cDNA from the successfully created FAK-depleted line FAK-/- 
(identified via western blot) was isolated using Qiagen DNeasy Blood & Tissue Kit 
(Qiagen) as per manufactures instructions. Primer sequences flanking the genomic 
region targeted by the guide sequences were designed and used to PCR amplify a 














200ng of genomic cDNA was combined with 1.25μl of 10μM FAK 740 Forward 
primer, 1.25μl of 10μM FAK 1053 Reverse primer, 25μl NEB Phusion master mix 
(2x stock solution) and made up to 50μl sterile water in a 0.2μl PCR tube. PCR 
conditions as detailed below 
 
 
Temperature (oC)  Time (minutes) 
Hot start 95 10 
Number of cycles 40   
Denature 95 0.5 
Anneal 62 0.5 
Elongation  72 1 
End cycle  _  _ 
Finish 72 7 
Storage 4   
   
Using the FAK forward and reverse primers again, direct sequencing of this PCR 
product was performed at the IGMM sequencing facility to confirm depletion of 
FAK and identify the mutation that had occurred (figure 3.5). Sequences were 
aligned using ClutsalW (European Bioinformatics Institute) software, identifying 
a 4 base pair deletion at position 579 of the cds (complete coding sequence) (figure 
3.5A). Comparison of the predicted protein sequence with that of wild-type FAK 
identified a premature STOP codon at AA position 193 (figure 3.5B) confirming that 
if a protein were to be produced, it would result in a severely truncated protein 
produced with a predicted molecular weight of approximately 22.4KDa. This protein 
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is unlikely to be functional or stable and a protein of this size was not detected on 
WB using an N terminal FAK specific antibody (figure 3.6A). 
2.1.3 FAK re-expression 
To generate a cell model with which to further study FAK function, I re-expressed 
FAK into Panc47 FAK-/- cells using retroviral transduction, thus creating identical 
FAK positive and negative clones.  
Phoenix Ecotropic cells were transfected with a pWZL FAK-wt construct, previously 
used in the lab, using lipofectamine® 2000 (ThermoFisher Scientific) and Opti-
MEM (ThermoFisher Scientific) as described in 2.2.2.2. The FAK protein within the 
pWZL FAK-wt construct was originally derived form chicken. Mouse and chicken 
FAK polypeptides have been shown to be structurally similar throughout their 
lengths305 as detailed below in appendix 2. 
After 24 hours, virus-containing media was collected from phoenix ecotropic cells. 
This media was filtered through a 0.45μM Millex-HA filter (Merck Millipore), 
supplemented with 5μg/ml polybrene and applied to FAK-/- cells and cultured at 
37oC/ 5% CO2 in Dulbecco's Minimum Essential Medium - high glucose (DMEM - 
high glucose; Life Technologies) supplemented with 20% foetal bovine serum (FBS, 
Life Technologies). After 24 hours a second round of infection was performed. 
Following the second round of infection, cells were cultured at 37oC/ 5% CO2 in 
DMEM supplemented with 10% FBS and maintained under selection using 
0.25mg/ml hygromycin (Merck Millipore). Successful re-expression of FAK-wt was 
confirmed using western blotting (figure 3.6A). Biochemical fractionation to 
separate nuclear and cytoplasmic extracts followed by western blotting of protein 
extracts was carried out using anti-FAK antibodies (figure 3.6B) and FAK was 
found to be readily detectable in the nucleus of Panc47 FAK-wt cells.  
2.1.4 shRNA (short hairpin) mediated IL6 knockdown 
Lentiviral particles for infection of FAK-wt cells were generated by transfecting 
2x106 HEK23FT cells with a mixture of 2.5g of each pLKO IL6 shRNA; 
TRCN0000067548, TRCN0000067549, TRCN0000067550, TRCN0000067551, 
TRCN0000067552 (RMM4534-EG16193, Dharmacon), or non targeting control 
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pLKO-NTCO (kind gift from Sonja Vermeren), 2.5g of the viral packaging vector 
(psPAX2) and 2.5g of the viral envelop (pMD2.G) mammalian expression 
packaging vectors (Addgene), 5ml Opti-MEMTM media (Thermofisher) with 
Lipofectamine 2000 (Thermofisher) as per manufacture’s protocol. Transfected 
HEK23FT cells were incubated for 8 hours at 37oC, media was removed and 
replaced with media optimal for the target cell (FAK-wt): DMEM- high glucose 
supplemented with 20% FBS. After a further 24 hours of culture, media was 
removed and filtered through a 0.45M Millex-AC filter (Millipore), supplemented 
with polybrene to a final concentration of 5g/ml and added to the FAK-wt cells for 
24 hours. Cells were subject to two rounds of lentiviral infection prior to selection 
with puromycin at a final concentration of 2g/ml. 
2.1.5 Re-expression of NLS mutant and KD mutant 
Retroviral particles for infection of the FAK-/- cell line were generated by 
transfecting 2x106 Phoenix ecotropic (Phoenix-Eco, Thermofisher) cells with a 
mixture of 3g vector (NLS mutant, KD mutant or PWZL empty vector control), 
5ml Opti-MEMTM media (Thermofisher) with Lipofectamine 2000 (Thermofisher) as 
per manufacture’s protocol. Transfected Phoenix-Eco cells were incubated for 24 
hours at 37oC, media was removed, replaced with media optimal for the target cell 
(FAK-/-): DMEM-high glucose supplemented with 20% FBS. After a further 24 
hours of culture media was removed and filtered through a 0.45M Millex-AC filter 
(Millipore), supplemented with polybrene to a final concentration of 5g/ml and 
added to the FAK-/- cells for 24 hours. Cells were subject to two rounds of infection 
prior to selection with hygromycin at a final concentration of 10g/ml.  
2.1.6 IL6 re-expression into FAK-/- 
Lentiviral particles for infection of the FAK-/- cell line were generated by 
transfecting 2x106 HEK23FT cells with a mixture of 5g IL6 vector (IL6 supplied in 
pLenti-C-Myc-DDKIRES-GFP vector, MR227281L2, OriGene Technologies), 
2.5g of each of the viral packaging (psPAX2) and viral envelop (pMD2.G) 
mammalian expression packaging vectors (Addgene), 5ml Opti-MEMTM media 
(Thermofisher) with Lipofectamine 2000 (Thermofisher) as per manufacture’s 
protocol. Transfected HEK23FT cells were incubated for 8 hours at 37oC, media was 
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removed, replaced with media optimal for the target cell (FAK-wt): DMEM- high 
glucose supplemented with 20% FBS. After a further 24 hours of culture, media was 
removed and filtered through a 0.45M Millex-AC filter (Millipore), supplemented 
with polybrene to a final concentration of 5g/ml and added to the FAK-wt cells for 
24 hours. Cells were subject to two rounds of lentiviral infection prior to selection 
with chloramphemicol at a final concentration of 34g/ml.  
2.1.7 Western blot 
Plated cells were washed twice with chilled PBS and lysed in radioimmuno- 
precipitation assay (RIPA) buffer (50mmol/L Tris (pH 7.6), 150mmol/L sodium 
chloride, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS) supplemented with 
phosphatase inhibitor cocktail (Roche) and protease inhibitor cocktail (Roche). 
Lysates were cleared by centrifugation at 13000 rpm for 15 minutes at 4oC. Protein 
concentration was determined using PierceTM BCA protein Assay kit (Thermo 
Fisher). Absorbance was measured with a Beckman DU 650 spectrophotometer 
(Beckman Coulter, Luton, UK) and read at 562nm wavelength. 20g of each sample 
was added to 10l 2x sample buffer and made up to a total of 20l with RIPA buffer. 
Lysate mixtures were then incubated at 95oC for 10 minutes. 2l of pre-stained 
protein ladder Precision plus proteinTM dual color standard (biorad cat 161-0374) 
was used as MW marker. Lysates were resolved by 4-15% Bis-Tris gel 
electrophoresis (Biorad) and proteins transferred to nitrocellulose membranes using 
the Trans-Blot® TurboTM Transfer System (Biorad). Membranes were then blocked 
(5% BSA/TBST) for 1 hour at room temperature and probed with relevant primary 
antibody: anti-FAK antibody (1:1000, clone 4.47 in 5% BSA/TBST; Millipore) or 
FAK pY397 antibody (1:1000, 3283; Cell Signalling Technology, in 5% BSA/TBST) 
overnight at 4oC. Membranes were then washed three times with TBST buffer (Tris 
Buffered Saline with Tween) and bound antibody was detected by 1-hour room 
temperature incubation with anti-mouse or anti-rabbit HRP-conjugated secondary 
antibody (1:5000 in 5% BSA/TBST; Cell Signaling Technology). Membranes were 
washed three times with TBST and prepared for chemiluminescent visualisation by 
incubation in ClarityTM Western ECL Blotting Substrate (Biorad). Membranes were 
visualised using a ChemiDoc MP Imaging System (Biorad). Membranes were then 
washed with distilled water at room temperature for 20 minutes and stripped with 
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Re-Blot Plus Strong Antibody Stripping solution (Merek Millipore). Membranes 
were washed twice with distilled water and blocked (5% BSA/TBST) for 1 hour at 
room temperature. Stripped membranes were then re-probed with anti-GAPDH 
(1:10000 in 5% BSA/TBST, Cell Signaling Technology) or anti-tubulin (-tubulin, 
clone DN1A, Cell Signalling Technology) overnight at 4oC to assess equal protein 
loading or to assess efficient fractionation for western blots following nuclear 
fractionation. Membranes were then washed three times with TBST and bound 
antibody was detected by 1-hour room temperature incubation with anti-mouse or 
anti-rabbit HRP-conjugated secondary antibody (1:5000 in 5% BSA/TBST; Cell 
Signaling Technology). Membranes were washed three times with TBST and 
prepared for chemiluminescent visualisation as before. For western blots following 
nuclear fractionation, membranes were again stripped as before and washed twice 
with distilled water. Again membranes were blocked (5% BSA/TBST) for 1 hour at 
room temperature. Stripped membranes were then re-probed with anti-PARP 
(1:10,000 in 5% BSA/TBST, Cell Signaling Technology) primary antibody overnight 
to check for efficient fractionation. Membranes were washed three times with TBST 
and prepared for chemiluminescent visualisation as described above.  
2.1.8 Nuclear fractionation 
Plated Panc47, FAK-wt, FAK-/- or FAK-NLS cells were washed twice with chilled 
PBS and lysed in CYTO buffer (10 mM Tris-HCl pH 7.5, 0.05mM NP-40, 3mM 
MgCl2, 100mM Sodium Chloride (NaCl), 1mM EGTA (Sigma Chemical Co), 
phosphatase inhibitor cocktail (Roche) and protease inhibitor cocktail (Roche). 
Lysates were centrifuged at 13000 rpm for 15 minutes at 4oC to separate the nuclear 
pellet from the cytoplasmic fraction. The cytoplasmic fraction was then transferred 
into a new tube and an equal volume of 2x RIPA buffer added. The nuclear pellet 
was washed twice in CYTO buffer and centrifuged at 1000rcf. Remaining CYTO 
buffer was aspirated and purified nuclear pellets were lysed in 150l RIPA buffer for 
15 minutes at 4oC and centrifuged at 16000 rpm for 15 minutes to separate the non-
soluble portion of the nuclear fraction. The supernatant was transferred into a new 
tube. Protein concentration was then determined using PierceTM BCA protein Assay 
kit (Thermo Fisher). Absorbance was measured with Synergy 2 Multi-Mode Reader 
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(BioTek®, Swindon, UK) and read at 562nm wavelength. Western blot performed as 
described above.  
2.1.9 Enzyme-linked immunosorbent assay (ELISA) 
Cell lines were counted and plated equally into 6 well plates (costar®). After 24 
hours, media was changed and appropriate amount of mouse IL17 recombinant 
protein (eBioscience) containing media was applied to plates. Plates were then 
incubated at 37oC / 5% CO2 for 48 hours. Media was collected and ELISA assay 
carried out using mouse IL6 DuoSet ELISA kit (R&D systems) according to the 
manufacturer’s instructions. The samples were analysed with a plate reader by 
optical density (OD) at a wavelength of 450nm (Synergy 2 Multi- Mode Reader, 
BioTek®). Readings were conducted in duplicate. Plates were washed twice with 
chilled PBS and protein concentrations were determined in order to normalise ELISA 
results using PierceTM BCA protein Assay kit (Thermo Fisher).  
2.1.10 Flow cytometry of cultured cells 
Cells were cultured in 75cm2 Cell Star® cell culture flasks (Greiner bio-one). Cells 
were removed using 1x non-enzymatic cell dissociation solution (Sigma Life 
Technologies) and pelleted by centrifugation at 1600rpm for 5 minutes at 4oC. Cell 
pellets were re-suspended in PBS and passed through a 70μm cell strainer (Becton 
Dickinson) to create a single cell suspension. This was then pelleted by 
centrifugation at 1600rpm for 5 minutes at 4oC and this PBS wash was repeated 
before transferring 200μl of appropriate sample into each well of a 96-well round-
bottomed plate. The plate was centrifuged at 1600rpm for 5 minutes at 4oC. Cell 
pellets were re-suspended in 200μl PBS (unstained control), and the rest in 200μl of 
Zombie NIR™ (fixable viability dye, Biolegend), diluted 1:1000 in PBS. Plates were 
sealed and incubated at 4oC for 30 minutes in the dark. Plates were then centrifuged 
at 1600rpm for 5 minutes at 4oC and re-suspended in FACS buffer (Phosphate-
buffered saline solution (PBS) supplemented with 2% heat-inactivated FCS 
(Labtech) and 0.1% sodium azide (Sigma). This step was repeated for a total of 3 
times. Cell pellets were then re-suspended in 100μl of Fc block (1:200 dilution of Fc 
antibody (eBioscience) in FACS buffer) and incubated for 15 minutes at room 
temperature in the dark. Into the appropriate samples, 100μl of antibody was added: 
either IL-17A receptor antibody (anti-mouse CD217 (IL-17 Receptor A) PE, 
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eBioscience), or isotype control (anti-mouse IgG conjugated to PE, eBioscience), or 
antibodies as described in STAIN 1, 2,  and 4 (tables 4.1, 6.1 and 6.2). Appropriate 
FMOs (fluorescence minus one) controls for gating were also created at this time. All 
antibodies were made up at a concentration of 1 in 200 FACS buffer giving a final 
concentration of 1:400. Plates were incubated for 30 minutes in the dark at 4oC. 
Plates were then centrifuged at 1600rpm for 5 minutes at 4oC and re-suspended in 
FACS buffer. This step was repeated for a total of 3 times. Cell pellets were then re-
suspended in FACS buffer and analysed using a BD FACS Aria II (Becton 
Dickinson). Data analysis was performed using FlowJo software. Statistics and 
graphs were calculated using Prism (Graphpad).  
 
2.1.11 Forward-Phase Protein Arrays (FPPA) 
FAK-wt and FAK-/- cell lines were trypsinised, counted and 0.25 x 106 cells were 
added to each well of a 6 well plate. After 24 hours, media was changed and these 
cells were cultured at 37oC / 5% CO2 in Dulbecco's Minimum Essential Medium - 
high glucose (DMEM - high glucose; Life Technologies) supplemented with 1% 
foetal bovine serum (FBS; Life Technologies). Media was collected for FPPA 
analysis after 48 hours of incubation. Microarrays were generated using the in-house 
Aushon BioSystems’ 2470 array printing platform. In order to normalise array 
results, plates were washed twice with cold PBS, protein lysates made and protein 
concentration was determined using PierceTM BCA protein Assay kit as per 
manufacturers instructions (Thermo Fisher). Microarrays were blocked for 1 hour 
with SuperGTM Blocking Buffer (Grace Bio Labs) at room temperature on a rocker. 
Media from samples were centrifuged at 1000rcf for 5 minutes at 4oC. Supernatants 
were added to microarrays for 12 hours at 4oC. Microarrays were washed three times 
for 5 minutes in TBST, and blocked for 10 minutes with SuperGTM Blocking Buffer 
at room temperature on an orbital shaker, then washed again washed three times for 5 
minutes in TBST. Detection antibodies (1:500 antibody diluted in 5% BSA/PBST, 
1% SuperGTM Blocking Buffer) mixtures were made in plates and 2μl of each 
antibody was applied to each well of the microarrays. Microarrays were clamped and 
50μl of each antibody was added to corresponding microarray wells. Microarrays 
were incubated for 1 hour on a flat surface. Clamps were removed and microarrays 
were washed three times for 5 minutes in TBST. Microarrays were then blocked for 
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10 minutes with SuperGTM Blocking Buffer at room temperature on a rocker and 
again washed three times for 5 minutes in PBST. 3ml of IRDye® 800CW 
Streptavidin (LI-COR Biosciences) diluted 1 in 5000 in PBST supplemented with 5% 
BSA, 1% SuperGTM Blocking Buffer. Microarrays were covered and incubated on a 
rocker at room temperature for 45 minutes then washed for 5 minutes, three times in 
PBST followed by three 5 minute PBS washes and then washed with distilled water. 
Microarrays were dried then scanned on the InnoScan 710 high resolution 
Microarray scanner (Innopsys Life Sciences). Data was normalised for protein 
concentration and background fluorescence in Microsoft Excel. Graphs were 
calculated using Prism (Graphpad).  
2.1.12 Optimisation of BI853520 dose 
I undertook a series of experiments utilising the FAK kinase inhibitor BI853520, a 
drug currently in clinical development306,307. It was necessary to first optimise the 
dose of BI853520 required to selectively inhibit FAK kinase in my pancreatic tumour 
cell line in-vitro.  
A dose response experiment was carried out to establish the dose required to inhibit 
FAK phosphorylation, indicating successful FAK kinase inhibition in-vitro. FAK-wt 
cells were treated with escalating doses of BI853520 ranging from 0.25nM to 250nM 
diluted in DMEM- high glucose (Sigma Life Technologies). Western blotting was 
performed as described in 2.2.7 however fluorescent secondary antibodies: 
DyLight™ 800 or DyLight™ 800 Conjugate (Cell Signalling Technology; #5366) 
were used in place of HRP-conjugated secondary antibody and fluorescent intensity 
was determined using the Licor fluorescent imager.  
2.1.13 In-vitro phenotypical characterisation of BMDMs 
cultured in FAK-wt conditioned media 
Bilateral tibias and femurs dissected from C57BL/6 mice were flushed with 5ml of 
DMEM medium supplemented with 10% FBS and 1% Penicillin/Streptomycin into a 
50 ml tube, washed in medium once and filtered through a 70μm cell strainer (Becton 
Dickinson). Cells were seeded at 1 x 106 per well in a 6 well plate and cultured in 
2ml of DMEM with 10% FCS and 25ng/ml recombinant mouse M-CSF 
(Thermofisher). Cells were incubated for 7 days then washed with PBS followed by 
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replacement with fresh media (DMEM medium supplemented with 10% FBS) or 
conditioned media from FAK-wt cells cultured for 48 hours with/without the 
addition of 20ng/ml recombinant mouse IL4 (Thermofisher), or fresh media with 
recombinant mouse G-CSF, GM-CSF or IL6 (Thermofisher). All additional 
cytokines were added at 20ng/ml. Cells were cultured for a further 24 hours, washed 
with PBS and harvested using non-enzymatic dissociation buffer, incubated with an 
Fc block, and stained for surface receptors using flow cytometry (2.2.10). 
2.1.14 CD4+ T-cell polarisation 
Splenocytes were obtained by mechanical disaggregation of the tissue (between 
layers of sterile gauze) and re-suspended as a single-cell suspension in wash buffer 
(HBSS; Sigma). For all wash steps, cells were centrifuged at 1600rpm for 5 minutes. 
Red blood cells (RBCs) were lysed at room temperature for two minutes using RBC 
lysis buffer (Sigma). 
Cells were then washed in MACS buffer (HANKS balanced salt solution 
supplemented with 2% heat-inactivated FCS, Sigma) and CD4+ T-cells isolated from 
splenocytes with CD4 microbeads (Miltenyi) using the autoMACS®Pro Separator as 
per manufacturers instructions. Cells were re-suspended in RMPI and seeded at 2 x 
105 cells in a 48 well plate and cultured in 1ml of FAK-wt or FAK-/- RMPI 
conditioned media (RMPI with 20% FCS, 1x L-Glutmaine, 1x Pen/Step, 80 U/ml 
IL2 and -50 µM mercaptothanol). Cells were harvested after 24, 48 72 and 96 
hours. 
 
2.2 Material and methods (in-vivo) 
2.2.1 Mice 
Female C57BL/6 mice (Charles River; Kent, UK) were used for all in-vivo 
experiments. 
All mice were supplied as age matched, 5-week old females and isolated for one 
week after delivery. All experiments had University of Edinburgh ethical approval 
and were carried out in accordance with the United Kingdom Animal Scientific 
Procedures Act (1986). 
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2.2.2 Orthotopic implantation of cancer cells into the 
pancreas 
Mice were anaethestised with inhalational isoflurane anaesthetic in oxygen, and 
received perioperative analgesia: buprenorphine (Vetergesic, 0.1mg/kg s.c) and 
carprofen (Rimadyl, 10mg/kg s.c) and also post surgery, once daily for 48 hours. Cell 
lines were propagated to sub-confluency to ensure they were in their exponential 
growth phase. Once detached from the flask and washed with PBS, 0.5x106 cells of 
the appropriate cell line was suspended in growth factor reduced matrigel basement 
membrane matrix (Scientific Laboratory Supplies Ltd.), at a concentration of 0.5x106 
cells in 25μl. Using aseptic technique, a 3mm skin inscision was made in the left 
lateral flank and lateral abdominal muscles in order to visualise the pancreas. 0.5x106 
cells in 25μl matrigel were injected into the pancreas in a sterile manner. The 
abdominal wall was closed with Polyglactin 910 (Vicryl, 2M; Henry Schein), with a 
single cruciate suture. Skin was closure was optimised. Skin clips and Vicryl sutures 
were compared and skin clips were deemed superior with regards to closure time and 
post-operative mouse interference. Mice were monitored in a heat box set to 37oC 
post surgery for 1 hour. Mice were closely monitored daily with twice weekly weight 
checks following implantation. If any one terminal symptom caused by pancreatic 
tumour growth including weight loss equal or exceeding 10% of the starting weight, 
signs of abdominal pain or abdominal distension became apparent, the animal was 
humanely euthanized. After two weeks, the animals were culled (cervical 
dislocation) and the pancreatic tumours were harvested for analysis.   
2.2.3 Flow cytometry analysis of tissue 
Tumour tissue was mashed into a pulp using a scalpel and re-suspended in DMEM 
(Life Technologies) supplemented with 2mg/ml collagenase D (Roche) and 10μl/ml 
DNase 1 (Roche). Samples were incubated for one hour at 37oC, shaking at 150rpm. 
Samples were then pelleted by centrifugation at 1600 rpm for 5 minutes at 4oC, and 
re-suspended in 5ml of 1x red blood cell lysis buffer (Pharm Lysis Buffer; Becton 
Dickinson) followed by incubation at 37oC for 10 minutes. Samples were pelleted by 
centrifugation at 1600 rpm for 5 minutes at 4oC, and re-suspended in PBS then 
passed through a 70μm cell strainer (Becton Dickinson) to create a single cell 
suspension. Cells were pelleted by centrifugation at 1600 rpm for 5 minutes at 4oC, 
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and re- suspended in PBS before pipetting 100μl of each sample into well of a 96-
well plate. The plate was then centrifuged at 1600 rpm for 5 minutes at 4oC. Cell 
pellets were re-suspended in 200μl PBS (unstained control), and the rest in 200μl of 
Zombie NIR™ (fixable viability dye; Biolegend), diluted 1:1000 in PBS. Plates were 
sealed and incubated at 4oC for 30 minutes in the dark. Samples were pelleted by 
centrifugation at 1600 rpm for 5 minutes at 4oC, and re-suspended in FACS buffer 
(PBS + 1% FBS + 0.1% sodium azide; Sigma). This wash step was repeated. 
Samples were re- suspended in 100μl Fc block (CD16/32; eBioscience) diluted 1 in 
200 in FACS buffer. Samples were incubated for 15 minutes at 4oC. 100μl of surface 
staining antibody mixture was then added to each well, apart from FMOs and 
unstained control, and the samples incubated for 30 minutes in the dark at 4oC. All 
antibodies were used at a concentration of 1 in 200 diluted in a 50:50 mix of Fc block 
and BD Horizon™ Brilliant Stain Buffer, giving a final concentration in the well of 1 
in 400. The samples were incubated for 30 minutes in the dark at 4oC. Samples were 
pelleted by centrifugation at 1600 rpm for 5 minutes at 4oC, and re-suspended in 
FACS buffer. This wash step was repeated. Intracellular transcription factor FoxP3 
staining was performed using a Treg staining kit (Biolegend). Samples were re-
suspended in 200μl 1x FoxP3 Fix/Perm Buffer made up as per manufacturers 
instructions. Samples were incubated for 12 hours at 4oC in the dark. Samples were 
pelleted by centrifugation at 1600 rpm for 5 minutes at 4oC, and re-suspended in 1x 
FoxP3 Perm buffer. This wash step was repeated. Samples were re-suspended in 
100μl Fc block (CD16/32; eBioscience) diluted 1 in 200 in FACS buffer. Samples 
were incubated for 15 minutes at 4oC. 100μl of FoxP3 antibody mixture was then 
added to each well, apart from FoxP3 FMO and the unstained control. The samples 
were incubated for 30 minutes in the dark at 4oC. All antibodies were made up at a 
concentration of 1 in 100, giving a final concentration 1 in 200 in the well. Samples 
were pelleted by centrifugation at 1600 rpm for 5 minutes at 4oC, and re-suspended 
in FACS buffer and transferred into sterile 1.2ml Microtubes (StarLabs), pre-filled 
with a further 200μl FACS buffer. Samples were analysed using a BD FACS Aria II 
(Becton Dickinson). Data analysis was performed using FlowJo Software. Graphs 
were calculated using Prism (Graphpad).  
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2.2.4 CD4+/CD8+ antibody depletion 
T-cell depletion was achieved following intra-peritoneal (IP) injection of 150μg of 
anti-mouse CD4 (GK1.5, ATCC TIB-207), anti-mouse CD8 (2.43, ATCC TIB-210) 
depleting antibodies or Rat IgG isotype control (all eBioscience) into female, age 
matched C57BL/6 mice for two consecutive days. Following two days of no 
treatment, mice were surgically implanted with 0.5x106 cells of the appropriate cell 
line. IP antibody administration was repeated again on the day of surgery, days 8, 12 
and 15 (figure 4.2A). Mice were culled two weeks after surgery and pancreatic 
tumours harvested for analysis. 
2.3 Statistics 
Statistical analysis was carried out using Graph Pad Prism7 for Mac (Graph Pad 
Software). All error bars on graphs represent standard error of the mean (SEM). 
Statistical tests used were analysis of variance (ANOVA) with Tukey’s multiple 
comparisons test and paired T-test. P-value = not significant >0.05, *<0.05, ** 
<0.01, ***<0.001, **** < 0.0001 
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2.4 List of antibodies 
 
Table 2.1 List of antibodies, clones and suppliers for stains 1, 2 and 3 
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3 Generation of a FAK-/- and FAK-wt PDAC cell 
line   
3.1 Introduction 
Recent studies using murine models of pancreatic cancer have identified a potentially 
important role for FAK in regulating the composition of the immuno-suppressive 
tumour microenvironment (TME)142,303. Mechanisms underpinning this regulation 
however are poorly understood. I therefore set out to use genetic manipulation of 
pancreatic cancer cells in order to investigate the role of cancer-cell intrinsic FAK 
signalling in modulating pancreatic tumour growth and the immuno-suppressive 
TME.  
Genome sequencing has identified that the most commonly mutated genes in human 
PDAC are KRAS, TP53, CDKN2A, SMAD4, and transforming growth factor-β 
(TGF-β) pathway alterations35,308. Although activation of oncogenic KRAS alone in 
pancreatic epithelial cells is sufficient to initiate PDAC in murine models, additional 
mutations in TP53, CDKN2A or SMAD4 can accelerate PDAC progression309. Thus 
there are now a number of transplantable and genetically engineered mouse (GEM) 
models routinely used in pre-clinical pancreatic cancer research, developed to 
incorporate one or more of these mutations whilst reliably emulating many features 
of this disease in humans. Patient derived cell lines and organoid-based xenograft 
models309 are also available but these require implantation into immune 
compromised hosts and are therefore not suitable for the purpose of my study. GEM 
models currently available are listed in table 3.1310,311,320,321,312–319 
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Table 3.1 List of current GEM models of PDAC322,323  
 
The LSL-KrasG12D/+;LSL-Trp53R172H/+; Pdx1 Cre (KPC)310 GEM model of pancreatic 
cancer is regarded as one of the best autochthonous murine models of pancreatic 
cancer currently available. This is for a number of reasons, firstly, it harbours an 
activating mutation in KRAS and an inactivating or gain-of-function mutation in the 
tumour suppressor p5318,35. These reflect two of the most frequent mutations 
identified in human pancreatic cancers; point mutations in the KRAS2 proto-
oncogene are found in 80-90% of PDACs, and point mutations in TP53 in 50-75% 
310. Secondly, the model accurately reproduces stages of disease progression in 
human PDAC, progressing from pancreata devoid of neoplastic cells in new born 
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mice to early pre-invasive lesions (PanIN 1,2 and 3) by 8-10 weeks, and to full 
PDAC by 4 – 5 months of age324. KRAS mutation rate increases in frequency as 
disease stage advances with TP53 mutations generally found in later stages of 
disease progression26 (figure 1.1). Thirdly, the KPC model reproduces many of the 
major characteristics observed in human PDAC including significant infiltration of 
F480+ macrophages, an intense desmoplastic reaction and exclusion of cytotoxic T-
cells324. Lastly, it the most comprehensively evaluated genetic mouse model of 
PDAC for studying immunotherapies, exhibiting similar responses to that reported in 
man325–328. I therefore opted to use a syngeneic cell line isolated from PDAC arising 
on the KPC model as the starting point for my studies.  
The goal of this work was to interrogate the role of cancer cell intrinsic FAK 
signalling in regulating pancreatic tumour growth and the immuno-suppressive TME. 
Therefore, it was necessary to use targeted deletion of FAK expression specifically in 
pancreatic cancer cells. A number of technologies are available for the genetic 
manipulation of cells, including CRISPR/Cas9 genome editing technology, zinc 
finger nucleases (ZFNs) and transcription activator-like effector nucleases 
(TALENs). CRISPR/Cas9 genome editing is the most recently developed method. 
Due to it’s reliance on simple base-pairing between the PAM preceded target DNA 
with the sgRNA, CRISPR/Cas9 based gene editing is now widely used as an efficient 
and reliable tool for knocking out a broad spectrum of genes from various cell lines. 
The design and engineering of sequence-specific DNA binding proteins for ZFNs 
and TALENS remains costly, time-consuming and experimentally complex and 
therefore CRISPR/Cas9 gene editing has largely superseded these other nuclease 
gene editing tools329. The speed, efficiency, low cost and ease of CRISPR/Cas9 gene 
editing technology329 represented an attractive option for rapidly creating a FAK 
depleted PDAC cell line. 
The type II clustered regularly interspaced short palindromic repeats (CRISPR) 
RNA-guided Cas9 nuclease system is a programmable nuclease based genome 
editing technology. The technology was developed from naturally occurring viral 
host defence mechanisms within various bacterial species that identify and degrade 
invading foreign nucleic acids330,331. The system works by incorporating invading 
viral DNA into the bacterial host genome within its CRISPR arrays. This enables 
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host bacteria to recognise and destroy the invading pathogenic DNA upon 
reinfection. This bacterial defence mechanism is harnessed in CRISPR/Cas genome 
editing and CRISPR constructs can be designed to recognise and nuclease cleave 
targeted areas of DNA within the target mammalian cell genome. After cleaving 
specific sites, non-homologous end joining (NHEJ) repair mechanisms result in indel 
mutations in the genome caused by insertions and/or deletions304. Indels occurring 
within coding exons can result in frameshift mutations leading to premature stop 
codons or unstable truncated protein products. 
Previous work has uncovered a novel role for FAK in controlling the composition of 
the immunosuppressive TME through FAK-dependent regulation of chemokines and 
cytokines197. Using a syngeneic transplantable cell model of SCC of the skin, FAK 
was found to translocate to the nucleus where it interacts with a number of 
transcription factors and transcriptional regulators to enhance the expression of a 
variety of chemokines and cytokines. This leads to elevated intra-tumoural Treg 
levels and suppression of the anti-tumour CD8+ T-cell response. During the course of 
my PhD, more recent work published by the Denardo lab identified a role for FAK 
signalling within pancreatic cancer cells. They found FAK signalling from pancreatic 
cancer cells broadly regulates the fibrotic and immunosuppressive tumour 
microenvironment in favour of immunosuppression142. Specifically, they focused on 
FAK’s regulation of tumour derived CXCL12 and its function in stromal expansion 
in PDAC. In order to further investigate how FAK regulates the immunosuppressive 
TME in pancreatic cancer, I chose to use of a syngeneic transplantable cell model of 
pancreatic cancer, the Panc47 cell line, isolated from pancreatic tumours arising on 
the KPC mouse model of PDAC. Using CRISPR/Cas9 genome editing I set out to 
deplete FAK expression and then reconstitute wild type FAK, thus creating two 
syngeneic cell lines that are genetically identical apart from FAK expression: FAK-
wt and FAK-/-. This approach also allows investigation of the effects of any mutant 
FAK protein on an identical genetic background in PDAC.  
In this chapter, I describe the target selection and design of sgRNA, construction of 
the CRISPR plasmid and the generation of a FAK-depleted cell line derived from 
LSL-KrasG12D/+;LSL-Trp53R172H/+ cell model of PDAC.  




1) To generate a pancreatic cancer cell line model for the study of FAK 
function.  
3.1.2 Experimental Approach 
This chapter describes the use of CRISPR/Cas9 genome editing to deplete fak 
expression in a pancreatic cancer cell line, and the subsequent re-expression of wild-
type FAK  (FAK-wt) into selected FAK-depleted (FAK-/-) cell clones. Figure 3.1 
illustrates the experimental workflow followed. To investigate the role of FAK in 
regulating the immune environment in pancreatic cancer, the syngeneic 
transplantable cell model named T332047, hereafter referred to as Panc47, was 
utilised. Panc47 was originally derived from a PDAC tumour arising on the KPC 
mouse model of pancreatic cancer.  
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• Identify target sequences within the FERM domain of FAK
CONSTRUCT
• anneal sgRNA CRISPR oligos into the pSPCas9(BB)-2A-GFP  expression 
plasmid
• screen plasmids to ensure correct gRNA insertion
TRANSFECT
• transfect target cells (Panc47) with expression plasmid containing 
sgRNA oligos
FLOW SORT
• single cell flow sort for GFP and expand colonies to create colonies of 
genetically identical cells 
SCREEN
• Screen for FAK depletion with WB and select a colony for further work
SEQUENCE
• PCR amplify target area and isolate genomic DNA for sequencing to 
identify mutation/s  
RE-EXPRESS
• re-express FAK using retroviral transduction in the FAK depleted clone 
to create 2 identical PDAC cell lines apart from expression of FAK
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3.2 Results 
3.2.1 Panc47 cells express FAK and nuclear FAK 
FAK not only localises at sites of cell-extracellular matrix contact termed Focal 
Adhesions (FAs), but also translocates to the nucleus where the function remains 
poorly characterized332. Previous studies have established that nuclear FAK can 
regulate the expression of chemokines and cytokines in SCC cells, and that this plays 
a role in establishing an immuno-suppressive tumour environment required to evade 
the anti-tumour immune response in SCC333. We hypothesised that this could be a 
potential mechanism for immunosuppression in PDAC. Therefore I first set out to 
establish that FAK was expressed in Panc47 cells in order to ensure that this was a 
suitable model for studying FAK-dependent immune regulation in PDAC. Using 
whole cell lysates and biochemical fractionation to isolate cytoplasmic and nuclear 
extracts, followed by western blotting, protein extracts (nuclear, cytoplasmic and 
whole cell lysates) were probed for FAK (figure 3.2) and FAK was found to be 
readily detectable.   
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Figure 3.2 Parental PDAC cell line (Panc47) derived from LSL-KrasG12D/+;LSL-Trp53R172H/+ 
pancreatic cancer cells express total and nuclear FAK.  
Western blot of whole cell, nuclear and cytoplasmic fractions obtained after either cell lysis or nuclear 
fractionation of Panc47 cells. The western blot was probed with antibodies specific to FAK, PARP 
(nucleus) and GAPDH (cytoplasm), demonstrating efficient fractionation and the presence of 
cytoplasmic and nuclear FAK. Refer to appendix 1 for full western blot.  
  
 
3.2.2 Guide sequence (sgRNA) design and plasmid 
construction.  
Having identified that Panc47 cells express FAK and nuclear FAK, I used 
CRISPR/Cas9 genome editing to deplete FAK. The type II CRISPR-Cas system 
described in this thesis and in the protocol published by Ran et al 304 was derived 
from S.pyogenes bacteria. This system consists of two components: the Cas9 
nuclease and a guide RNA (gRNA). The gRNA is comprised of the CRISPR RNA 
(crRNA) fused to the auxiliary trans-activating crRNA (tracrRNA). The tracrRNA is 
involved in initiating the cleavage process and the 20 nucleotides to the 5’ end of the 
gRNA guides the Cas9 nuclease to the target gene of interest, in this case the FAK 
gene, through Watson-Crick base pairing329. For S.pyogenes derived Cas9 to 
function, the target cell DNA must immediately precede a 5’NGG-PAM (protospacer 
adjacent motif) sequence329,330. Although these targeting sites occur frequently at a 
rate of 1 in every 32bp329, this must be taken into account when identifying 
appropriate gRNA sequences. The online CRISPR design tool (http://crispr.mit.edu/) 
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(figure 3.3). The gRNAs were designed to sites near the N terminus of the FAK 
gene, the region encompassing the FERM domain, in order to minimise the chances 
of a functional protein being produced following successful genome editing. 
Frameshift mutations are more likely to cause premature stop codons and therefore 
disruption in protein synthesis via nonsense mediated mRNA decay (NMD) if the 
stop codon is located near to the 5’ end of a gene334. Given that the mutation is found 
in the N terminus region of the FERM domain, mutant mRNA transcripts would 
likely not be expressed or if expressed would be unstable, resulting in degradation. 
Additionally there is a single identified FAK promotor and therefore a single start 
site, thus making production of FAK isoforms not detected on WB unlikely. The 
CRISPR design software identifies suitable complementary pairs of gRNAs and then 
ranks them according to the number of potential off target binding sites, enabling 
selection of optimal sgRNA oligonucleotides. The resulting two top ranking guide 
oligonucleotide pairs (gFAK4 and gFAK6) were synthesised to include overhangs 
complementary to those created by Bbs1 digestion of the expression plasmid to allow 
annealing into the expression plasmid. 
The mammalian expression plasmid pSPCas9(BB)-2A-GFP was chosen because it 
constitutively expresses the Cas9 protein and contains a GFP selection cassette to 
enable easy identification of cell clones where retroviral transfection into cells has 
been successful. Complementary guide oligonucleotides were annealed and cloned 
into this plasmid, and the plasmid transformed into chemically competent Top10 
bacteria and cultured overnight in LB containing ampicillin to take advantage of 
selection using the ampicillin resistance gene within the plasmid. DNA was extracted 
from bacterial colonies and sent for sequencing using the U6 forward primer. 
Sequences were aligned to determine if they contained the inserted oligos; clones 1 








Figure 3.3 cloning strategy of guide sequence into pSPCas9(BB)-2A-GFP (PX458) expression 
plasmid. 
Schematic of the pSPCas9(BB)-2A-GFP expression plasmid. The plasmid contains the ampicillin 
resistance gene (blue box), U6 promotor (purple arrow) and Cas9 expression cassette (orange box). 
Guide target sequences were synthesised as complementary oligonucleotides, annealed, and ligated 
into a BbsI cut expression plasmid upstream of tracrRNA scaffold to form the guide RNA (gRNA). 
Extra bases (blue italics) were added to 5’-ends of oligonucleotides to create matching overhangs to 
BbsI cut plasmid. Transcription of the gRNA was driven by the U6 promotor (purple arrow). The 
extract of sequence traces confirms successful cloning of CRISPR guide sequences into the expression 
plasmid. Guide sequences are highlighted in red. The plasmid was lipofectamine transfected into the 
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3.2.3 Clone generation and isolation  
To generate FAK-depleted Panc47 cell clones, cells were transfected with the 
expression plasmids containing either the gFAK4 or gFAK6 guide sequences, and 
GFP positive clones were sorted into 96-well plates using FACS (Fluorescence-
activated cell sorting). Resulting cell colonies were tested for successful depletion of 
FAK expression using anti-FAK western blotting. From a total of 16 colonies tested, 
12 were identified to be FAK deficient (figure3.4). 
 
Figure 3.4 Screening of CRISPR clones derived from the parental Panc47 PDAC cell line 
Western blots demonstrating successful knock out of clones: 47-g6-clone3, 47-g64clone2, 47-g4-




3.2.4 Identification of the genetic mutation arising from 
CRISPR genome editing 
One FAK depleted clone, 47-g4-clone2, was selected as it was a clear FAK deficient 
knock out on WB, displayed similar growth characteristics and appeared 
morphologically similar in cell culture to the other successful FAK knock out 
clones.. Therefore clone 47-g4-clone2 (hereafter referred to as FAK-/-) was chosen 
as a good representative clone for follow up work. Genomic cDNA was extracted 
and PCR amplified using FAK specific primers. Using the FAK forward and reverse 
primers again, direct sequencing of this PCR product was performed to confirm 
depletion of FAK and identify the mutation that had occurred (figure 3.5). 
Sequences were aligned using ClutsalW (European Bioinformatics Institute) 
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coding sequence) (figure 3.5A). Comparison of the predicted protein sequence with 
that of wild-type FAK identified a premature STOP codon at amino acid position 193 
(figure 3.5B) confirming that if a protein were to be produced, it would result in a 
severely truncated protein produced with a predicted molecular weight of 
approximately 22.4KDa. Western blotting using a FAK antibody raised to an epitope 
in the N-terminus did not detect a protein product of the predicted molecular weight, 
suggesting that if a product is produced then it is likely to be unstable and rapidly 
degraded (figure 3.6A). 
 
 
Figure 3.5 Successful creation of CRISPR generated FAK -/- PDAC clone. Confirmation via 
genomic sequencing and protein alignment 
A Sequencing of genomic region targeted by guide sequences showing the guide sequence and 
mutation created at position 579, aligned to sequence from mouse genome database. B Protein 
alignment demonstrating an early stop codon at AA position and a truncated protein 
  
 
3.2.5 Reconstitution to create a FAK-wt clone 
To generate a cell model with which to further study FAK function, I next re-
expressed wild-type FAK (FAK-wt) into Panc47 FAK-/- cells using retroviral 
transduction. Successful re-expression of FAK-wt was confirmed using western 
blotting (figure 3.6B). Biochemical fractionation was used to isolate nuclear and 
cytoplasmic fractions. Western blotting of protein extracts was carried out using an 
anti-FAK antibody (figure 3.6C) and FAK was found to be readily detectable in the 



















A   Sequencing of FAK -/- clone vs murine FAK
B   Protein alignment of FAK -/- clone vs murine FAK
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Figure 3.6 CRISPR generated FAK -/- PDAC clone and FAK-wt (reconstituted clone from 47-
g4-clone2)  
A Full length WB showing MW (molecular weight) markers (Bio-Rad Precision Plus Protein Dual 
Colour Standard), probed with monoclonal anti-FAK (4.47) antibody specific to the N-terminal 
domain of FAK, demonstrating absence of 22.4kDa fragment. B Cropped WB as in 3.6 A 
demonstrating absence of FAK in the CRISPR knock out cell line (FAK-/-) and additionally the re-
expression in the FAK-wt cell line. C WB of nuclear and cytoplasmic fractions obtained after nuclear 
fractionation of FAK-/- and FAK-wt cell line. This demonstrates the absence of FAK and nuclear 
FAK in the FAK-/- cell line and presence of FAK and nuclear FAK in the FAK-wt cell line. The 
western blot was probed with antibodies specific to FAK, nuclear PARP and cytoplasmic GAPDH, 





































B   WB of chosen FAK wt and FAK -/- clones 
C   WB of chosen FAK-wt and FAK-/- clones 
A   Full length WB of chosen FAK wt and FAK -/- clones 




  -50 
-37 
-25 


















  CHAPTER 3 RESULTS 
 62 
3.3 Discussion 
Using CRISPR genome editing, I have successfully generated a pancreatic cancer 
cell model that enables the study of cancer cell intrinsic FAK signalling in the 
regulation of pancreatic tumour growth and the immuno-suppressive TME. This 
approach was employed, as it is not only time efficient and cost-effective, but also 
because it facilitates detailed mechanistic downstream studies. An alternative 
approach would have been to generate a GEM model in which fak expression is 
specifically depleted in the pancreatic cancer cell of origin. This would have been 
possible through crossing mice carrying a conditional knockout floxed fak allele335 
with the KPC mouse to generate experimental Pdx1 Cre LSL-KrasG12D/+;LSL-
Trp53R172H/+; FAKflox/flox mice. However, the drawbacks of this approach would have 
been the time taken to generate this model, in addition to some of the impracticalities 
involved in generating adequate KPC mouse numbers. Once this model is 
successfully created, not only is the mean latency approximately 4-5 months310 for 
the KPC mice to generate pancreatic tumours, but KPC mice normally have to be 
enrolled in experiments on a rolling basis due the complicated breeding strategy and 
enrolment criteria324. This may have resulted in insufficient numbers to fill 
experimental groups. Therefore this approach would have been difficult to achieve in 
the time frame I had available to me. The use of implanted PDAC cell lines have 
been shown to have a similar histological appearance and immune cell profile to 
those PDACs arising spontaneously in the KPC mouse model324 and therefore a 
transplantable model was deemed the most suitable model system to use.  
CRISPR/Cas 9 gene editing technology was employed to create a FAK knock out 
line in the Panc47 cells. This is an efficient and reliable gene-editing tool and has 
largely superseded other nuclease gene editing technologies, thus was the most 
appropriate choice. In this chapter I show successful FAK-depletion using CRISPR 
gene editing in 12 clones. One clone was carried forward for further experiments and 
FAK re-expression. There are however some drawbacks of this technology that can 
affect specificity and efficiency. Two potential concerns with use of plasmid 
transfection is the possibility for immune responses to viral particles336 and long 
lasting Cas9:sgRNA expression, increasing the potential for off target genome 
editing after it has successfully modified the target locus337. Since commencing my 
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PhD studies there have been some advances in CRISPR/Cas9 genome editing 
technology, developed to overcome some of these issues. Direct delivery of 
Cas9:sgRNA ribonucleotide protein complexes (RNPs) into cells via cationic lipid 
delivery338,339 and cell penetrating peptide-mediated delivery336,340 can now be 
achieved to allow for transient Cas9 activity without the use of viral transfection. 
Systems inducing temporal Cas9 activity through light activation341 or small 
molecule activation342,343 can also be employed to address concern around the 
longevity of Cas9 activity within cells. These new technologies have been shown to 
not only increase the efficiency but also the specificity of genome modification 
compared to transfection techniques.  
In this chapter I describe the successful generation of a FAK-depleted pancreatic cell 
line and re-expression of FAK-wt to create a genetically identical cell line, other than 
expression of FAK, to allow dissection of FAK’s contribution to the 
immunosuppressive TME present in PDAC. The comparison of these two syngeneic 
clones allows clinically relevant insights into the immunotherapeutic potential of 
pharmacological inhibitors of FAK’s function in cancer treatment. 
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4 The role of FAK in tumour growth and on 
the tumour myeloid population in-vivo  
4.1 Introduction 
Previous studies using mouse models of pancreatic cancer have demonstrated that 
treatment with FAK kinase inhibitors can impair pancreatic tumour growth142,303. 
However, the precise mechanisms that underpin this response have not been fully 
elucidated. While FAK is known to regulate multiple cellular processes that can 
impact on tumour growth, including cancer cell cycle progression, adhesion, 
polarisation, migration, apoptosis, proliferation and survival263, emerging evidence 
has also identified a role for FAK in regulating the pancreatic tumour 
microenvironment. For example, inhibition of pancreatic tumour growth in 
response to treatment with the FAK inhibitor PF562271 was associated with a 
reduction in tumour infiltrating macrophages. In support of this, Jiang et al 
identified that treatment with the pharmacological inhibitor VS4718 resulted in 
reduced growth of pancreatic tumours and this was associated with broad 
reprogramming of the immune environment, including macrophage regulation142. 
This study, published during the course of my PhD, used short hairpin RNA 
(shRNA) to deplete FAK expression in KPC-derived pancreatic cancer cell lines 
and demonstrated reduced tumour growth in response to FAK depletion. Thus, 
FAK regulates pancreatic tumour growth and the immunosuppressive tumour 
environment. However, the mechanisms that govern this remain poorly 
characterised.   
Components of the PDAC TME are known to promote tumour growth and 
progression. The highly immunosuppressive TME is characteristic of PDAC and 
stromal components occupy the majority of the tumour mass39–41. Many of these 
cell types have been shown to promote pancreatic tumour growth. These include 
macrophages, MDSCs, Tregs, TH2 cells, CAFs, myofibroblasts and endothelial 
cells48,49. The most numerous immunosuppressive population is the extensive 
myeloid cell population, with tumour associated macrophages (TAMs) being the 
most abundant, far outnumbering other immunosuppressive cells types such as the 
more scarce T-cell population56,64. The high numbers of TAMs in the PDAC TME 
perhaps reflects their critical role in pancreatic tumour progression. TAMs exhibit 
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extensive heterogeneity in function and phenotype, and grouping these different 
subpopulations is a constantly evolving topic. Macrophages historically have been 
subdivided into ‘classically activated’ macrophages and ‘alternatively activated’ 
macrophages, now designated as M1 and M2 macrophages respectively344,345. M2 
macrophages are gaining increasing interest due to their correlation with a poorer 
prognosis and ability to modify and maintain the immunosuppressive TME in 
various tumour types64. In a study analysing surgical patients with pancreatic 
cancer, accumulation of M2 TAMs correlated with earlier metastasis, larger tumour 
size and shorter survival times65. Traditionally it was also thought that TAMs were 
derived from circulating monocytes, but recent evidence suggest that in the normal 
pancreas, tissue resident macrophages are almost entirely embryonically derived 
from the yolk sac346, and that both resident and recruited Ly6Chi bone marrow 
derived macrophages are expanded through in situ proliferation during pancreatic 
tumour progression56. It is likely that phenotypically distinct macrophage subsets 
possessing different functions exist in PDAC. The mechanism and complexity of 
the FAK driven TAM compartment within the PDAC TME and the expression 
pattern that clearly define the macrophage subsets regulating immunosuppression in 
PDAC models is yet to be fully unravelled56,347. Therefore I focused on initially 
exploring FAK-dependent regulation of the tumour myeloid compartment using 
orthotopic implantation of the two syngeneic PDAC cell lines: Panc47 FAK-wt and 
Panc47 FAK-/-, derived from Panc47 LSL-KrasG12D/+;LSL-Trp53R172H/+, the 
generation of which is described in chapter 3. These cell lines are genetically 
identical apart from FAK expression and therefore this approach allows for 
investigation of the effects of mutant FAK in-vivo on an identical genetic 
background.  
4.1.1 Aims 
1. To determine whether FAK-depletion in Panc47 cells results in a 
tumour growth delay and improved survival. 
2. To determine whether FAK regulates the immune cell infiltrate in 
orthotopic Panc47 tumours. 
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4.2 Results 
4.2.1 FAK-depletion delays tumour growth, resulting in 
improved overall survival 
FAK inhibition has previously been shown to impair pancreatic tumour 
growth142,303. I therefore set out to identify whether FAK depletion in Panc47 cells 
resulted in a tumour growth delay and improved overall survival. 0.5x106 Panc47 
FAK-wt or FAK-/- cells were implanted into the pancreas of immune competent 
C57BL/6 mice under sterile surgical conditions and allowed to grow for either two 
or three weeks, before harvesting and weighing the tumours. Tumours were 
analysed by a pathologist. FAK-wt and FAK-/- tumours were largely comparable 
(table 4.1) but the FAK-wt tumours had a more fibrotic stroma, consistent with 
other studies reported in the literature with FAK depletion in PDAC142. Implanted 
tumours were also largely comparable to tumours arising in the KPC GEM model 
of pancreatic adenocarcinoma. Average tumour weight was calculated and plotted 
as a line graph of tumour weight over time (figure 4.1 A). Results show a 
significant reduction in tumour weight at both 2 and 3 weeks in the Panc47 FAK-/- 
tumours when compared with Panc47 FAK-wt tumours, consistent with previous 
reports142,303. To determine whether this tumour growth delay resulted in an 
improvement in overall survival, 0.5 x 106 Panc47 FAK-wt or FAK-/- cells were 
implanted into the pancreas of C57BL/6 mice, and mice were monitored for 
terminal symptoms caused by pancreatic tumour growth including weight loss 
equal or exceeding 10% of starting weight, signs of abdominal pain and abdominal 
distension. If any one symptom became apparent, the animal was euthanized. The 












Table 4.1 Histological comparison tumours arising on the KPC model of pancreatic 
adenocarcinoma and implanted FAK-wt and FAK-/- tumours  
Histological analysis for table courtesy of Dr James Baily, BVM&S MSc PhD DiplECVP MRCVS 
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Figure 4.1 FAK-depletion in Panc47 pancreatic cancer cells results in impaired tumour 
growth and improved overall survival  
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK wt or FAK -/- cell lines A 
Tumours were harvested at two or three weeks (n= 20 mice per group; error bars represent SEM; 
statistical test used was Students T-test). B Survival curves of mice with pancreatic implantation of 
Panc47 FAK-wt or FAK-/- cell lines. Mice were sacrificed once they presented with terminal 
symptoms related to pancreatic neoplasia (n= 7 mice per group; error bars represent SEM; statistical 
test used was Log-rank). FAK-depletion in Panc47 pancreatic cancer cells results in impaired 
tumour growth and reduced overall survival. P-value = not significant >0.05, *<0.05, ** <0.01, 
***<0.001, **** < 0.0001 
 
4.2.2 CD8+ T-cell depletion restores FAK-dependent growth 
delay 
Previous studies have demonstrated a link between FAK expression and regulation 
of immunosuppressive cell types that then inhibit cytotoxic T-cells within the TME 
in murine models of SCC301 and pancreatic cancer142. I therefore sought to 
determine whether the observed growth delay was a consequence of an anti-tumour 
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immune response. To investigate this, C57BL/6 mice were treated with a CD8+ T-
cell depleting antibody and 0.5 x 106 Panc47 FAK-wt or FAK-/- cells were 
implanted into the pancreas. CD8+ T-cell depletion was initiated prior to tumour 
implantation to achieve a CD8+ T-cell depleted background to ensure these cells did 
not play a role in the biology of tumour progression. Depletion was maintained 
throughout the course of the experiment by a twice-weekly injection of anti-CD8 
antibody (figure 4.2 A). Mice were sacrificed two weeks after tumour cell 
implantation and tumours weighed. Tumour growth was significantly restored in 
anti-CD8 treated mice bearing Panc47 FAK-/- tumours (figure 4.2 B) when 
compared with isotype control antibody treated mice. No effect on tumour growth 
was evident between isotype control and anti-CD8 antibody treated mice bearing 
Panc47 FAK-wt tumours. These results imply that a significant proportion of the 
Panc47 FAK-/- tumour growth delay is the result of an anti-tumour CD8+ T cell 
response. 
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Figure 4.2 Pancreatic tumour growth +/- CD8+ T-cell depletion and FAK-depletion.  
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt or FAK-/- cell lines. 
Groups (n= 6 per group) were treated with either CD8+ depleting antibody or isotype control. A 
Dosing schedule B Tumours were harvested and weights recorded at 14 days post implantation (n= 
6 per group; error bars represent SEM; statistical test used was Students T-test, P-value = not 
significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 0.0001 
 
4.2.3 FAK promotes M2 polarisation of Ly6C+ TAMs 
Recruitment and expansion of immune cells including macrophages, MDSCs and 
Tregs with intrinsic immunosuppressive capabilities have been shown to suppress 
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the anti-tumour immune response and promote tumour survival in pancreatic 
cancer48. Therefore, I next sought to determine whether FAK driven changes in 
these immunosuppressive populations could correlate with the CD8+ T-cell 
mediated change in the observed growth characteristics between Panc47 FAK-wt 
and FAK-/- tumours. Thus I set out to investigate whether cancer cell FAK 
signalling influences changes in the abundance or phenotype of these immune 
populations. 0.5x106 Panc47 FAK-wt or FAK-/- cells were implanted into the 
pancreas of C57BL/6 mice and tumours harvested at two weeks for disaggregation 
and analysis by flow cytometry with stain 1 and stain 2 (table 4.2). The immune 
cell markers and gating strategy used to identify Tregs and myeloid populations are 
demonstrated in table 4.3 and figure 4.3 A and B respectively. Immune profiling of 
Panc47 FAK-wt and FAK-/- tumours identified that FAK depletion results in a 
significant reduction in Tregs known to influence cytotoxic T-cell activity (figure 
4.4). 
Detailed analysis identified four distinct populations of macrophages within 
pancreatic tumours defined by their expression level of CD11b and Ly6C: 
CD45+CD11bhiF480+Ly6C+ (inflammatory macrophage/ TAM), 
CD45+CD11bhiF480+Ly6C- (resident macrophage), CD45+CD11bloF480+Ly6C+ and 
CD45+CD11bloF480+Ly6C- macrophages. Recent evidence has shown differential 
expression of CD11b and Ly6C in pancreatic TAMs based on whether these 
macrophages were derived from tissue resident or bone marrow recruited 
macrophages56, however further analysis was not carried out to determine which 
population these cells were derived from. The total frequency of macrophages was 
not found to be different between Panc47 FAK-wt and FAK-/- tumours, and neither 
was the frequency of the different macrophage subsets. Total levels of G-MDSC 
and M-MDSCs were also not different (figure 4.4). Using markers indicative of 
classical M1 macrophage activation (MMR-CD86+) and the alternative M2 
activation (MMR+CD86-), I found a shift in the proportion of alternatively activated 
M2-like polarised macrophages within the subpopulations of macrophages 
identified when comparing Panc47 FAK-wt and FAK-/- tumours. The proportion of 
alternatively activated M2-like polarised macrophages was significantly higher in 
the Ly6C+ subpopulations (CD45+CD11bhiF480+Ly6C+ and 
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CD45+CD11bloF480+Ly6C+) within Panc47 FAK-wt tumours when compared to 
Panc47 FAK-/- tumours. The proportions of classically activated M1-like 
macrophages in these same macrophage subpopulations were significantly higher in 
Panc47 FAK-/- tumours verses Panc47 FAK-wt tumours (figure 4.5). This suggests 




Table 4.2 Flow cytometry stain used to identify myeloid (stain 1) and Treg (stain 2) 
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Figure 4.3 Gating strategy for flow cytometry analysis of Tregs, tumour macrophages and 
their polarisation status.  
A Gating strategy applied to stain 1 (Table 4.1) and FMO control samples to determine proportions 
of TAMs. TAM polarisation was determined using MMR and CD86 expression. B Gating strategy 
applied to stain 2 (Table 4.1) to identify Tregs and FMO control samples used to determine Treg 
population. Each FMO control sample contains every marker in stain 2 except for the named 
marker. FMO control samples were used to determine the correct gating positions in flow cytometry 
analysis to exclude false positive results. FMO=Fluorescence minus one, FSC-A= forward scatter 
area, SSC-A= side scatter area. 
  




Figure 4.4 FAK-depletion in Panc47 pancreatic cancer cells alters total Treg levels but does 
not alter total levels of intra-tumoural macrophage, G-MDSC or M-MDSC. 
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt or FAK -/- cell lines 
and harvested at 14 days post implantation. (n= 3 per group; error bars represent SEM; statistical test 
used was Students T-test), gating and stains as described in figures 4.3 and table 4.1 respectively. A 
total intra-tumoural Tregs, B total intra-tumoural macrophages C CD11blo intra-tumoural 
macrophages D CD11bhi intra-tumoural macrophages E CD11bhi/lo Ly6C+/- intra-tumoural 











Figure 4.5 FAK-depletion in Panc47 pancreatic cancer cells results in M2-like to M1-like 
polarisation of Ly6C+ tumour associated macrophages  
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt or FAK -/- cell lines 
and harvested at 14 days post implantation. (n= 3 mice per group; error bars represent SEM; 
statistical test used was Students T-test, P-value = not significant >0.05, *<0.05, ** <0.01, 
***<0.001, **** < 0.0001, gating as described in figure 4.2) A M2 (CD86+ MMR-) in 
CD11bhi/loLy6C+/- macrophages in FAK-wt and FAK-/- pancreatic tumours B M1 (CD86- MMR+) in 
CD11bhi/loLy6C+/- macrophages in FAK-wt and FAK-/- pancreatic tumours 
 
 
4.2.4 FAK promotes PD-L2 expression in the myeloid cell 
compartment  
PD-L1 (also known as B7-H1/ CD274) is widely expressed whereas PD-L2 (also 
known as B7-DC/ CD273) has a more restricted expression pattern and both are 
ligands for PD-1, a co-inhibitory receptor expressed by activated T-cells that acts as 
an immune checkpoint to regulate T-cell activity. Both ligands have been found to 
be over expressed in post-surgical PDAC specimens258 and are thought to be 
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involved in immune evasion in cancer. Therefore, I sought to investigate whether 
expression of PD-L1 and / or PD-L2 was different in myeloid cell subsets present 
in Panc47 FAK-wt and FAK-/- tumours. 0.5x106 Panc47 FAK-wt or FAK-/- cells 
were implanted into the pancreas of C57BL/6 mice and tumours harvested at two 
weeks for disaggregation and analysis by flow cytometry with stain 1 (table 4.2). 
The immune cell markers and gating strategy used to identify the various myeloid 
populations and macrophage subpopulations are demonstrated in table 4.3 and 
figure 4.2 respectively. Both macrophages and MDSCs from Panc47 FAK-/- 
tumours were found to have reduced surface expression of the immune checkpoint 
ligand PD-L2 but not PD-L1 (figure 4.6). PD-L1 expression was reduced on 
Panc47 FAK-/- tumour cells/ stromal fibroblasts. This is an interesting finding but 
was not investigated further in this study. PD-L2, induced on monocytes and 
macrophages by CSF1, IL4, and INF-γ 348, is linked to immunosuppressive 
macrophage function349. I demonstrate that FAK expression in pancreatic cancer 
cells increases the percentage of macrophages expressing PD-L2, implying that 
FAK-dependent signalling in pancreatic cancer cells can influence the 
immunosuppressive function of TAMs. PD-L2 has a more restricted expression 
profile than PD-L1, but expression is not restricted to the macrophage population 
and has also been reported on dendritic cells350,endothelial cells351, tumour 
cells352,353,B-cells354, TH2 cells
355 and MDSCs356. I therefore looked at PD-L2 
expression on other cells in the PDAC TME and identified regulation of PD-L2 
expression in the wider myeloid population including G-MDSCs and M-MDSCs 
(figure 4.7 A). PD-L1 expression was not regulated (figure 4.7 B). 
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Figure 4.6 FAK-depletion in Panc47 pancreatic cancer cells results in reduced surface 
expression of the immune checkpoint ligand PD-L2 but not PD-L1 in all tumour associated 
macrophage subsets  
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt or FAK-/- cell lines 
and harvested at 14 days post implantation. (n= 3 per group; error bars represent SEM; statistical test 
used was Students T-test, P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 
0.0001, gating as described in figure 4.2 A PD-L1 expression on CD45+CD11bhi/loF480+Ly6C+/- 
TAM B PD-L2 expression on CD45+CD11bhi/loF480+Ly6C+/- TAM  
  




Figure 4.7 FAK-depletion in Panc47 pancreatic cancer cells results in reduced surface 
expression of the immune checkpoint ligand PD-L2 specifically in the myeloid compartment  
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt or FAK-/- cell lines 
and harvested at 14 days post implantation. (n= 3 per group; error bars represent SEM; statistical test 
used was Students T-test, P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 
0.0001, gating as described in figure 4.2 and immune cell population markers as described in table 
4.1. A PD-L2 expression on CD45+CD11bhi/loF480+Ly6C+/- TAM, G-MDSCs, M-MDSCs, 
endothelial cells, dendritic (CD11b-/+) cells, T/B cells and other cells (presumed to be tumour cells 
and stromal fibroblasts). B PD-L1 expression on CD45+CD11bhi/loF480+Ly6C+/- TAM, G-MDSCs, 
M-MDSCs, endothelial cells, dendritic (CD11b-/+) cells, T/B cells and other cells (presumed to be 
tumour cells and stromal fibroblasts). 




In this chapter I show that cancer cell intrinsic FAK signalling regulates Panc47 
tumour growth and overall survival, at least in part through regulating the anti-
tumour CD8+ T-cell response.  This mirrors clinical findings in surgical cases 
where increased levels of FAK expression correlate positively with pancreatic 
tumour size300 and negatively with patient survival142.  
For the purpose of this study I elected to implant the pancreatic tumour cell lines 
into the pancreas of immune competent mice. My main interest is the immune TME 
and therefore this method was selected in order to recapitulate the local immune 
environment as closely as possible. Tumour growth was estimated by the difference 
in tumour weight at 2 and 3 weeks. The pitfall of this method is lack of kinetic 
measurements over time. Growth of tumours implanted subcutaneously can be 
more easily monitored using callipers, however orthotopically implanted tumours, 
although more difficult to monitor due to their intra-abdominal position, have the 
advantage of developing in their native organ. One way to overcome the difficulty 
in monitoring intra-abdominal tumour growth in live mice is through sequential 
MRI scans303, ultrasound imaging324 or through the use of bioluminescence imaging 
as PDAC cell lines can be engineered to express a luciferase reporter324. MRI has 
significant cost implications due to equipment requirements and therefore would 
likely not be the method of choice for my study but all of these methods would 
allow for longitudinal imaging of tumour growth, thus refining my experimental 
approach.  
FAK has a number of cellular functions in cancer including regulation of cancer 
cell proliferation, survival, invasion, migration and adhesion267. There are 
consequently a multitude of FAK functions that could account for an increase in 
tumour growth and reduced mouse survival in this model. Previous work has 
demonstrated a novel function for FAK in mediating SCC growth in immune 
competent FVB mice via FAK-dependent regulation of chemokines and cytokines. 
These changes in the chemokine/cytokine and ligand-receptor networks were found 
to control the composition of the immunosuppressive TME to increase numbers of 
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immunosuppressive Tregs and inhibit antigen-primed cytotoxic CD8+ T cell 
activity, permitting growth of FAK-expressing SCC tumours. I therefore wanted to 
explore the possibility of FAK dependent changes in the pancreatic tumour TME, 
and whether these changes contribute to the accelerated growth observed in 
implanted pancreatic tumours.   
Tumour associated macrophages are gaining increasing interest due to their role in 
modifying the immunosuppressive tumour microenvironment and supporting 
cancer cell survival. Macrophages display a high amount of plasticity and can adopt 
different phenotypes depending on the micro-environmental stimuli they are 
exposed to. In the context of cancer, studies have demonstrated phenotypically 
distinct macrophage subpopulations357 and although it is likely that subpopulations 
have different functions, studies fully exploring these potential diverging roles are 
currently lacking. We show that analysis of disaggregated orthotopically implanted 
pancreatic tumours by flow cytometry identified four different sub-populations of 
macrophages; (CD45+CD11bhiF480+Ly6C+, CD45+CD11bhiF480+Ly6C, 
CD45+CD11bloF480+Ly6C+ and CD45+CD11bloF480+Ly6C-), based on separation 
of populations seen on analysis. FACS separation and further in-vitro functional 
assays of these identified populations were not performed in this study, however 
further flow cytometry analysis revealed two main additional findings: FAK-
depletion in pancreatic cancer cells results in M1-like polarisation of Ly6C+ tumour 
associated macrophages, and reduced surface expression of the immune checkpoint 
ligand PD-L2 in all tumour associated macrophages.  
Though there is some debate around the existence of alternatively activated/ M2 
and classically activated/ M1 macrophage phenotypes358, it is generally thought that 
the M2 phenotype is pro-tumour and the M1 phenotype is tumouricidal61. Tumours 
are often driven to a TH2 polarised TME which results in escape from immune 
surveillance350. IL4 and IFNγ are two of the main drivers of the TH2 and TH1 
immune responses respectively and likewise, are drivers of respective M2 and M1 
macrophage polarisation61. In PDAC, 85% of all TAM are of the M2 phenotype64 
and their increased numbers correlate with increased tumour size and shorter 
survival times in post surgical patients65. Therefore the changes I observe in the 
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polarization of macrophages are likely to contribute to the tumour growth delay and 
increased survival in mice with FAK-/- tumours. 
 
Figure 4.8 FAK signalling in pancreatic cancer cells regulates mechanisms of immune evasion 
to promote tumour growth (conclusions so far) 
FAK-regulated cancer cell derived IL6 to reprogram tumour associated macrophages to a phenotype 
associated with tumour promotion, thus creating an immunosuppressive tumour microenvironment, 
with inhibition of cytotoxic T-cells and acceleration of tumour growth.  
The PD-L1/PD-1 pathway has been extensively studied in the context of cancer and 
therapies inhibiting this pathway are currently undergoing clinical trials. Less 
emphasis has been placed on PD-L2, the other PD-1 ligand; the role of up-regulated 
PD-L2 in modulating tumour immunity is less well understood. Compared to PD-
L1, constitutive basal expression of PD-L2 is low and expression is largely 
restricted to antigen presenting cells such as myeloid cells and DCs350 but it has 
been reported on some other cell types. Both PD-L1 and PD-L2 are over expressed 
in human PDAC cancer258. Despite this, PD-1 inhibition has yet to yield a 
therapeutic advantage in clinical trials. A reduced tumour growth rate however was 
recorded when mice bearing Pan02 tumours were treated with PD-L2 blocking 
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antibodies, and this was comparable to that seen when PD-L1 or PD-1 was 
inhibited359, suggesting that PD-L2 inhibition can effectively induce anti-tumour 
responses, even in the absence of PD-L1 inhibition.  On the one hand this may 
reflect targeting of PD-L2 is a potential untapped therapeutic option, however the 
model used should also be taken into consideration. The Pan02 cell line is derived 
from PDAC tumours arising in the pancreas of C57BL/6 mice implanted with 3-
methyl-cholanthrene (3-MCA)-saturated threads of cotton in the pancreas360. This 
carcinogen induced cell line model reproduces human PDAC histologically but it 
lacks some of the most common driving mutations present in human PDAC: Kras 
and Trp53361, and it may also generally harbour a higher mutational burden as a 
consequence of the way in which it was derived. A higher neoantigen level could 
potentially make this model more immunogenic, therefore lacking clinical 
significance when compared to the low immunogenicity of the majority of human 
PDAC. Thus the jury is still out as to whether a clinical advantage can be gleaned 
from inhibiting the PD-L1/PD-L2-PD-1 axis in pancreatic cancer.  
PD-1 may not be the only receptor by which PD-L2 exerts its effects in T-cell 
activation. Murine models of allergy show more severe disease when PD-L2 is 
inhibited but not PD-L1, and PD-L2 can still exert functional effects on T-cells 
derived from PD-1 deficient mice362,363. It may be that therapeutic approaches 
targeting PD-L2 remains an untapped avenue for treatment of pancreatic cancer.  
In recent years several groups have shown that murine macrophage PD-L1 and PD-
L2 expression is differentially regulated by TH1 and TH2 T cells respectively
348,350. 
Various studies show that PD-L2 on macrophages is up-regulated in an 
immunosuppressive environment in response to TH2 cytokines such IL10
364, and 
IL4365. A TH2 polarised microenvironment contains the same environmental stimuli 
required for M2 polarisation of TAMs. It is therefore not surprising that both M2 
macrophage polarisation and PD-L2 up-regulation were found concurrently on 
PDAC TAMs. FAK appears to be inducing PD-L2 across the tumour myeloid 
populations but only induces MMR expression in Ly6C+ macrophages. This 
suggests that MMR and PD-L2 are regulated by independent mechanisms.  
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As shown in this chapter, cancer cell FAK signalling appears to enhance both M2-
like macrophage polarisation and myeloid compartment PD-L2 expression. 
Therefore, our next line of enquiry was to investigate whether cancer cell FAK 
signalling is responsible for alteration in cancer cell derived cytokines expression, 
including production of TH2 cytokines, and whether there was any subsequent 
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5 FAK-dependent IL6 shifts the TAM 
phenotype to the pro-tumour phenotype and 
regulates pancreatic tumour growth in-vivo 
5.1 Introduction  
The phenotype of tumour associated macrophages (TAMs) can be shaped by signals 
they receive from their surrounding microenvironment61. Examples of these signals 
include cytokines such as, but not limited to, IL4, CSF-1, IL13, IL1060,67, IL6366,367, 
G-CSF368,369 and GM-CSF76,370,371. FAK has previously been shown to regulate 
tumour-derived factors that can influence the composition of the TME within various 
cancer models including SCC197 and  pancreatic cancer142. In SCC, this immune cell 
TME regulation was found to be dependent upon both FAK kinase activity and also 
nuclear translocation of FAK, where FAK regulated transcription of various 
chemokines and cytokines. CCL5 expression in SCC cancer cells led to elevated 
levels of Tregs in the TME and subsequent suppression of the anti-tumour CD8+ T-
cell response, permitting growth of FAK-expressing tumours197. I therefore 
hypothesised that FAK-dependent regulation of paracrine signalling represents a 
potential mechanism through which FAK signalling in pancreatic cancer cells can 
influence the phenotype of TAMs.  
 
5.1.1 Aims 
1. To determine whether FAK regulates chemokine / cytokine secretion 
from pancreatic cancer cells, and if so: 
 
2. Determine whether FAK-dependent paracrine signalling regulates the 








5.2.1 FAK regulates chemokine / cytokine secretion from 
pancreatic cancer cells.  
To investigate how FAK expression in Panc47 cells might regulate the phenotype of 
TAMs in pancreatic tumours, I first sought to determine whether FAK regulates the 
secretion of chemokines and cytokines from pancreatic cancer cells. Using forward-
phase protein arrays (FPPA) that enabled the measurement of a set of 44 
chemokines/cytokines present in cancer cell conditioned media (table 5.1), I 
identified that loss of FAK expression in Panc47 cells resulted in broad 
reprogramming of chemokine/cytokine secretion (figure 5.1A). Data for 
differentially expressed genes were median centred and subjected to unsupervised 
agglomerative hierarchical clustering on the basis of Euclidean distance, computed 
with a complete-linkage matrix, using Cluster 3.0 (Clustering Library, version 1.37) 
372. Clustering results were visualized using Java TreeView (version 1.1.1)373. 
 A number of these FAK regulated cytokines including IL6366,374, G-CSF368,369, GM-
CSF370,371,375 have been shown previously to influence macrophage proliferation and 
function. I initially selected IL6 as a promising candidate for further investigation 
due to the well-established links between IL6 over-expression and pancreatic cancer 
progression. In the clinical setting, increased serum levels of IL6 or IL6 
overexpression in patients with pancreatic cancer is associated with reduced survival, 
cancer cachexia and increasing tumour stage93,171,376,377. In the pre-clinical setting, 
several studies utilising KRAS-induced models of murine PDAC have found 
increased IL6 is required for PDAC progression93,181,182,378. To confirm the results 
from the FPPA, Panc47 FAK-wt and FAK-/- cells were cultured in-vitro for 48 
hours, and an IL6 specific ELISA used to measure IL6 levels in cancer cell 
conditioned media (figure 5.1B). These results confirmed that FAK loss resulted in 
reduced IL6 secretion. Given that in the in-vivo environment, cancer cells will be 
subject to stimulation by other cytokines that might alter IL6 expression, I also 
investigated FAK-dependent IL6 regulation following stimulation with IL17, a 
potent inducer of IL6 expression114,379–382 that is also present in the pancreatic tumour 
microenvironment93,383. Indeed IL17 secreted by Th17 cells384 can promote initiation 
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and progression of PDAC383,385 and the pancreatic stem cell niche386. Panc47 FAK-
wt and FAK-/- cells were cultured in-vitro and stimulated with the recommended 
reported dose in the literature for stimulation of cultured cell lines in-vitro at 10ng/ml 
IL17387, for 48hours. An IL6 specific ELISA was used to measure IL6 concentration 
in conditioned media (figure 5.1C). These results further confirmed that even in the 
presence of a strong stimulus, FAK loss results in a significant reduction in IL6 
secretion. Furthermore, the extent of FAK-dependent IL6 regulation was not 
dependent on the concentration of IL17 used (figure 5.2A), neither was it due to 
differences in IL17 receptor surface expression on Panc47 FAK-wt and FAK-/- cells 
(figure 5.2B). Therefore, FAK regulates IL6 secretion under both normal culture 




Table 5.1 List of FPPA capture antibodies 





Figure 5.1 FAK regulates the secretion of a number of chemokines and cytokines including IL6 
in Panc47 pancreatic tumour cell lines  
A FFPA heat map generated by hierarchical clustering of changes between Panc47 FAK-wt and FAK-
/- tumour cell lines. Colour and intensity indicate relative protein expression levels in culture medium. 
Over-expressed cytokines (red) include IL6, G-CSF, GM-CSF, CCL28 and CXCL-9 (data analysis for 
figure courtesy of Dr Alan Serrels) B Panc47 FAK-wt and FAK-/- cells were cultured in-vitro and 
basal IL6 production was measured from supernatants using ELISA C Panc47 FAK-wt and FAK-/- 
cells were cultured in-vitro and stimulated with 10ng/ml IL17 for 48hours, IL6 production was 
measured from supernatants using ELISA. Error bars represent SEM, data are representative of three 
experiments; statistical analysis was performed using Student’s T test; P-value = not significant >0.05, 

































































Figure 5.2 FAK regulates secretion of IL6 from Panc47 pancreatic tumour cells after 
stimulation at a range of IL17 concentrations. IL17 receptor expression is independent of FAK 
expression and IL17 stimulation   
A Panc47 FAK-wt and FAK-/- cells were cultured in-vitro with increasing concentrations of IL17 for 
48 hours; IL6 production was measured from supernatants using ELISA B Panc47 FAK-wt and FAK 
-/- pancreatic tumour cells were culture in-vitro with or without IL17 stimulation at 10ng/ml for 48 
hours and surface IL17 receptor expression and MFI (mean fluorescence intensity) was analysed with 
flow cytometry. Error bars represent SEM, data are representative of three experiments; statistical 
analysis was performed using Student’s T test and one-way ANOVA respectively; P-value = not 
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5.2.2 FAK-kinase activity is required for secretion of IL6 
FAK is a protein tyrosine kinase and many of its cellular functions including cell 
survival, motility, invasion, epithelial-to-mesenchymal transition (EMT), 
angiogenesis and chemokine/ cytokine secretion142,197,263,388 are regulated by its 
kinase activity. FAK also has kinase-independent scaffolding functions through 
FERM domain interactions by acting as a bridge between proteins or as a platform 
for assembly of protein complexes389. These can also contribute to FAK-dependent 
regulation of cell migration, cell polarity, survival, proliferation and cancer 
metastasis267,277. In order to determine whether IL6 regulation was dependent on 
FAK kinase activity, I expressed a kinase-deficient FAK mutant into Panc47 FAK-/- 
cells (KD G431). This allowed delineation between FAK kinase dependent and 
independent functions, enabling me to further explore the mechanism underpinning 
FAK-dependent IL6 expression.  
FAK exists in an auto-inhibited state through intra-molecular FERM-kinase domain 
interactions. Disruption of these interactions leads to phosphorylation of tyrosine 397 
(pY397) by the FAK kinase domain. Auto-phosphorylation of pY397 leads to 
activation of FAK’s intrinsic kinase function and downstream kinase-dependent 
signalling pathways268,390. The use of antibodies specific to both total FAK and the 
auto- phosphorylation site pY397 demonstrated selective loss of FAK kinase in the 
KD G431 mutant cell line (figure 5.3A). Analysis of IL6 protein secretion using 
ELISA analysis revealed reduced IL6 secretion from KD G431 cells, comparable to 
that of FAK-/- cells (figure 5.3B). Thus FAK kinase activity is required for FAK-
dependent regulation of IL6 secretion. 
A number of small molecule FAK kinase inhibitors are currently being tested in 
early-phase (I/II) clinical trials. I therefore used one of these inhibitors, 
BI853520306,307, to investigate whether pharmacological inhibition of FAK kinase 
activity could also reduce IL6 secretion from Panc47 FAK-wt cells.  To determine 
the optimal the dose of BI853520 required to selectively inhibit FAK kinase activity 
in Panc47 FAK-wt cells in-vitro, I treated cells with increasing doses of BI853520 
and used FAK auto-phosphorylation of tyrosine 397 as a readout of kinase inhibition 
using western blotting (figure 5.4A). Quantification of the fluorescent intensity of 
the band corresponding to FAK Y397 on the western blot identified 100nM as the 
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lowest concentration required to achieve maximal de-phosphorylation of FAK 
(figure 5.4B). In agreement with the IL6 ELISA analysis utilising the FAK kinase 
deficient cell line (KD G431), treatment of Panc47 FAK-wt cells with 100nM 
BI853520 resulted in a reduction of IL6 secretion comparable to that of FAK-/- cells 






Figure 5.3 FAK’s regulation of IL6 in Panc47 pancreatic tumour cells is a dependent on FAK’s 
kinase function 
A Western blot of total lysates from FAK-wt, FAK-/- and KD mutant (G431). Tubulin was used as a 
loading control. The western blot was probed with antibodies specific to FAK and pY397, 
demonstrating loss of pY397 in the KD mutant (KD G43). B Panc47 FAK-wt and FAK-/- and KD 
G431 pancreatic tumour cells were cultured in-vitro and stimulated with 10ng/ml IL17 for 48hours. 
IL6 production was measured from supernatants using ELISA. Error bars represent SEM, data are 
representative of one experiment with two biological replicates; statistical analysis was performed 
using one-way ANOVA; P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 
0.0001 
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Figure 5.4 IL6 secretion from in Panc47 pancreatic tumour cells is regulated by FAK kinase 
inhibitor BI1853520 in-vitro  
A Dose determination of FAK kinase inhibitor BI853520. Representative western blot of total lysates 
from FAK-wt cell lines. The FAK kinase inhibitor BI853520 was added to supernatants for 48 hours 
at increasing doses ranging from 10nM to 5μM in order to establish the minimum dose required to 
dephosphorylate FAK. FAK-/- cells were used as a negative control and tubulin was used as a loading 
control. B Graph of fluorescent intensity from WB analysis against FAK kinase inhibitor BI853520 
dose, demonstrating maximal dephosphorylation begins at 100nM. C Panc47 FAK-wt and FAK-/- 
were cultured in-vitro and stimulated with 10ng/ml IL17 for 48hours, with or without the addition of 
100nM BI853520. IL6 production was measured from supernatants using ELISA. Error bars represent 
SEM, data are representative of one experiment with two biological replicates; statistical analysis was 
performed using one-way ANOVA; P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, 
**** < 0.0001 
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5.2.3 Nuclear localisation of FAK is required for secretion of 
IL6 
Having established that FAK kinase activity was required for FAK-dependent IL6 
secretion, I next investigated whether FAK nuclear localisation was also important. 
The N-terminal FERM (band 4.1, ezrin, radixin, moesin homology) domain consists 
of 3 subdomains; F1, F2, and F3. The F2 lobe of the FERM domain contains nuclear 
localisation sequences required for FAK to shuttle from its cytoplasmic position at 
sites of focal adhesions to the nucleus277 where it complexes with transcriptional 
regulators290,292,293,391. Nuclear FAK has been found to have a number of functions 
including transcriptional control of chemokines/ cytokines CCL5 and TGFβ in SCC 
to promote an immunosuppressive TME301, suppression of GATA4 to repress 
VCAM-1 expression and enhancement of proteosomal degradation of TP53 to 
promote cell survival291. Additionally, nuclear FAK correlates with reduced survival 
in patients with colorectal cancer392. To investigate FAK nuclear function, I 
expressed a mutant FAK deficient in nuclear targeting197,393 into Panc47 FAK-/- 
cells. Biochemical fractionation to separate nuclear and cytoplasmic extracts 
followed by western blotting of protein extracts confirmed that the FAK-NLS mutant 
cell line was defective in nuclear FAK (figure 5.5A). Subsequent ELISA analysis 
identified reduced IL6 secretion from Panc47 FAK-NLS cells, comparable to that 
secreted by the FAK-/- cells (figure 5.5C). Furthermore, implantation of 0.5 x 106 
Panc47 FAK-NLS cells into the pancreas of C57BL/6 mice identified a similar 
reduction in growth to that observed with Panc47 FAK-/- cells (figure 5.5B). Thus, I 
can conclude from this and the results presented in 5.2.2 that FAK nuclear 
translocation promotes growth of Panc47 tumours and regulates IL6 secretion in a 
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Figure 5.5 FAK regulates transcription of IL6 and this is partly dependent on FAK’s nuclear 
translocation  
A Western blot of total, nuclear and cytoplasmic fractions obtained after nuclear fractionation of 
FAK-wt and NLS mutant pancreatic cell line. FAK-/- acts as a negative control. Western blot 
demonstrates comparable levels of total FAK in FAK-wt and NLS mutant lines and absence of 
nuclear FAK in the NLS mutant line.  The western blot was probed with antibodies specific to FAK, 
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cytoplasmic and nuclear FAK B The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 
FAK-wt, FAK-/- or FAK NLS cell lines. Tumours were harvested at two weeks (n= 7 mice per group; 
error bars represent SEM; statistical test used was Students T-test) C Panc47 FAK-wt, FAK-/- and 
NLS pancreatic tumour cells were cultured in-vitro and stimulated with 10ng/ml IL17 for 48hours. 
IL6 production was measured from supernatants using ELISA. Error bars represent SEM, data are 
representative of one experiment with two biological replicates; statistical analysis was performed 
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5.2.4 FAK-regulated secretion of IL6 controls pancreatic 
tumour growth, the M2 tumour macrophage phenotype 
and PD-L2 expression in-vivo 
Having established that FAK expression in Panc47 cells plays a role in regulating 
pancreatic tumour growth and the TAM phenotype, I next set out to determine 
whether FAK-regulated IL6 plays a role in any of these outcomes. IL6 mediates 
several important physiological functions: the acute phase inflammatory response, 
cell growth, survival and regulation of B-cells and T-cell differentiation and 
activation394. Most notably, IL6 is widely reported to tip the infiltrating leucocyte 
TH1/TH2 balance towards TH2 cells
94,162,172,394–396, cells well recognised for their 
tumour- promoting capabilities. Specifically in pancreatic cancer, tumour cell 
derived IL6 has previously been shown to regulate tumour growth through 
influencing various immune cell types within the TME. For example, Bellone el al 
demonstrated that pancreatic cancer cell derived IL6 can act together with IL10 and 
TGF-β to reduce activation and proliferation of DCs, resulting in a diminished anti-
tumour response396. Conversely, Gnerlich et al. observed that overexpression of IL6 
in a TGF-β secreting murine model of pancreatic cancer, can shift the balance from a 
Treg to a Th17 predominant environment, resulting in delayed tumour growth and 
improved survival114. Due to the known influence of IL6 on the immune populations 
within the TME, I therefore hypothesized that FAK-dependent expression of IL6 
might play an important role in regulating Panc47 tumour growth through 
influencing the TAM phenotype. To investigate this further, and to dissect the 
function of FAK-regulated IL6 as opposed to other tumour promoting FAK 
functions, I first generated Panc47 FAK-wt cells in which IL6 expression was 
selectively depleted. To do this, I used lentiviral-mediated delivery of DNA 
constructs encoding shRNA specifically targeting IL6, and identified successful IL6 
depletion using an IL6 specific ELISA assay. This approach resulted in the 
generation of two IL6 depleted Panc47 FAK-wt cell lines: FAK-wt IL6 shRNA1 and 
FAK-wt IL6 shRNA2. IL6 protein expression was reduced to a level comparable to 
that of the FAK-/- cell line. A non-targeting control (NTCO) line was created to 
ensure that any effects observed were due specifically to IL6 depletion. Western 
blotting demonstrated comparable levels of FAK expression in all cell lines, 
confirming no alteration in FAK expression following IL6 depletion occurred (figure 
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5.6A). To complement this approach, I also generated an additional cell line in which 
IL6 was re-expressed into Panc47 FAK-/- cells, resulting in IL6 secretion at 
comparable levels to that of Panc47 FAK-wt cells. This was also achieved using 
lentiviral infection and validated with western blotting (figure 5.9A) and ELISA 
(figure 5.9B). To determine the contribution of IL6 to Panc47 tumour growth, 
0.5x106 FAK-wt, FAK-/-, FAK-wt NTCO, FAK-wt IL6 shRNA1 and FAK-wt IL6 
shRNA2 cells were orthotopically implanted into the pancreas of C57BL/6 mice. 
Mice were culled 14 days later and their tumours removed and weighed. Comparison 
of tumour weights revealed that IL6 depletion in Panc47 FAK-wt cells resulted in a 
significant reduction in tumour weight, indicating IL6 plays an important role in 
promoting FAK-wt tumour growth (figure 5.6C, figure 5.9C). It should be noted 
that although the difference between the IL6 knockdown groups and the FAK-/- 
group was comparable and non-significant, the decrease in tumour size between the 
FAK-wt and FAK-/- is approximately 2.5 fold, whereas the decrease in tumour size 
between the FAK-wt and the IL6 knockdown lines is approximately 1.7 fold. 
Similarly, re-expression of IL6 into the FAK-/- pancreatic cancer cell line (FAK-/- 
IL6) restores growth of FAK-/- IL6 tumours to a level not significantly different to 
FAK-wt tumours, but does not fully restore the growth phenotype observed in-vivo 
(figure 5.9C). FAK has a plethora of functions in cancer and it is therefore not 
surprising that IL6 knockdown alone in FAK-wt tumours does not reduce the tumour 
growth to that of the FAK-/- tumours. I therefore conclude that pancreatic FAK-wt 
tumour growth in-vivo is partly dependant on cancer cell IL6 expression.  
I next set out to determine whether FAK-IL6-dependent tumour growth was 
associated with regulation of the TAM phenotype. C57BL/6 mice were 
orthotopically implanted with 0.5x106 FAK-wt, FAK-/-, FAK-wt NTCO, FAK-wt 
IL6 shRNA1 and FAK-wt IL6 shRNA2 cells, and tumours harvested at day 14, 
disaggregated and stained for flow cytometry analysis using an optimised panel of 
antibodies (stain1, table 4.1). Comparison between FAK-wt and FAKwt-NTCO 
with FAK-/- and the IL6 knockdown lines demonstrates a reduction in MMR+ CD86- 
cells, implying a switch from M2-like to M1-like phenotype in the Ly6C+ TAM 
population (figure 5.7) and a significant reduction in surface expression of PD-L2 in 
all TAM populations (figure 5.8). Re-expression of IL6 into the FAK-/- pancreatic 
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cancer cell line increased the proportion of MMR+ CD86- Ly6C+ TAMs indicating a 
switch from the M1-like to M2-like phenotype (figure 5.10A, 5.10B). Hence, IL6 
plays an important role in regulating the TAM phenotype, driving the expression of 














Figure 5.6 IL6 knockdown in Panc47 FAK-wt pancreatic tumour cells partly controls 
pancreatic tumour growth in-vivo 
A Validation of FAK-wt IL6 shRNA lines and shRNA empty vector control (FAK-wt NTCO. 
Representative western blot of total lysates from Panc47 FAK-wt, FAK-/-, FAK-wt NTCO, FAK-wt 
IL6 shRNA1 and FAK-wt IL6 shRNA2. Tubulin was used as a loading control. The western blot was 
probed with antibodies specific to FAK and pY397, demonstrating comparable levels of FAK 
expression in all cell lines. B Panc47 FAK-wt, FAK-wt NTCO, FAK-/-, FAK-wt IL6 shRNA1 and 
FAK-wt IL6 shRNA2 cell lines were cultured in-vitro and stimulated with 10ng/ml IL17 for 48hours, 
IL6 production was measured from supernatants using ELISA. Error bars represent SEM, data are 
representative of a combination of 5 experiments; statistical analysis was performed using one-way 
ANOVA; P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 0.0001. C The 
pancreas of C57BL/6 mice were implanted with 0.5x106 FAK-wt, FAK-wt NTCO, FAK-/- , FAK-wt 
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IL6 shRNA1 and FAK-wt IL6 shRNA2 cell lines derived from the LSL-KrasG12D/+;LSL-Trp53R172H/+ 
pancreatic cancer cell line. Tumours were harvested at two weeks (data are representative of 
combined experiments total n= 45 mice; error bars represent SEM; statistical analysis was performed 

































Figure 5.7 FAK regulated secretion of IL6 from Panc47 pancreatic tumour cells controls the 
Ly6C+ tumour macrophage phenotype 
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt, FAK-/-, FAK-wt 
NTCO, FAK-wt IL6 shRNA1, FAK-wt shRNA2 or FAK-/- cell lines. Tumours were harvested at 14 
days post implantation (data represents combined experiments n= 6 per group; error bars represent 
SEM; statistical test used was one-way ANOVA, P-value = not significant >0.05, *<0.05, ** <0.01, 
***<0.001, **** < 0.0001, gating as described in figure 4.2) A M2 (CD86+ MMR-) macrophages in 
CD11bhiLy6C+ and CD11bloLy6C+ TAMS. B M1 (CD86+ MMR-) ) macrophages in CD11bhiLy6C+ 
and CD11bloLy6C+ TAMSCD11bhiLy6C+ TAMs B M2 (CD86+ MMR-) and M1 (CD86+ MMR-) 












Figure 5.8 FAK regulated secretion of IL6 from Panc47 pancreatic tumour cells controls PD-L2 
expression in all tumour associated macrophage subsets  
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt, FAK-/-, FAK-wt 
NTCO, FAK-wt IL6 shRNA1, and FAK-wt shRNA2 cell lines. Tumours were harvested at 14 days 
post implantation. (Data represents combined experiments n= 6 per group; error bars represent SEM; 
statistical test used was one-way ANOVA, P-value = not significant >0.05, *<0.05, ** <0.01, 
***<0.001, **** < 0.0001, gating as described in figure 4.3) Graph shows % PD-L2 expression on all 
four TAM subsets; CD45+CD11bhiF480+Ly6C+ TAM, CD45+CD11bhiF480+Ly6C-, 
CD45+CD11bloF480+Ly6C+, CD45+CD11bloF480+Ly6C- TAM 
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Figure 5.9 Re-expression of IL6 into FAK-/- Panc47 pancreatic tumour cells partially restores 
tumour growth in-vivo 
A Validation of Panc47 FAK-/- IL6 lenti re-expression line. Representative western blot of total 
lysates from Panc47 FAK-wt, FAK-/- and FAK-/- IL6 lenti re-expression line. Tubulin was used as a 
loading control. The western blot was probed with antibodies specific to FAK and pY397, 
demonstrating comparable levels of FAK expression in all cell lines. B FAK-wt, FAK-/- and FAK-/- 
IL6 cell lines were cultured in-vitro and stimulated with 10ng/ml IL17 for 48hours, IL6 production 
was measured from supernatants using ELISA. Error bars represent SEM, data are representative of a 
combination of 3 experiments; statistical analysis was performed using one-way ANOVA; P-value = 
not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 0.0001. C The pancreas of C57BL/6 mice 
were implanted with 0.5x106 Panc47 FAK-wt, FAK-/- and FAK-/- IL6 lenti re-expression cell lines. 
Tumours were harvested at two weeks (n= 12 mice in total, 6 mice in the FAK-/- IL6 group and 3 in 
each of the FAK-wt and FAK-/- groups; error bars represent SEM; statistical analysis was performed 
using one-way ANOVA; P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 
0.0001) 




Figure 5.10 Re-expression of IL6 into FAK-/- Panc47 pancreatic tumour cells promotes re-
polarisation of Ly6C+ macrophages in-vivo 
The pancreas of C57BL6 mice were implanted with 0.5x106 Panc47 FAK-/- and FAK-/- IL6 lenti re-
expression cells. Tumours were harvested at two weeks (n= 9 mice in total, 6 mice in the FAK-/- IL6 
group and 3 in the FAK-/- groups; error bars represent SEM; statistical analysis was performed using 
one-way ANOVA; P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 0.0001) A 
M2 (CD86+ MMR-) in CD11bhi/loLy6C+ macrophages in FAK-/- and FAK-/- IL6 lenti re-expression 
cell line tumours B M1 (CD86- MMR+) CD11bhi/loLy6C+ macrophages in FAK-/- and FAK-/- IL6 
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5.3 Discussion 
The central objective of this chapter was to determine whether FAK regulates 
chemokine / cytokine secretion from pancreatic cancer cells and whether any of these 
FAK-regulated tumour derived signals were responsible for controlling the pro-
tumour associated TAM phenotype and the acceleration of pancreatic tumour growth 
observed in-vivo. A number of FAK-regulated cytokines were identified in-vitro 
using FFPA. IL6 was chosen as a target cytokine to further investigate due to its well 
described association with pancreatic tumour progression in both the clinical and 
pre-clinical setting93,171,181,182,376–378. I show that regulation of IL6 is dependent on 
FAK kinase activity and FAK nuclear localisation. Further I show that IL6 plays an 
important role in accelerating pancreatic tumour growth and regulating the TAM 
phenotype, driving the expression of markers associated with a pro-tumour function 
and increased immuno-suppressive activity in-vivo. Tumour size has not been 
controlled for in this series of experiments. Future experiments would include 
comparison between FAK-/- tumours and mice implanted with FAK-wt cell lines 
and treated with a FAK inhibitor drug to control for tumour size.  
FPPAs are microarrays consisting of a defined set of immobilised capture antibodies, 
in this case targeting various inflammatory cytokines and chemokines, detected with 
a fluorescent dye-conjugated detection antibody to allow multiple targets to be 
analysed simultaneously. This method achieves a high degree of specificity397 and an 
increased throughput speed at a reduced cost. It therefore represented a good method 
for screening several biomarkers at one time. Analysis of the resultant data identified 
over-expression of a number of cytokines/chemokines, most notably IL6, G-CSF, 
CM-CSF, CCL28 and CXCL-9 (figure 5.1A) at basal level in-vitro. FAK-dependent 
IL6 regulation was confirmed with ELISA analysis, and although expression of IL6 
was detectable, it was at a low level.  In the in-vivo setting, pancreatic tumour cells 
exposed to a variety of other cytokines that influence their behaviour, one of which is 
IL17383–385. Pancreatic cancer cells exposed to IL17 are induced to secrete IL6114,379–
382, a pathway principally regulated by NF-κB384. Given the low basal levels of IL6 
secretion in the in-vitro environment, I opted to add IL17 to culture media to increase 
IL6 secretion and therefore increase sensitivity for analysis going forward. Despite 
IL17 being a robust IL6 stimulus, FAK depletion results in a significant reduction in 
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IL6 secretion. This regulation was not found to be dependent on levels of IL17 
receptor expression on cancer cells but was found to be dependent on both nuclear 
shuttling and the kinase function of FAK. 
Different drugs could preferentially target either the FAK-kinase or the kinase-
independent scaffolding function265. Therefore an understanding of the mechanism 
behind FAK-dependent outcomes is important in both selection and development of 
appropriate drugs for pancreatic cancer treatment and interpretation of drug trials 
going forward. I show that expression of a catalytically inactive mutant FAK protein 
(KD G431) and treatment of FAK-wt cells with a small-molecule kinase inhibitor 
(BI853520), significantly inhibits IL6 production to levels comparable to that of 
Panc47 FAK-/- cells in-vitro. Further pre-clinical studies, including treatment of 
mice with small-molecule kinase inhibitors, should be employed to assess whether 
global FAK kinase inhibition results in the same outcome as specific inactivation of 
FAK kinase function within tumour cells only.  
The in-vitro regulation of IL6 production was also found to be dependent on nuclear 
localisation of FAK in pancreatic cancer cells. In normal cells, nuclear FAK is absent 
or present at low levels and FAK has been shown to accumulate in the nucleus in 
response to cellular stress such as hypoxia277, a condition common in the PDAC 
TME. Further, nuclear FAK has been identified as an indicator of poor prognostic 
outcome in colorectal cancer392. If nuclear FAK is specific to cancer cells, this may 
provide a new therapeutic opportunity; however further work will be required to 
establish the absence or level of nuclear FAK in normal pancreatic tissue. 
I investigated the impact of IL6 on the in-vivo TAM populations using shRNA IL6 
knockdown. Several approaches are available to induce targeted gene silencing or 
gene knockout in mammalian cells. shRNA knockdown was selected as the method 
of IL6 depletion. Using this method, target sequences are cloned into a lentiviral 
backbone. Once transfected into target cells, the viral vector containing the DNA 
target sequence, consisting of a sense and antisense copy of the target sequence 
separated by a loop sequence, is transcribed, exported from the nucleus, and the loop 
removed by a dicer. This results in two single stranded small interfering RNA 
(siRNA). The siRNA binds to the target mRNA with an identical sequence and is 
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degraded398. This was chosen as the preferred method rather than other gene 
modification methods such as CRISPR/Cas9 genome editing used previously, which 
achieves full gene knockout. Whilst infection with viral vectors allows for stable 
integration of shRNA, it does not completely shut off the gene; some functional 
RNA remains and is translated at lower levels, thereby reducing gene function but 
doesn’t eliminate the gene altogether. The advantage of this is that IL6 production 
could be brought down to levels comparable to the Panc47 FAK-/- cell line, thus 
creating a more suitable and comparable model for investigation of FAK-dependent 
IL6 signalling in pancreatic tumours.  
There are many cellular sources of IL6 within the PDAC TME: macrophages93, 
epithelial cells, fibroblasts182 and pancreatic cancer cells114,170,181,183. Here we show 
that IL6, specifically derived from pancreatic tumour cells, is crucial to shaping the 
immunosuppressive macrophage phenotype and subsequent control of tumour 
growth in-vivo. IL6 is already known to be fundamental to PDAC development and 
progression. It may be that tumour cells, although not the only producer of IL6, may 
instigate the cascade of phenotypic changes in the PDAC TAMs, resulting in an 
altered PDAC immune-TME. The identification of FAK-dependent cancer cell 
sourced IL6 in repolarising TAM to the pro-tumour phenotype enables a better 
understanding of the PDAC TME and may allow more effective immunotherapy 
strategies and/or aid personalised medicine strategies.  
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6 Cancer cell derived IL6 acts indirectly to 
modulate TAMs  
6.1 Introduction  
I have shown that FAK regulates pancreatic tumour growth and the TAM phenotype 
through a mechanism that is dependent on the action of IL6. IL6 has been associated 
with promoting the differentiation of TAMs to the pro-tumour M2 phenotype in pre-
clinical murine lung cancer models176. However, TH2 type cytokines such as IL4, 
IL10 and/or IL13 are far more widely reported to induce both M2 macrophages and 
PD-L2 expression348,358. Therefore, I set out to determine whether IL6 was acting in a 
direct manner from FAK expressing pancreatic cancer cells to macrophages, or 
whether there were intermediaries involved within the PDAC TME.  
 
6.1.1 Aims 
1. To establish whether FAK-wt pancreatic tumour cells directly induce the 
pro-tumour M2 macrophage phenotype in-vitro and if not: 




6.2.1 IL6 alone is not sufficient to drive expression of MMR 
and PD-L2 on TAMs  
Having established that IL6 plays an important role in regulating the TAM 
phenotype in-vivo, I next wanted to determine whether this was a direct signalling 
mechanism between cancer cells and macrophages. To address this, Panc47 FAK-wt 
cells were cultured in normal growth media for 48 hours, and this media was 
transferred onto a culture of bone-marrow derived macrophages for a further 72 
hours. Flow cytometry identified that Panc47 FAK-wt conditioned media (CM) was 
sufficient to induce expression of MMR but not PD-L2 in macrophages (table 6.1, 
stain 3 and figure 6.1). IL4 has been shown to polarise macrophages to the M2 
phenotype and increase PD-L2 expression349,399. Analysis of FAK-wt and FAK-/- 
  CHAPTER 6 RESULTS 
 110 
CM with FFPA revealed that IL4 was either not expressed or not secreted at 
detectable levels. I therefore added IL4 to Panc47 FAK-wt conditioned media and 
measured MMR and PDL2 expression on BMDMs. These results identified that 
while CM alone can induce expression of MMR, it is enhanced by the addition of 
IL4. Furthermore, expression of PD-L2 requires IL4, but can be further enhanced by 
the addition of FAK-wt CM (figure 6.1). Therefore, IL4 works in concert with 
secreted factors present in Panc47 FAK-wt CM to recapitulate the phenotype of 
macrophages observed in Panc47 FAK-wt tumours. To further probe the identity of 
the secreted factors enhancing the action of IL4 within FAK-wt conditioned media, I 
treated BMDMs with either IL4 + IL6, IL4 + G-CSF, or IL4 + GM-CSF, and 
determined the effects on MMR and PD-L2 expression using flow cytometry. IL6, 
G-CSF, and GM-CSF are all secreted by Panc47 FAK-wt cells and have been 
previously shown to regulate macrophage function366,368–370,374. These results 
identified that IL6 in combination with IL4 as the most potent combination in terms 
of MMR and PD-L2 up-regulation in BMDM (figure 6.2). These results imply that 
IL6 is not sufficient on its own to drive the changes in observed phenotype of 
macrophages in Panc47 FAK-wt tumours, and that it requires the action of IL4. This 
does not exclude the possibility that other cytokines may also be able to work in 
concert with IL6 to regulate the macrophage phenotype. I therefore sought to identify 
whether an accessory cell type, capable of  IL4 production, was additionally required 
for FAK-dependent regulation of the macrophage phenotype. 
 
 
Table 6.1 Flow cytometry marker panel used to identify BMDM MMR and PD-L2 expression 





Figure 6.1 Panc47 FAK-wt CM requires the addition of IL4 to achieve high levels of MMR and 
PD-L2 expression on BMDMs 
BMDM macrophages were cultured for 7 days in media (DMEM, M-CSF and10% FCS). Media was 
replaced with fresh DMEM + FCS (M), Panc47 FAK-wt media (CM) or Panc47 FAK-wt media with 
recombinant mouse IL4 (CM + IL4) for a further 24 hours. A MMR and B PD-L2 were measured 
with flow cytometry and are expressed as mean fluorescence intensity (MFI). Results represent n=3, 
error bars represent SEM; statistical analysis was performed using one-way ANOVA; P-value = not 
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Figure 6.2 Effects of Panc47 FAK-wt expressed cytokines on MMR and PD-L2 expression in 
BMDMs  
A Forward Phase Protein Array (FFPA) heat map generated by hierarchical clustering of changes 
between FAK-wt and FAK-/- tumour cell lines. Colour and intensity indicate relative protein 
expression levels in culture medium. Arrows indicate over-expressed cytokines (red) that are 
regulated by FAK and have been shown to play a role in macrophage polarisation (IL6, G-CSF, GM-
CSF). BMDM macrophages were cultured for 7 days in media (DMEM, M-CSF and 10% FCS). 
Media was replaced with fresh DMEM + FCS (M), or M with recombinant mouse G-CSF, GM-CSF 
or IL6 at 20ng/ml for a further 24 hours. A MMR and B PD-L2 were measured with flow cytometry 
































































































































































A    B    
C    
 PD-L2 
  CHAPTER 6 RESULTS 
 113 
6.2.2 CD4+ T-cells are necessary for FAK-mediated pancreatic 
tumour growth and the pro-tumour macrophage 
phenotype in-vivo  
A candidate source of IL4 is TH2 polarised CD4
+ T-cells. TH2 polarised tumour 
microenvironments358 and specifically IL4 produced from CD4+ T-cells 64,400,401 have 
been shown to induce M2 TAM polarisation. Therefore to address whether CD4+ T-
cells are important for FAK-dependent pancreatic tumour growth acceleration and 
the pro-tumour macrophage phenotype observed in my model, I selectively depleted 
CD4+ T-cells using an anti-CD4+ T-cell depleting antibody in C57BL/6 mice, 
implanted with either Panc47 FAK-wt or FAK-/- cell lines. Tumour growth was 
significantly reduced, near that of the Panc47 FAK-/- tumours, in mice implanted 
with Panc47 FAK-wt tumours and treated with CD4+ T-cell depleting antibody 
(figure 6.2A). No significant difference in tumour weight was observed between 
FAK-/- tumours from mice treated with either CD4+ T-cell depleting antibody or 
isotype control. These results suggest that CD4+ T-cells are important for FAK-
dependent tumour growth. Further, I analysed the macrophage populations within 
these tumours (stain 1, figure 6.2 B). In Panc47 FAK-wt tumours harvested from 
mice treated with CD4+ T-cell depleting antibody, there was a significant reduction 
in the percentage of macrophages expressing MMR and PD-L2, indicating a reduced 
number of M2-like/ pro-tumour associated macrophages within the TME when CD4+ 
T-cells are absent. MMR and PD-L2 expression on macrophages from Panc47 FAK-
/- tumours from mice treated with CD4+ T-cell depleting antibody are comparable to 
those receiving isotype control. Therefore I conclude that CD4+ T-cells play an 
important role in promoting Panc47 FAK-wt tumours growth, and are required to 
promote the pro-tumour associated macrophage phenotype observed in this model. 
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Figure 6.2 CD4+ T-cells are required for FAK-dependent pancreatic tumour growth and 
reprogramming of the macrophage phenotype 
The pancreas of C57BL/6 mice were implanted with 0.5x106 Panc47 FAK-wt or FAK-/- cells and 
harvested at 14 days post implantation. Mice were treated with either CD4 depleting antibody or 
isotype control  (n= 12; 3 mice per group; error bars represent SEM; statistical test used was Students 
T-test, P-value = not significant >0.05, *<0.05, ** <0.01, ***<0.001, **** < 0.0001, gating as 
described in figure 4.2) A tumour weight at 14 days. B M2 (CD86- MMR+) in 
CD11bhi/loLy6C+macrophages from Panc47 FAK-wt and FAK-/- pancreatic tumours in mice treated 
with CD4 depleting antibody or isotype control C PD-L2 expression in CD11bhi/loLy6C+ and 
CD11bhi/loLy6C- macrophages from Panc47 FAK-wt and FAK-/- pancreatic tumours in mice treated 
with CD4 depleting antibody or isotype control   
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6.2.3 The secretome of Panc47 FAK-wt cells is sufficient to 
drive differentiation of naïve CD4+ T-cells to the TH2 
phenotype 
IL6 is a known to induce naïve CD4+ T-cell to the TH2 phenotype. This is through 
two independent mechanisms. Firstly by promoting early IL4 expression through up-
regulation of Nuclear Factor of Activated T cells (NFAT)c2 expression. Secondly by 
rendering CD4+ T-cells unresponsive to IFNγ signals through up-regulation of 
Silencer of Cytokine Signalling (SOCS)1 which leads to interference in IFNγ 
expression94, the effector TH1 cytokine. I have demonstrated a role for CD4
+ T-cells 
in pancreatic tumour growth and the requirement of both IL4 and IL6 in the 
polarisation of TAMs to the M2-like phenotype associated a pro-tumour function. 
Taken together, I hypothesised that conditioned media from FAK-wt tumours would 
polarise naïve CD4+ T-cell to the TH2 phenotype. CD4
+ T-cells derived from 
splenocytes from C57BL/6 mice were isolated using CD4 microbeads, cultured in 
either CM derived from FAK-wt or FAK-/- tumour cell lines and harvested after 24, 
48 72 and 96 hours. Cells were disaggregated and analysed using an intracellular 
transcription staining panel to identify TH2 cells (stain 4, table 6.2). The percentage 
of CD4+ T-cells expressing GATA3, a transcription factor used to identify TH2 cells, 
increases in a time dependent manner in CD4+ T-cells cultured in Panc47 FAK-wt 
CM and is expressed at barely detectable levels in CD4+ T-cells cultured in Panc47 
FAK-/- CM. These results show that Panc47 FAK-wt CM is sufficient to induce 
expression of a hallmark transcription factor that drives differentiation of CD4+ T-
cell to the TH2 phenotype, providing the first evidence that FAK may regulate the 















Figure 6.3 Effects of FAK-wt and FAK-/- CM on GATA3 expression of naïve CD4+ T-cells  
CD4+ T-cells were isolated with CD4 microbeads using the autoMACS® Pro Separator from 
splenocytes derived from C57BL/6 mice. Cells were seeded at 2 x 105 cells in a 48 well plate and 
cultured in 1ml of FAK-wt or FAK-/- CM supplemented with an extra 10% FCS, then harvested after 
24, 48 72 and 96 hours. (Figure courtesy of Dr David Taggart) GATA3 was measured with flow 
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6.3 Discussion 
The in-vitro induction of macrophages to a pro-tumour associated phenotype by IL6 
was found to require the addition of IL4. A likely source of IL4 in the PDAC TME is 
TH2 polarised CD4
+ T-cells. In support of a potential role for these cells in regulating 
the macrophage phenotype in Panc47 FAK-wt tumours, I identified that CD4+ T-
cells were required for FAK-mediated PDAC growth acceleration and induction of 
the pro-tumour associated macrophage phenotype in-vivo. IL4 is not produced at 
detectable levels by Panc47 FAK-wt cells leading me to conclude that IL6 mediated 
induction of MMR and PD-L2 on TAMs requires the addition of IL4, which likely 
come from CD4+ T-cells. IL6 is known to induce TH2 cells. FAK-wt conditioned 
media induced naïve CD4+ T-cells to the TH2 phenotype and I propose that FAK-
regulated IL6 derived from pancreatic tumour cells drives this phenotypic switch. 
Further in-vitro work is required to confirm that FAK-dependent IL6 specifically 
drives this regulation and additional in-vivo analysis is necessary to establish an 
increased presence of TH2 cells in FAK-wt tumours compared to FAK-/- tumours. 
Nevertheless I show that FAK drives a hallmark of TH2 T-cells, the first evidence to 
suggest FAK may shift the TH1/TH2 TME balance towards TH2.  
Whilst IL6 alone or Panc47 FAK-wt conditioned media induced a moderate 
expression of MMR in BMDM in-vitro, this was enhanced by the addition of IL4. 
However IL6 alone or Panc47 FAK-wt conditioned media minimally induced 
expression of PD-L2, but a moderate increase in expression was induced by IL4 
alone. This was enhanced by the addition of IL6 or Panc47 FAK-wt CM. I therefore 
conclude from this that both IL4 and IL6 are important in up-regulation of MMR and 
PD-L2, but are perhaps not working though the same mechanism. Indeed, up-
regulation of PD-L2 is thought to be a Stat-6 dependent process whereas MMR 
expression is independent of Stat-6399. 
TH2-type inflammation facilitates tumour growth
358 and as such, the presence of TH2 
cells are a negative indicator of patient survival in pancreatic cancer99. IL4 plays a 
key role in the TH2 immune response, serving as both an initiator and effector of TH2 
immune reactions344. Increased IL4 is associated with increased pancreatic cancer 
growth and invasion401 and the predominant source of IL4 within the tumour 
microenvironment is TH2 polarised CD4
+ T-cells402. When CD4+ T-cells were 
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depleted in mice, there was a significant reduction in tumour size and reduced 
expression of pro-tumour associated macrophage markers in Panc47 FAK-wt 
tumours. Further, the requirement of IL4 in polarising macrophages to the pro-
tumour associated phenotype in-vitro substantiates the importance of TH2 cells in this 
mechanism. 
No significant difference in tumour weight was observed between Panc47 FAK-wt 
tumours from mice treated with CD4+ T-cell depleting antibody and Panc47 FAK-/- 
tumours treated with either isotype control or CD4+ depleting antibody, although 
Panc47 FAK-wt tumours from mice treated with CD4+ T-cell depleting antibody 
were in general slightly heavier. This is perhaps not surprising given the pleotropic 
role FAK plays in regulating multiple cellular processes that contribute to tumour 
growth, and these results further support a contribution from FAK regulated immune 
independent mechanisms in the growth delay of FAK-/- tumours.  
IL6 was also shown to be crucial to FAK-dependent polarisation of macrophages in-
vitro (figure 6.2) and in-vivo (chapter 5), in addition to acceleration of tumour 
growth (chapter 5). The additional requirement of IL4 and CD4+ T-cells suggests 
that this is both a direct and an indirect mechanism. IL6 is known to induce naïve 
CD4+ T-cell to the TH2 (GATA3
+) phenotype. The TH2 marker GATA3 is associated 
with rapid disease progression and diminished overall patient survival in pancreatic 
cancer99.  During antigen stimulation of naïve CD4+ T-cells, IL6 induces autocrine, 
self-sustaining IL4 production in CD4+ T-cells94,403 and inhibits expression of the 
TH1 cytokine IFNγ
95. Conditioned media from Panc47 FAK-wt cells increased 
GATA3+ CD4+ T-cells, indicating a switch to the TH2 phenotype. Further in-vitro 
work is required to establish whether FAK-dependent IL6 specifically drives this 
regulation, and further in-vivo analysis will be required to confirm an increased 
presence of TH2 cells in Panc47 FAK-wt tumours compared to FAK-/- tumours. 
Nevertheless I show that FAK drives a hallmark of TH2 T-cells, the first evidence to 
suggest FAK may shift the TH1/TH2 TME balance towards TH2. 
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7 General Discussion 
7.1 Principle findings 
 FAK expression in pancreatic cancer accelerates tumour growth by 
suppressing an anti-tumour CD8+ T-cell response. 
 FAK expression in pancreatic cancer results in reprogramming of 
macrophages within the tumour microenvironment to a phenotype associated 
with a pro-tumour response.   
 FAK-dependent regulation of the macrophage phenotype and pancreatic 
tumour growth is dependent on CD4+ T-cells and cancer cell derived IL6, a 
FAK-regulated cytokine requiring FAK-kinase activity and nuclear FAK 
localisation. 
 Expression of MMR and PD-L2 on macrophages is driven by the cooperative 
action of IL6 and IL4. 
 The secretome of Panc47 FAK-wt pancreatic cancer cells can polarise CD4+ 
T-cells towards a TH2 phenotype. 
 
 
7.2 General discussion and therapeutic implications 
I show that pancreatic cancer cell intrinsic FAK signalling plays an important role in 
regulating pancreatic tumour growth through promoting evasion of the CD8+ T-cell 
anti-tumour immune response, and that this is associated with regulation of the 
tumour associated macrophage (TAM) phenotype. Specifically I identify that FAK-
depletion in pancreatic cancer cells shifts the balance from Ly6C+MMR+CD86- 
macrophages towards Ly6C+MMR-CD86+ macrophages, a change that is frequently 
associated with acquisition of an anti-tumour phenotype59. Further, I also observe a 
significant down-regulation of PD-L2 expression on the surface of all TAMs in 
FAK-depleted pancreatic tumours, implying that FAK-dependent paracrine 
signalling between cancer cells and macrophages can regulate macrophage 
immunosuppressive function. Mechanistically, I identify FAK-dependent regulation 
of IL6 secretion from pancreatic cancer cells as a key pathway in controlling both 
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pancreatic tumour growth and the TAM phenotype, and further show that this 
requires a contribution from tumour infiltrating CD4+ T-cells, suggesting a complex 
multicellular mechanism that is driven by FAK-dependent IL6 secretion. Using bone 
marrow derived macrophage cultures, I establish that the macrophage phenotype 
observed in Panc47 FAK-wt tumours can be recapitulated with a combination of IL6 
and IL4, but not either cytokine alone. Furthermore, naïve CD4+ T-cells cultured in 
the presence of Panc47 FAK-wt or FAK-/- tumour cell conditioned media (CM) 
identified that only Panc47 FAK-wt CM drives expression of the transcription factor 
GATA3 in CD4+ T-cells. This implies that the secretome of Panc47 FAK-wt 
pancreatic cancer cells can polarise CD4+ T-cells towards a TH2 phenotype, a 
phenotype typically associated with expression of IL4. Therefore, I report a 
previously unknown mechanism through which pancreatic cancer cell intrinsic FAK 
signalling drives expression of IL6 and TH2 polarisation of CD4
+ T-cells in order to 
reprogram the TAM phenotype and promote pancreatic tumour growth and immune 
suppression (summarised in figure 7.1).   
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Figure 7.1 FAK signalling in pancreatic cancer cells regulates mechanisms of immune evasion to 
promote tumour growth  
FAK-regulated cytokines secreted by pancreatic cancer cells initiates induction of naïve CD4+ T-cells 
to the TH2 phenotype. IL4 most likely produced by TH2 cells acts in combination with cancer cell 
derived IL6 to reprogram tumour associated macrophages to a phenotype associated with tumour 
promotion, thus creating an immunosuppressive tumour microenvironment, with inhibition of 
cytotoxic T-cells and acceleration of tumour growth.  
 
Macrophages are the most abundant immune cell type within the pancreatic TME, 
and a number of previous studies have established an important role for these cells in 
promoting pancreatic tumour development and progression, through regulating 
invasion, angiogenesis, matrix remodelling, metastasis, immunosuppression and 
suppression of the CD8+ T-cell anti-tumour immune response42,56,60,404. For this 
reason they have become an attractive therapeutic target for the treatment of cancer 
and a number of experimental therapeutics targeting macrophage recruitment and / or 
function are currently in clinical testing including CCR2 and CSF1R inhibitors 
(clinicaltrials.gov NCT01413022, NCT03184870, NCT02452424, NCT02829723, 
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specifically target tumour associated macrophage populations, rather they target all 
macrophages, and as a consequence may perturb the homeostatic function of 
macrophages within other tissues of the body, leading to unwanted immune-mediated 
side-effects. Similar problems blight many current immunotherapy approaches, 
highlighting a need to identify more tumour-specific approaches for targeting 
immune cell function. FAK, in particular neoplastic cell intrinsic FAK signalling, is 
emerging as an important regulator of the immunosuppressive TME in cancer. In a 
mouse model of skin SCC, FAK-dependent expression of the chemokine CCL5 was 
shown to drive increased Treg recruitment to tumours, resulting in suppression of the 
anti-tumour CD8+ T-cell response and tumour survival197. Importantly, this was 
mediated by nuclear FAK signalling which does not appear to be prevalent in normal 
cells, suggesting that FAK-mediated immune regulation may have an element of 
tumour specificity. Similar findings demonstrating FAK’s role in general regulation 
of the immunosuppressive TME have since been reported in mouse models of 
pancreatic cancer. Treatment with a FAK kinase inhibitor resulted in broad 
reprograming of the immunosuppressive TME and sensitization to a combination of 
chemotherapy (Gemcitabine) and immune checkpoint blockade (anti-PD-1 + anti-
CTLA4)142. Here I show that FAK signalling in pancreatic cancer cells can regulate 
the macrophage phenotype in pancreatic tumours through control of a paracrine 
signalling axis that requires the cytokine IL6, a cytokine regulated by nuclear FAK in 
a kinase-dependent manner.  
Specifically, I found that this axis enriches for MMR+CD86- macrophages in the 
Ly6C+ population. Ly6C marks a population of inflammatory or immature 
macrophages undergoing differentiation from bone marrow derived monocytes into 
mature macrophages405,406, and MMR is typically associated with a pro-tumour 
phenotype407,408. Therefore, these findings suggest that FAK, at least in part through 
the action of IL6, reprograms macrophages during differentiation to adopt a more 
pro-tumour phenotype. The lack of MMR regulation in Ly6C- macrophages also 
suggests a distinct mechanism of regulation following differentiation that is not 
dependent on the action of IL6. I additionally identified that FAK loss in pancreatic 
cancer cells results in a reduction in the expression of the immune checkpoint ligand 
PD-L2 in all macrophage populations, and that this was also dependent on IL6 
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signalling. PD-L2 blockade has been shown to reduce the ability of macrophages to 
inhibit cytotoxic T-cell proliferation409 and expression is thought to be a Stat-6 
dependent process. In contrast MMR expression is independent of Stat-6399,409, 
supporting my findings that MMR and PDL2 are likely regulated via distinct 
mechanisms. There is an increasing appreciation that macrophages display a high 
amount of phenotypic plasticity and different sub-populations are likely to have 
different functions and/ or origins in the cancer TME, which may differ between 
cancer types357. This also may provide an alternative explanation for the differential 
regulation of FAK-induced receptor/ ligand expression. Based on separation of 
populations seen on flow cytometry analysis, we identified four different sub-
populations of macrophages: (CD45+CD11bhiF480+Ly6C+, 
CD45+CD11bhiF480+Ly6C, CD45+CD11bloF480+Ly6C+ and 
CD45+CD11bloF480+Ly6C-). Separation and further in-vitro functional assays of 
these identified populations were not performed, therefore we can only speculate on 
differences between FAK-induced receptor/ ligand expression and function between 
these subpopulations. However in addition to potentially differing functions, these 
subpopulations may also have different origins. There are conflicting reports in the 
literature regarding the origin of TAMs. Several studies suggest that most TAMs 
arise from the Ly6C+ population of circulating monocytes, for example in mouse 
models of mammary tumours357,410, and in murine lung metastases411. However 
recent reports demonstrate that tissue resident macrophages in the normal pancreas 
are embryonically derived346, and that in pancreatic cancer, both these embryonically 
derived tissue resident macrophages as well as infiltrating bone marrow derived 
macrophages contribute to the TAM population. Lineage tracing experiments were 
not performed but would be an interesting series of follow up experiments. Both of 
these populations increase in density as the tumour progresses56. In-vitro analysis of 
BMDM receptor expression demonstrated differing responses to cytokine exposure. 
IL6 alone or Panc47 FAK-wt conditioned media induced a moderate expression of 
MMR in BMDM in-vitro, and this was enhanced by the addition of IL4. However 
IL6 alone or Panc47 FAK-wt conditioned media minimally induced expression of 
PD-L2 and a moderate increase in expression was induced by IL4 alone. This was 
enhanced by the addition of IL6 or Panc47 FAK-wt CM. Notably, the vast majority 
of BMDMs were Ly6C+ (data not shown). IL4 induces alternative activation of 
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macrophages in both embryonically or monocyte-derived populations regardless of 
origins412 but IL4 induced up-regulation of PD-L2 is limited to monocyte-derived 
macrophages399. My in-vitro macrophage polarisation experiments were conducted 
on BMDMs, which may represent only the monocyte-derived populations of the 
TAMs found within the PDAC TME. It would therefore be interesting to FACS sort 
macrophages from implanted Panc47 FAK-wt and FAK-/- tumours grown in-vivo 
and repeat these stimulation experiments and re-assess the resultant surface receptor 
expression. 
IL6 is emerging as an important cytokine in the development and progression of 
pancreatic cancer. Recent evidence has uncovered the role of cancer cell derived IL6 
in immune evasion and its role in shaping immune cell populations such as dendritic 
cells, macrophages and T-cells within the TME, disabling both the innate and 
adaptive immune system. Increased IL6 pathway signalling is thought to be in part 
responsible for the TH2 polarised TME and impaired TH1 response found in 
cancer96,413. Indeed inhibition of the IL6 receptor has been found to improve TH1 
development resulting in an antitumor response92 and IL6 inhibition in ovarian 
cancer patients, combined with interferon treatment, has recently demonstrated some 
treatment success in reversing cancer associated immunosuppression with increased 
tumour anti-tumour CD8+ T-cell infiltration414. IL6 has also been linked to age 
related intrinsic T-cell dysfunction and decreased susceptibility to cancer 
immunotherapies96. As elderly people represent the vast majority of cancer patients, 
control of IL6 levels should perhaps be taken into account in a comprehensive 
treatment strategy in cancer therapy. Therefore treatment strategies targeting IL6 
may indirectly impact downstream immunosuppressive targets as well as cytotoxic 
T-cell dysfunction. This new knowledge makes strategies targeting IL6 in 
combination with current immunotherapies appealing and as such IL6 inhibition has 
already been shown to improve responses to immunotherapies in pre-clinical 
models97,98. I show FAK-dependent regulation of IL6 secretion from pancreatic 
cancer cells regulates both pancreatic tumour growth and the TAM phenotype, in 
agreement with previous reports demonstrating the role of IL6 in pro-tumour 
macrophage polarisation176,415. FAK inhibition may therefore represent a novel 
avenue for control of IL6 within the PDAC TME, in addition to a plethora of other 
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anti-cancer benefits that FAK inhibition brings such as blockage of VEGF 
production and reduced micro-vessel density, reduced tumour cell survival and 
proliferation, reduced migration and invasion, amongst other benefits267,416.  
However, my results suggest that IL6 does not function alone, but rather cooperates 
with IL4, and likely other cytokines, to establish a tumour promoting and immune 
suppressive TME. I found that IL6 was not sufficient to induce the phenotype of 
macrophages identified in Panc47 FAK-wt tumours when applied to bone marrow 
derived macrophage cultures in-vitro. Rather, it required the addition of IL4 to fully 
recapitulate the macrophage phenotype. However, analysis of the cytokine secretion 
from Panc47 FAK-wt tumour cells did not identify any IL4 secretion, implying that 
it must come from a different source within the TME. Further functional studies 
identified that CD4+ T-cells were required to promote Panc47 FAK-wt tumour 
growth, and that CD4+ T-cell depletion resulted in a reduction of MMR+CD86- 
macrophages in the Ly6C+ population and a reduction in PD-L2 expression across all 
macrophage subsets, similar to the results found with FAK-depletion. Thus there is a 
requirement of an accessory cell type in this mechanism, most likely the TH2 
polarised CD4+ T-cell. This highlights the complexity of the pancreatic TME and it 
is likely that multiple cell types are recruited and cell phenotypes induced, which 
may vary between patients and in temporal fashion. Additionally, downstream 
effects of tumour-derived cytokines such as IL6 may not be limited to the local 
effects influencing the TME. Tumour cell production of IL6417 and also G-CSF and 
GM-CSF can induce bone marrow myeloid progenitor expansion, leading to 
increased myeloid cells in the circulation and resultant infiltration into tumours and 
disease progression418,419. Furthermore, in KPC murine PDAC models, tumour-
derived IL6 has been shown to alter liver metabolism and consequently, in the 
context of caloric restriction, leads to increased corticosterone production and 
suppressed antitumor immunity420. Therefore it may be that cytokines derived from 
the tumour site are working in complex, multimodal, local and systemic mechanisms. 
Understanding the individual complexities unique to the TME of individual cancer 
types is imperative in the selection of therapies designed to treat different cancer 
types. Multiple arms of cancer-induced immunosuppression must be addressed to 
avoid some of the pitfalls in currently available immunotherapies and also in the 
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development of novel therapeutic approaches to target aspects of the 
immunosuppressive TME and reverse immune evasion. 
There is an increasing appreciation that TH2 polarised TMEs are important in the 
context of cancer. Specifically in pancreatic cancer, TH2 cells are negative indicators 
of patient survival99. Therapeutic strategies targeting the TH2 weighted environment 
will likely be required to effectively target M2 TAMS and address cancer immune 
evasion. The pro-tumour M2 TAM phenotype is induced not only by IL6176, but also 
by IL4399 and are more generally promoted in a TH2 weighted TME, a TME that is 
known to favour pancreatic tumour progression47. Further to FAK’s regulation of 
IL6, I show the first evidence demonstrating that FAK may shift the TH1/TH2 TME 
balance towards TH2. IL6 is a component of Panc47 FAK-wt CM, which I show 
polarises naïve CD4+ T-cells to the TH2 (GATA3
+) phenotype. I show that cancer 
cell derived IL6 polarises BMDM to the M2/ pro-tumour associated phenotype but 
requires the addition of IL4, a cytokine secreted by TH2 cells. This novel function of 
FAK corroborates previous reports demonstrating the requirement of IL4 in skewing 
TAMs toward the pro-tumorigenic M2 phenotype in mammary cancer421, the 
requirement of IL6 in promoting the pro-tumour M2 phenotype in TAMs in lung 
cancer176 and IL6 mediated TH1 inhibition
92.  
I set out to identify novel mechanisms of FAK-dependent immune regulation in 
pancreatic cancer. The result of my research establishes FAK as an important regulator 
of the immunosuppressive environment within pancreatic cancer via a multicellular 
mechanism that is driven by FAK-dependent secretion of IL6. Thus this provides new 
insights into the complexity of FAK-dependent immune regulation in pancreatic cancer, 
and supports further investigation of FAK inhibitors in combination with other 
immunotherapy treatments for the management of PDAC.  
7.3 Future work 
One pitfall of using discrete flow cytometry marker panels to define macrophage 
subpopulations and to infer functional changes within the pancreatic TME is that this 
approach may oversimplify the range of phenotypes present within the TME and the 
varying functions of these cells. Although this provides a foundation for future 
efforts, deeper analysis of the complexity of cells within the pancreatic TME, using 
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technologies such as high- resolution single-cell RNA sequencing and intra-vital 
imaging, will provide exceptionally detailed information on the polarisation status, 
composition, function and spatial distribution of cells such as macrophages with in 
the PDAC TME. The information gained from a deeper understanding of the 
complexity of the TME through improved resolution of the cellular composition 
could also prove useful in identifying novel therapeutic targets and also in the 
individualised medicine arena, if paired with relevant patient outcomes, and may 
better identify patients who may derive benefit from these therapies. Single cell RNA 
sequencing is currently underway to examine the macrophage populations within 
Panc47 tumours in finer detail.  
Future work will also focus on further defining FAK’s role in polarising CD4+T-cells 
to the TH2 phenotype. This will include further in-vitro assays comparing CD4
+ T-
cell polarisation using Panc47 FAK-wt IL6 shRNA1/2 and the FAK-/- IL6 lenti re-
expression lines to determine if cancer cell derived IL6 is specifically involved in 
TH2 polarisation, which will expand on the work already completed comparing 
Panc47 FAK-wt and FAK-/- CM on GATA3 expression. Additionally, we will 
compare levels of TH2 cells between FAK-wt and FAK-/- tumours. There are a 
variety of ways of conducting these experiments in-vivo, either with use of flow 
cytometry with specific transcription and intracellular cytokine panels, or with 
histology using GATA3, STAT5 and CD4 co-staining. It would additionally be 
interesting to utilise the inducible IL4 reporter mouse to ascertain whether there are 
higher numbers of CD4+ T-cells within FAK-wt tumours compared to FAK-/- 
tumour
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9 Appendices 
9.1 Appendix 1: Full western blot of parental PDAC cell line 
(Panc47)  
 
Full western blot of parental PDAC cell line (Panc47) corresponding to figure 3.2. Western blot 
demonstrates whole cell, nuclear and cytoplasmic fractions probed with antibodies specific to total 
FAK and GAPDH. Lane 2 contains whole cell Panc47. Lane 4 contains Panc47 cytoplasmic portion 
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9.2 Appendix 2: Comparison of human, chicken and mouse FAK 
DNA sequence  
 
